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ABSTRACT 
Background 
In the late seventies the term “Haematological Stress Syndrome” defined some 
haematological abnormalities appearing in the course of acute and chronic disorders, such as 
raised plasma levels of fibrinogen (FNG) and factor VIII, reduced fibrinolytic activity and 
hyperviscosity. In the early nineties the “Membrane stress syndrome hypothesis” proposed the 
unification of the concepts of haematological stress syndrome with those of oxidation, 
inflammation and immune activation to explain the pathogenesis of the antiphospholipid 
syndrome (APS) 
Antiphospholipid antibodies, coagulation, fibrinolysis and thrombosis 
This chapter investigated the occurrence of the “Haematological Stress Syndrome” and 
thrombosis in 144 participants positive for aPL detected by clotting and immune tests. Among 
the clotting assays for the detection of lupus anticoagulant, dilute Russell's viper venom time 
better correlated with a history of venous thrombosis than activated partial thromboplastin 
time (p<0.0002 vs p<0.009) and was the only test correlated with a history of arterial 
thrombosis (p<0.01). By regression analysis, serum levels of IgG anticardiolipin antibodies 
(aCL) associated with the number of venous occlusions (p<0.001). With regards to FNG and 
von Willebrand factor (vWF), the former rose by 36% (95% CI; 21%, 53%) and the latter by 
50% (95% CI; 29%, 75%) at the first venous occlusion and remained unchanged after 
subsequent occlusions. At variance FNG rose by 45% (95% CI; 31%, 60%) per arterial 
occlusion and vWF by 27% (95% CI; 10%, 47%) per arterial occlusion throughout.  
The coagulation/fibrinolytic balance was cross-sectionally evaluated on 18 thrombotic 
PAPS patients, 18 subjects with persistence of idiopathic aPL and in healthy controls. 
Markers of thrombin generation prothrombin fragment 1+2 (F1+2), thrombin-antithrombin 
complex (TAT) and of fibrin turnover D-Dimer (D-D) were higher in thrombotic (p=0.006) 
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and non-thrombotic subjects (p=0.0001) than in controls as were those of D-D (p<0.0001 and 
p=0.003 respectively). TAT levels did not differ. Gender analysed data revealed blunted tPA 
release (hence a negative venous occlusion test) in thrombotic females but neither in 
thrombotic males (p=0.01) nor in asymptomatic subjects of either sex. Also, in both patient 
groups females had higher mean PAI than males (p<0.0002) and control females (p<0.02).  
The activity of factor XIII (FXIIIa) was evaluated was evaluated in 29 patients with 
PAPS, 14 persistent carriers of aPL without thrombosis, 24 thrombotic patients with inherited 
thrombophilia, 28 healthy controls and 32 patients with mitral and aortic valve prosthesis as 
controls for FXIII only. FXIIIa was highest in PAPS (p=0.001), particularly in patients with 
multiple (n=12) than single occlusion (p=0.02) and in correlation with PAI (p=0.003) and 
FNG (p=0.005). Moreover FXIIIa was strongly associated with IgG aCL and IgG anti-2GPI 
(p=0.005 for both) in the PAPS group and to a lesser degree in the aPL group (FXIIIa with 
IgG aCL, p=0.02, with IgG anti-2GPI, p=0.04). Altogether these results indicate: 1) a 
differential relationship of aPL, vWF and FNG with venous and arterial thrombosis; 2) 
heightened thrombin generation, accelerated fibrin turnover and fibrinolysis abnormalities 
also in asymptomatic carriers of aPLs; 3) enhanced FXIIIa that may contribute to 
atherothrombosis via increased fibrin/fibrinogen cross-linking. 
Lipid profile, lipid peroxidation and anti-lipoprotein antibodies in thrombotic primary 
antiphospholipid syndrome.  
Given the atherogenic lipid profile of SLE, the same possibility was explored in PAPS by 
comparing high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol 
(CHO), apolipoprotein AI (ApoAI), apolipoprotein B (ApoB), triglycerides (TG), anti-
lipoprotein antibodies, beta-2-glycoprotein I complexed to oxidized low-density lipoprotein 
(oxLDL-2GPI) and C-reactive protein (CRP) in 34 thrombotic PAPS patients compared to 
36 thrombotic patients with inherited thrombophilia (IT), to 18 subjects persistently positive 
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for antiphospholipid antibodies (aPL) with no underlying autoimmune or non-autoimmune 
disorders and to 28 healthy controls. Average concentrations of HDL (p<0.0001), LDL 
(p<0.0001), CHO (p=0.0002), ApoAI (p=0.002) were lower in PAPS whereas average TRY 
was higher (p=0.01) than other groups. Moreover PAPS showed higher IgG anti-
HDL (p=0.01) and IgG anti-ApoAI (p<0.0001) as well as greater average oxLDL-2GPI 
(p=0.001) and CRP (p=0.003). Within PAPS, IgG anti-HDL correlated negatively to HDL 
(p=0.004) and was an independent predictor of oxLDL-2GPI (p=0.009). HDL and ApoAI 
correlated negatively with CRP (p=0.001 and p=0.007, respectively). IgG anti-HDL may 
hamper the antioxidant and anti-inflammatory effect of HDL favouring low-grade 
inflammation and enhanced oxidation in thrombotic PAPS. Indeed plasma 8-epi-
prostaglandin F2α (a very specific marker of lipid peroxidation) was significantly higher in 10 
patients with PAPS than 10 age and sex matched healthy subjects (p=0.0002) and strongly 
related to the titre of plasma IgG aCL (r=0.89, p=0.0004). Hence oxidative stress, a major 
player in atherogenesis, also characterises PAPS. 
Nitric oxide and nitrative stress in thrombotic primary antiphosholipid syndrome. 
Oxidative stress goes hand in hand with nitrative stress and to address the latter plasma 
nitrotyrosine (NT, marker of nitrative stress), nitrite (NO2
-
) and nitrate (NO3
-
) were measured 
in 46 thrombotic PAPS patients, 21 asymptomatic but persistent carriers of antiphospholipid 
antibodies (PCaPL), 38 patients with inherited thrombophilia (IT), 33 patients with systemic 
lupus erythematosus (SLE) and 29 healthy controls (CTR). Average crude NT was higher in 
PAPS and SLE (p=0.01) whereas average plasma NO2
-
 was lower in PAPS and average NO3
-
 
highest in SLE (p<0.0001). In PAPS, IgG aCL titer and number of vascular occlusions 
negatively predicted NO2
-
, (p=0.03 and p=0.001, respectively) whereas arterial occlusions and 
smoking positively predicted NO3
-
 (p=0.05 and p=0.005). Moreover CRP (an inflammatory 
marker) positively predicted NT (p=0.004). Nitric oxide metabolites relates to type and 
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number of vascular occlusions and to aPL titers, whereas nitrative stress relates to low grade 
inflammation and both phenomena may have implications for thrombosis and atherosclerosis 
in PAPS 
Inflammation and immune activation in thrombotic primary antiphospholipid syndrome. 
To investigate inflammation and immune activation in thrombotic PAPS high-sensitivity 
CRP (hs-CRP), serum amyloid A (SAA), oxLDL-2GPI, CRP bound to oxLDL-2GPI (CRP-
oxLDL-2GPI) (as inflammatory markers) neopterin (NPT) and soluble CD14 (sCD14) 
(as immune activation markers) were measured by ELISA in 41 PAPS patients, in 44 patients 
with inherited thrombophilia (IT) and 39 controls (CTR). Compared to other groups, PAPS 
presented with higher plasma concentrations of inflammatory, hs-CRP (p=0.0004), SAA 
(p<0.01), CRP-oxLDL-2GPI (p=0.0004) and immune activation markers, NPT (p<0.0001) 
and sCD14 (p=0.007). By regression analysis SAA independently predicted thrombosis 
number (p=0.003) and NPT independently predicted thrombosis type (arterial, p=0.03) and 
number (p=0.04). These data confirm that low-grade inflammation and immune activation 
occur and relate to vascular features of PAPS. 
Antiphosholipid antibodies, haemostatic variables and atherosclerosis in thrombotic primary 
antiphospholipid syndrome 
To evaluate whether IgG aCL titre, haemostatic variables and the lipid profile bore any 
relationship to the intima media thickness (IMT) of carotid arteries high-resolution 
sonography was applied to the common carotid (CC), carotid bifurcation (CB) and internal 
carotid (IC) of 42 aPL subjects, 29 with primary thrombotic antiphospholipid syndrome and 
13 with persistence of aPL in the absence of any underlying disorder. The following were 
measured: plasma FNG, vWF, PAI, homocysteine (HC), CHO, TG, HDL, LDL, platelet 
numbers and aCL of IgG and IgM isotype. By multiple regression analysis, IgG aCL titre 
independently predicted IMT at all carotid segments examined (p always <0.005). Plasma 
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FNG and HC independently predicted IMT at the CB (p=0.001 and p<0.0001, respectively) 
and IC (p=0.03 and p<0.0001, respectively). These data strongly support an atherogenic role 
for IgG aCL in patients with aPL in addition to traditional risk factors. The atherosclerosis 
hypothesis was investigated in an age and sex-matched case-double-control study including 
49 thrombotic PAPS patients (18 M, 31 F, mean age 37 ± 11), 49 thrombotic patients for IT 
and 49 healthy subjects. Average IMT was always greater in PAPS than control patients (CC: 
p=0.004, CB: p=0.013, IC: p=0.001). By dividing participants into age tertiles the IMT was 
greater in the second (CC: p=0.003, CB: p=0.023, IC: p=0.003) and third tertiles (CC: p=0.03, 
CB: p=0.004, IC: p=0.007). 
Conclusion 
Coagulation activation, fibrinolysis depression, hightened fibrin turnover, oxidative and 
nitrative stress in parallel with low grade inflammation and immune activation characterise 
thrombotic PAPS: all these are early atherogenic processes and contribute to the demonstrated 
premature atherosclerosis that should be considered a clinical feature of PAPS. 
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RESUMO 
Introdução 
No final dos anos setenta algumas alterações hematológicas como níveis elevados de 
fibrinogénio (FNG) e factor VIII, diminuição da actividade fibrinolítica e hiperviscosidade 
foram agrupadas na definição “Síndrome de Stress Hematológico”. 
Posteriormente, a hipótese da “Síndrome de Stress Membranar” veio propor a unificação 
dos conceitos de síndrome de stress hematológico, oxidação, inflamação e activação 
imunológica, numa tentativa de explicação da patogénese da síndrome de anticorpos 
antifosfolípidos (APS). 
Anticorpos antifosfolípidos, coagulação, fibrinólise e trombose 
Este capítulo aborda os conceitos da “Síndrome de stress hematológico” e trombose em 
144 doentes com anticorpos antifosfolípidos (aPL), detectados por testes imunológicos e de 
coagulação. Entre os testes para detecção do anticoagulante lúpico (LA), o “tempo de veneno 
de cobra” (DRVVT) apresentou uma melhor correlação com a ocorrência de tromboses 
venosas que o tempo de tromboplastina parcial activado (p < 0.0002 vs p < 0.009) e foi o 
único teste em que se verificou uma correlação com a presença de tromboses arteriais 
(p < 0.01). A análise de regressão, após correcção para potenciais factores de confundimento, 
verificou uma associação entre os níveis séricos de anticorpos anti-cardiolipina (aCL) IgG e o 
número de tromboses venosas (p < 0.001). No que se refere ao FNG e factor de Von 
Willebrand (vWF), verificou-se uma elevação de 36% do primeiro (95% CI; 21%, 53%) e de 
50% do segundo (95% CI; 29%, 75%) na primeira trombose venosa. Estes valores 
mantiveram-se inalterados nos eventos subsequentes. Em contraste, verificou-se uma subida 
de 45% do FNG (95% CI, 31%-60%) e de 27% do vWF (95% CI; 10%-47%) por cada evento 
trombótico arterial. O equilíbrio entre coagulação e fibrinólise foi avaliado de forma 
transversal em 18 doentes com PAPS, 18 doentes com aPL persistentemente elevados e em 
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controlos saudáveis. Marcadores de geração de trombina como o fragmento 1+2 da 
protrombina (F1+2) e complexos trombina-anti-trombina (TAT) e da renovação da fibrina 
como os dímeros D (DD) estavam mais elevados em doentes com tromboses (p=0.006) e 
mesmo em doentes sem tromboses (p=0.0001) do que no grupo controlo, tal como os DD 
(p<0.0001 e p=0.003 respectivamente). Os valores de TAT não foram significativamente 
diferentes. 
Níveis médios de proteína S livre mais baixos foram encontrados no grupo com PAPS 
(p=0.0006) e nos indivíduos sem tromboses (p=0.002) em comparação com os controlos 
saudáveis. Em ambos os grupos de estudo, os níveis de F1+2 eram mais elevados em doentes 
com níveis baixos de proteína S quando comparados com os indivíduos que apresentavam 
valores de proteína S normais (p=0.01). No que diz respeito ao género, observou-se uma 
redução do activador tissular do plasminogénio (rPA) (avaliado através do teste de oclusão 
venosa), em mulheres com PAPS (de 16.80 ± 0.79 para 21.3 ± 3.9 ng/ml, NS), mas não em 
homens com PAPS (de 18.2 ± 2.0 para 33.7 ± 4.9 ng/ml, p=0.01), nem nos doentes com 
anticorpos mas sem eventos trombóticos, independentemente do género. 
Da mesma forma, em ambos os grupos de doentes, as mulheres apresentaram níveis de 
inibidor do activador de plasminogénio (PAI) mais elevados que os homens (p<0.0002) e que 
os controlos femininos (p<0.02). 
A actividade do factor XIII (FXIIIa) foi avaliada em 29 doentes com PAPS, 14 portadores 
de anticorpos antifosfolípidos mas sem eventos trombóticos, 24 doentes com trombofilias 
hereditárias e tromboses, 28 controlos saudáveis e 32 doentes com próteses mitrais ou aórticas 
(utilizados apenas para controlo dos níveis de FXIII).  
A FXIIIa estava mais elevada em doentes com PAPS (p=0.001), particularmente em 
doentes com mais de um evento trombótico (158 ± 45% vs 118 ± 38%; p=0.02, n=12) e 
correlacionou-se com os níveis de PAI (p=0.003) e FNG (p=0.005). 
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A FXIIIa estava ainda fortemente associada aos títulos de aCL IgG e anti-2GPI IgG 
(p=0.005 para ambos) no grupo com PAPS e, embora de forma menos significativa, no grupo 
portador de anticorpos (aCL IgG, p=0.02; anti-2GPI IgG, p=0.04). 
Em conjunto estes resultados mostram: 1) uma relação diferencial de aPL, vWF e FNG 
com as tromboses arteriais e venosas; 2) o aumento da formação de trombina, o aumento da 
renovação da fibrina e a diminuição da actividade fibrinolítica ocorrem também nos 
portadores assintomáticos de aPL; 3) um papel central da deficiência de proteína S livre 
“adquirida” no risco trombótico dos doentes com APS; 4) um aumento da actividade do FXIII 
que poderá contribuir para aterotrombose através de um aumento das ligações cruzadas entre 
fibrina e fibrinogénio. 
Perfil lipidico, peroxidação lipidica e anticorpos anti-lipoproteinas na síndrome de anticorpos 
antifosfolípidos 
Estes aspectos foram estudados comparando os níveis de HDL, LDL, colesterol total 
(CHO), apolipoproteína AI (ApoAI), apolipoproteína B (ApoB), triglicéridos (TG), 
anticorpos anti-lipoproteínas, complexos beta-2-glicoproteína-I e LDL oxidada (oxLDL-
2GPI) e proteína C reactiva (CRP) em 34 doentes com PAPS, 36 doentes com trombofilias 
hereditárias e tromboses, 18 portadores persistentes de anticorpos antifosfolípidos e 28 
controlos saudáveis.  
Os níveis de HDL (p<0.0001), LDL (p<0.0001), CHO (p=0.0002) e ApoAI (p=0.002) 
foram mais baixos no grupo com PAPS, enquanto os TG foram mais elevados (p=0.01) que 
nos outros grupos. Doentes com PAPS mostraram ainda ter títulos mais elevados de anti-HDL 
IgG (p=0.01) e anti-ApoAI IgG (p<0.0001), e níveis superiores de oxLDL-2GPI (p=0.001) e 
CRP (p=0.003).  
Dentro do grupo com PAPS, os níveis de anti-HDL IgG correlacionaram-se 
negativamente com os valores de HDL (p=0.004) e foram predictores independentes dos 
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valores de oxLDL-2GPI (p=0.009). HDL e ApoAI também se correlacionaram 
negativamente com a CRP (p=0.001 e p=0.007, respectivamente).  
Anticorpos anti-HDL IgG podem bloquear os efeitos anti-oxidante e anti-inflamatório das 
HDL, favorecendo um estado de inflamação persistente e um aumento da oxidação no PAPS. 
De facto, a 8-epi-prostaglandina F2α (um marcador específico de peroxidação lipídica) estava 
significativamente mais elevado em 10 doentes com PAPS quando comparados com um 
grupo igual controlado para sexo e idade (234 ± 56 pg/ml vs 72 ± 14 pg/ml, p=0.0002) e 
correlacionou-se directamente com os títulos de aCL IgG (r=0.89, p=0.0004). Estes dados 
confirmam o facto de o stress oxidativo ser um factor importante no PAPS. 
Óxido nítrico (NO), stress nitrativo e PAPS 
O stress oxidativo associa-se ao stress nitrativo e para estudar o segundo, avaliaram-se os 
níveis plasmáticos de nitrotirosina (NT), nitrito (NO2
-
) e nitrato (NO3
-
) em 46 doentes com 
PAPS, 21 portadores assintomáticos de anticorpos aPL, 38 doentes com trombofilias 
hereditárias (IT), 33 doentes com lupus sistémico (SLE) e 29 controlos saudáveis. Os níveis 
de NT foram mais elevados nos grupos com PAPS e SLE (p=0.01), enquanto que os níveis de 
NO2
- 
foram mais baixos no PAPS e os de NO3
-
 mais elevados no SLE (p<0.0001). 
No grupo com PAPS, os títulos de aCL IgG e o número de oclusões vasculares foram 
predictores negativos dos níveis de NO2
-
, (p=0.03 e p=0.001, respectivamente), enquanto as 
oclusões arteriais e consumo de tabaco foram predictores positivos de NO3
-
 (p=0.05 e 
p=0.005). Para além destes dados, os valores de CRP foram predictores positivos dos níveis 
de NT (p=0.004). Os metabolitos do NO estão associados ao tipo e número de tromboses 
vasculares e aos títulos de aPL, enquanto que o stress nitrativo se associa à inflamação de 
baixa intensidade persistente. 
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Inflamação e activação imunológica no PAPS 
Para avaliar estes mecanismos em doentes com PAPS, foram medidos os níveis de CRP de 
alta sensibilidade (hs-CRP), amilóide sérico A (SAA), oxLDL-2GPI e CRP ligada a oxLDL-
2GPI (CRP-oxLDL-2GPI) (como marcadores inflamatórios), e neopterina (NPT) e CD14 
solúvel (sCD14) (como marcadores de activação imunológica) em 41 doentes com PAPS, 44 
doentes com IT e 39 controlos saudáveis. Comparado com os outros grupos, os doentes com 
PAPS apresentaram valores mais elevados de hs-CRP (p=0.0004), SAA (p<0.01), CRP-
oxLDL-2GPI (p=0.0004), NPT (p<0.0001) e sCD14 (p=0.007). A análise de regressão 
mostrou que o SAA é predictor independente do número de tromboses (p=0.003) e a NPT do 
tipo de trombose (arterial, p=0.03) e do número de eventos (p=0.04).  
Anticorpos antifosfolípidos, variáveis hemostáticas e aterosclerose no PAPS 
Para avaliar uma possível relação entre os títulos de aCL IgG, variáveis hemostáticas e 
perfil lipídico, e a espessura da íntima e da média da parede arterial (IMT), realizaram-se eco-
dopplers da carótida comum (CC), bifurcação (B) e carótida interna (IC) em 42 doentes com 
aPL (29 com PAPS e 13 portadores de aPL sem tromboses). Foram avaliados: FNG, vWF, 
PAI, homocisteína (HC), CHO, TG, HDL, LDL, número de plaquetas e aCL (IgG e IgM). A 
análise de regressão mostrou que os níveis de aCL IgG são predictores independentes da IMT 
em todos os segmentos (p<0.005 para todos). FNG e HC foram predictores independentes da 
IMT na bifurcação (p=0.001 e p<0.0001, respectivamente) e na IC (p=0.03 e p<0.0001, 
respectivamente). 
Estes dados suportam o papel pró-aterogénico dos aCL IgG em associação aos factores de 
risco tradicionais. Estes dados foram complementados com o estudo de 49 doentes com 
PAPS, 49 doentes com IT e 49 controlos saudáveis. A IMT média foi sempre maior no grupo 
do PAPS (CC: p=0.004; B: p=0.013; IC: p=0.001). Ao dividir os indivíduos estudados em 
tercis de acordo com a idade, a IMT era maior no segundo e terceiro tercis (CC: p=0.003; B: 
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p=0.023; IC: p=0.003) e (CC: p=0.03; B: p=0.004; IC: p=0.007), respectivamente. Desta 
forma confirma-se a existência de aterosclerose como manifestação integrante do síndrome de 
anticorpos antifosfolípidos primário. 
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CHAPTER I 
THE ANTIPHOSPHOLIPID SYNDROME: DIAGNOSIS, 
CLASSIFICATION AND CLINICAL MANIFESTATIONS 
HISTORICAL MILESTONES  
In the early ‘80s a syndrome characterized by thrombosis, thrombocytopenia and recurrent 
miscarriages was described in patients with systemic lupus erythematosus (SLE) who were 
found positive for antibodies to cardiolipin (CL). Anti CL antibodies (aCL) belong to the 
wider family of “antiphospholipid” antibodies (aPL) the specificity of which was initially 
attributed to negatively charged phospholipids. It became evident this was not the case and 
that the major aPL specificity was towards proteins bound to negatively charged 
phospholipids. The major antigenic target has been identified in beta-2-glycoprotein-I 
(2GPI), a plasma protein of liver origin whose functions are well beyond those of 
coagulation regulation. The immunisation of different strains of mice with 2GPI induce the 
appearance of specific antibodies that have thrombogenic properties in vitro and in vivo, and 
more interestingly 2GPI  immunisation of low density lipoprotein knockout mice induce the 
appearance of premature atherosclerosis. 
Although the antiphospholipid syndrome (APS) was described in 1983, the existence of 
aCL and lupus anticoagulant (LA) was already known. In 1906 Wasserman (1) described a 
complement fixation test to detect “reagin” in the sera of syphilitic patients and in 1941 
Pangborn (2) demonstrated that reagin bound to an antigen extracted from ox heart muscle. 
This antigenic extract was later named cardiolipin. In the following years Moore and Mohr 
(3) recognized that the “reagin test” was also positive in some patients who had never 
contracted a treponemal infection. By analysing these patients they identified a first group in 
whom the false positive “reagin” was a transient phenomenon, generally the result of an 
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infection, and a second group in which the false positive reaction was a persistent 
phenomenon. In this latter group there was a high prevalence of patients with SLE.  
The first description of a circulating anticoagulant in patients with SLE was given by 
Conley and Hartmann (4) in 1952. Their patients showed a bleeding tendency, contrary to the 
increased thrombotic risk recognized by Bowie in 1963 (5). A decade later Feinstein and 
Rappaport (6) named the inhibitor “lupus anticoagulant”. This was also found in association 
with placental infarctions and recurrent miscarriages. In 1983 Harris and colleagues (7) first 
detected aPLs as aCL by a radioimmunoassay and then by an enzyme linked immunoassay 
(Elisa) (8). In 1990, three independent groups of scientists (9-11) discovered that the aCL 
detected by Elisa was not directed towards CL alone. Purified IgG from aCL positive patients 
failed to bind CL, unless a “cofactor” was present. The “cofactor” was identified as 2GPI, a 
plasma apolipoprotein with phospholipid binding properties involved in several steps of the 
coagulation pathway.  
From the clinical perspective the independent existence of APS outside SLE had been 
suspected in the mid ’80 (12, 13) and in the late ‘80s a multicenter study documented the 
major clinical and serologic characteristics of a primary APS. Essentially these patients 
suffered deep vein thromboses, often accompanied by pulmonary embolism, eventually 
complicated by thromboembolic pulmonary hypertension, arterial occlusions (ischaemic 
strokes and myocardial infarctions) or fetal loss; thrombocytopaenia, haemolytic anaemias 
and isolated Coombs positivity were also described. The negativity of antinuclear antibodies, 
antibodies against dsDNA and exctractable nuclear antigens ENA was the main serologic 
features that discriminated them from SLE (14). These findings were confirmed in a later 
Eurpean survey (15). A survey performed ten years later revealed that patients with primary 
APS have little propensity to develop SLE (16). 
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BETA2-GLYCOPROTEIN I  
2GPI is a highly glycosylated protein synthesized in hepatocytes and circulates in the 
plasma at a concentration range between 50–500 mg/mL though approximately 40% 
associates with lipoproteins; this single chain protein consists of 326 amino acids and is 
arranged in five mutually homologous domains consisting of approximately 60 amino acids 
bridged by disulphide bonds to form five short consensus repeats called Sushi domains (17). 
2GPI circulates in blood in a circular conformation that shields the epitope for aPL binding 
within domain I, but after interaction of domain V with anionic surfaces in vivo or with 
anionic phospholipids in vitro, the circular structure opens up, the cryptic epitope is exposed 
and aPL can bind to it (18).  
Beta-2-glycoprotein I, antiphospholipid antibodies and thrombogenesis 
2GPI regulates several steps of the coagulation pathway, exerting both procoagulant and 
anticoagulant activities. β2GPI binds factor XI in vitro preventing activation of FXI to FXIa 
by thrombin and FXIIa. Proteolytic cleavage of the phospholipid binding domain of β2GPI 
abolishes its inhibition of FXI activation. β2GPI protects thrombin from heparin inactivation 
(19), modulates protein C activation, inhibits von Willebrand factor dependent platelet 
adhesion and aggregation (20) and stimulates fibrinolysis (21). Whenever aPL binds β2GPI 
the activity of the natural anticoagulant functions is lost and this effect, combined with the 
aPL induced over-expression of tissue factor on monocytes and endothelial cells lead to 
excessive thrombin generation. Thrombin promotes fibrinogen polimerisation, platelet 
activation and further endothelial cell activation with a shift from an anti-adhesive and anti-
thrombotic phenotype to a pro-adhesive and pro-thrombotic phenotype. Finally enhanced 
thrombin generation coupled with aPL impairment of fibrinolysis causes increased fibrin 
turnover.  
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Beta-2-glycoprotein I, antiphospholipid antibodies and atherogenesis 
Free radicals generated by endothelial cells and circulating neutrophils, monocytes and 
platelets may induce oxidative modifications within LDL (oxLDL) the uptake of which by 
mononuclear cells is mediated by their scavenger receptors and is followed by monocyte 
migration under the endothelial layer and then by their transformation in foam cells or lipid 
laden macrophages. During this process monocytes/macrophages release a number of 
inflammatory and chemotactic cytokines that contribute locally to the development of 
atherosclerosis. Immune-staining of human atherosclerotic lesions co-localized oxLDL with 
β2GPI. Indeed 2GPI may interact with oxLDL in an antioxidant fashion initially via 
electrostatic interactions that over time become covalent: this process takes place in the 
arterial intima of atherosclerotic lesions and produces stable and non-dissociable 
oxLDLβ2GPI complexes (reviewed in 22). From the cellular point of view, after co-
incubation of IgG anti-2GPI antibodies with oxLDL and 2GPI, the monocyte/macrophage 
uptake and intracellular accumulation of oxLDL accelerates and leads to up-regulation and 
enhanced surface expression of scavenger (CD36) and FcγRI receptors that perpetuates this 
cycle. Therefore, while antibodies again 2GPI favor the development of thrombosis, 
antibodies against oxLDL2GPI may favor the development of atherosclerosis (22).  
DIAGNOSIS AND CLASSIFICATION OF THE ANTIPHOSPHOLIPID SYNDROME 
Clinical diagnosis of antiphospholipid syndrome 
The diagnosis of the APS relies on clinical and laboratory criteria. The clinical criteria 
include one or more clinical episodes of arterial, venous, or small-vessel thrombosis in any 
organ or tissue confirmed by adequate imaging or histopathology findings. Occlusions may 
involve either venous or arterial vessels in the brain, heart, lungs, abdomen or limbs. 
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Investigations should be instigated if any of these occur in younger individuals (males < 55 y; 
females < 65 y) or in the absence of other risk factors. With regards to pregnancy morbidity, 
the criteria include one or more late-term (>10 weeks' gestation) spontaneous abortions, one 
or more premature births of a morphologically healthy neonate at or before 34 weeks of 
gestation for severe preeclampsia or eclampsia or severe placental insufficiency; three or 
more unexplained, consecutive, spontaneous abortions before 10 weeks of gestation (23).  
Clinical classification of antiphospholipid syndrome 
The APS may appear in different settings: 1) as primary APS (PAPS) in patients with no 
underlying disorder but for the presence and persistence of aPLs and clinical manifestations, 
2) in patients with definite SLE, 3) as secondary APS in a variety of other autoimmune and 
non-autoimmune conditions and as a “catastrophic” syndrome in patients with rapidly 
progressive multi-organ failure (23). 
Laboratory diagnosis of antiphospholipid syndrome 
The laboratory criteria include (1) medium to high levels of immunoglobulin (Ig) G or 
IgM aCL, (2) anti-2GPI, or (3) lupus anticoagulant on at least 2 occasions at least 12 weeks 
apart. Although the detection principles of these assays are different, the common 
denominator of these three assays is that a positive result depends on the presence of 2GPI 
(24).  
Immunological detection of antiphospholipid antibodies 
Two different but established enzyme linked immune assays are available for the detection 
of aPL: in the first, the microplate is coated with CL as the target antigen (though there is a 
minute amount of 2GPI) in the second the microplate is coated with 2GPI as the target 
antigen. The former assay is more sensitive but less specific, whereas the latter is highly 
specific (24).  
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Lupus anticoagulant testing 
Clotting assays for the identification of a LA rely on the ability of the immunoglobulin to 
interfere with phospholipid dependent stages of coagulation. Minimal criteria for the 
diagnosis of a LA are 1) prolongation of PL dependent coagulation test 2) discrimination 
between a clotting factor deficiency and circulating anticoagulant 3) confirmation of the lupus 
inhibitor activity of the anticoagulant. Common screening tests include kaolin clotting time 
(KCT), activated partial thromboplastin time (aPTT) and dilute Russell viper venom time 
(dRVVT). The KCT is highly sensitive, but lacks specificity and may be affected by residual 
platelets in plasma samples after centrifugation. The aPTT is widely used as a screening 
procedure, although its ability to detect LA varies according to the sensitivity of the reagent 
employed for the assay. The dRVVT is highly specific being associated with arterial 
thrombosis. Once a screening test shows prolongation of the clotting time, mixing studies 
using patient and normal plasma become mandatory. Correction of the prolonged clotting 
time suggests a clotting factor deficiency whereas failure of correction is diagnostic of an 
inhibitor. In this case a thrombin and a reptilase time must exclude the presence of heparin or 
an acquired dysfibrinogenaemia respectively. The antiphospholipid nature of the 
anticoagulant can be evaluated by several approaches. The inhibitor effect may be potentiated 
by decreasing the phospholipid concentration in the test systems, as in the dRVVT and the 
dilute aPTT. The inhibitor effect may be overcome by increasing the phospholipid 
concentration. This applies to the platelet or phospholipids neutralisation procedures in aPTT 
or dRVVT systems and to the KCT performed with low and high rabbit brain cephalin 
concentrations (25). Phospholipids with an altered configuration have been used to bypass the 
inhibitor effect of LA and a comparison between sensitive and insensitive reagents to LA has 
proven utility (26). 
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Laboratory classification of antiphospholipid syndrome 
The previous immunological and coagulation assays allow a classification of the 
laboratory criteria into 4 categories: category IIa as lupus anticoagulant alone, IIb as aCL 
alone, IIc as anti-2GPI alone and category I as any combination of the previous (23). 
CLINICAL MANIFESTATIONS 
aPL and venous thrombosis  
In the setting of SLE, an early study from the ‘90s revealed LA as the strongest risk factor 
for venous thrombosis with an odds ratio of 6.6 (27) whereas a later meta-analysis from the 
same decade found an odds ration of 5.6 for LA and 2.2 for aCL  (28). The more recent 
LUMINA Study showed that 9% of SLE patients had at least one episode of venous 
thrombosis independently predicted by LA (29). Outside the autoimmune setting, the 
association of venous thrombosis with aPLs has been assessed in patients with venous 
thrombosis as well as in population-based prospective studies. A meta-analysis from the mid 
‘90s found an overall odds ratio of 11.1 for LA whereas the odds ratio for aCL of any titer 
was approximately 1.6, and for high titer aCL was 3.2 (30). A later systematic review data 
from 25 primary studies including more than 7000 patients and controls, revealed LA as a 
strong risk factor for venous thrombosis with an odds ratios ranging from 5 to 16;  a weaker 
association was found for aCL that did not reach statistical significance in about half of the 
studies reviewed (31).  
aPL and ischemic stroke 
Amongst arterial vessels the cerebral circulation is most often occluded in APS patients 
leading to ischemic stroke or transient ischemic attacks; the middle cerebral artery is 
prevalently affected (32). The Eurolupus study showed that ischaemic stroke was the initial 
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presentation in 29.9% of adults with APS (33) and a lower 18% presentation prevalence was 
derived from APS patients of Latin American origin (34). Another study detected a very high 
odds ratio of 43.1 for LA tests with regards to ischemic strokes in a population with a low 
positivity rate for LA (35). Ischaemic stroke is also the most frequent recurrent occlusive 
event and responsible for elevated mortality. aPL-associated ischaemic strokes accounted for 
11.8% of these events in a predominantly young female cohort (36). Ischaemic stroke 
occurred also in 62% of the 250 patients in the European Catastrophic Antiphospholipid 
Antibody Syndrome (CAPS) registry and was the leading cause of death in 13% of the 114 
deaths in this registry (37). 
aPL and myocardial infarction 
Myocardial infarction is a consistent feature of APS being the presenting manifestation in 
2.8% (38) of patients and occurring in up to 5.5% of patients with APS (39) and vascular 
myocardial involvement is often asymptomatic (40). 
Catastrophic antiphospholipid syndrome 
A small number of patients with elevated titres of aPLs and/or LA may develop a 
syndrome characterized by the sudden onset of widespread vascular occlusions and rapidly 
progressive multiorgan failure. Fatality rate is high, and death may ensue as a result of 
irreversible renal, cardiac, pulmonary or cerebral damage as mentioned earlier (37). Acute 
respiratory distress syndrome appeared in some patients who presented with pulmonary 
microvascular thrombosis, alveolar hemorrhage and capillaritis. A disorder resembling 
thrombotic thrombocytopenic purpura developed in a small number of patients with SLE and 
aPLs. Major characteristics were microangiopathic hemolytic anemia with the presence of 
schistocytes, thrombocytopenia, renal dysfunction and central nervous system disease. 
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Pregnancy loss 
Recurrent spontaneous abortions were a consistent feature of the APS since its original 
description. They tend to occur during the second and third trimester of pregnancy, at 
variance with the usual pattern of first trimester pregnancy loss in the general population. The 
presence of moderate levels of aCL and/or of a LA may confer to a woman a 30% risk of 
having a miscarriage during her first pregnancy. The risk increases to 70% if a woman had 
already two miscarriages. There is now some agreement to suggest that the presence of aPLs 
is a predictor of poor fetal outcome as well as a poor obstetric history (41). Other obstetric 
associations of aPLs are early onset pre-eclampsia and intrauterine growth retardation. 
Progressive thrombosis of the placental microvasculature leading to placental insufficiency 
and infarction underlie these manifestations. However, not all examined placentae disclosed 
thrombosis or infarction, and other mechanisms may be operating in these patients.  
Other vascular manifestations 
Kidney involvement may be extraparenchymal or intraparenchymal. In the former case, 
unilateral or bilateral renal artery occlusion may occur, whereas glomerular thrombosis and a 
particular form of thrombotic microangiopathy are examples of the latter. Pathological data 
show re-canalized thrombi without inflammatory infiltrate, at variance with the typical 
features of lupus nephritis. Nephrovascular hypertension following arterial thrombosis, renal 
insufficiency and severe proteinuria may contribute to increased morbidity and mortality. 
Occlusion of mesenteric arteries may cause bowel infarction. Thrombosis of dermal vessels 
may lead to a variety of skin manifestations including cutaneous necrosis or gangrene, 
ulcerative lesions, erythematous macules, painful purpura and hemorrhagic bullae. These 
lesions are characterized by thrombosis of small dermal arterioles, capillaries and venules 
with no evidence of vasculitis. Interruption of the vascular supply to bones may cause 
osteonecrosis (42). 
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Non-thrombotic vascular manifestations 
In APS any organ may be affected although it is always possible to attribute the 
involvement to vascular occlusion. Heart valve lesions are common in APS and strongly 
associate with the presence of aPL and are progressive in patients with high titre aPL (43). 
Mitral and aortic valves may become regurgitant and may require replacement. Pulmonary 
hypertension is less common and may be a primary phenomenon or be secondary to 
pulmonary microembolism. Movement disorders are linked to the presence of aPLs. A 
significant association exists between movement disorders (epilepsy and chorea) and aPL and 
there are cases of transverse myelitis and Guillain-Barré syndrome (42). Skin involvement 
may appear as livedo reticularis, a blotchy white-purple discoloration due to reduced blood 
flow through sub-papillary and dermal vessels (42). 
Haematological manifestations 
Thrombocytopenia is commonly found in the APS, with a prevalence of approximately 
20%. Bleeding is not as rare as initially thought and is probably due to an acquired qualitative 
platelet disorder. Haemolytic anaemia has occurred in SLE patients with aCL generally of the 
IgM isotype (42).  
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CHAPTER II 
ANTIPHOSPHOLIPID ANTIBODIES AND ATHEROTHROMBOSIS IN 
SYSTEMIC LUPUS ERYTHEMATOSUS: A UNIFYING 'MEMBRANE 
STRESS SYNDROME' HYPOTHESIS 
Clinical evidence 
The survival of patients with SLE is influenced adversely by infection, renal failure and 
cardiac failure due in part to atherosclerosis and thrombosis (1).With regards to the latter, aPL 
seem to play a major role, being involved in multiple coagulation defects which lead 
ultimately to thrombosis. In contrast, the development of atherosclerosis in SLE is poorly 
understood and the available data are inconclusive as to whether a relation with aPLs exists. 
Early autopsy studies reported premature coronary atherosclerosis in SLE patients (2,3) and 
marked atherosclerosis of major cardiac vessels was found in several young SLE patients who 
died of acute myocardial infarction (4,5). Further studies supported the concept of accelerated 
coronary atherosclerosis in SLE (6,7). This acceleration was initially attributed to prolonged 
steroid therapy (6). However, it was subsequently thought that steroids, by suppressing the 
extravascular manifestations of SLE, allowed patients to live long enough to develop 
atherosclerosis (8). A more recent controlled autopsy study found coronary vessel 
involvement to be more premature and prevalent in SLE patients than in age and sex-matched 
controls and showed that the mean intimal thickening ratio of coronary vessels was 
significantly higher in SLE patients who had not been treated with steroids compared with 
those who had been. The authors suggested that a vascular inflammatory process could 
promote intimal thickening of coronary arteries leading to accelerated atherosclerosis (7). 
This study however, did not control for the presence of aPLs. On the other hand, an initial 
relationship found between ischaemic heart disease and aCL (9,10) was subsequently 
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challenged with the suggestion that the former studies had adopted low cut-off points for the 
detection of aCL (11, 12).  In addition, the low prevalence (4%) of myocardial infarction 
estimated in a cohort of 300 SLE and non-SLE patients with high levels of aCL is hard to 
reconcile with the preceding clinical and autopsy observations. Nevertheless, aPLs have been 
linked to the development of premature re-stenosis of vein autografts in patients undergoing 
aorto-coronary bypass and premature atherosclerosis may develop in heart transplants 
following postoperative infection by cytomegalovirus, a virus able to stimulate the appearance 
of aPL (16). The relation between aPLs and coronary heart disease thus remains to be 
clarified. Better established is the association between heart valve involvement and aPLs. 
Thickening of heart valve leaflets leading to varying degrees of valve dysfunction is often 
found in SLE patients with aPLs, and to a lesser extent, in patients with the PAPS (17-19). 
Atherosclerosis may also affect cerebral vessels. Several series reported stenosis of intra and 
extra cerebral arteries in patients who suffered ischemic stroke associated with aPL (20,21) 
and an autopsy study found arteriolar thickening of cerebral vessels in SLE patients with aPL 
(22). Despite the reports of an association between aPLs and ischemic stroke (23-25), a large 
prospective case-control study in men identified aCL (at a titer > 33 GPL units) as a risk 
factor for venous thrombosis and pulmonary embolism but not for ischaemic stroke (26) and a 
subsequent study could not find an association between aCL and stroke among survivors of 
myocardial infarction (27). Therefore, even the relationship between aCL, cerebral thrombosis 
and atherosclerosis remains equivocal. Data regarding atherosclerotic involvement of other 
vessels are limited. A few cases of premature non-thrombotic occlusions of lower limb 
arteries 28 and of renal artery stenosis (29-31) have been described. In some patients, 
histological findings of the biopsied vessels showed myointimal proliferation with fibrosis, a 
feature resembling endothelial injury types II and III of accelerated atherosclerosis (32). 
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Taken together, however, the autopsy studies and the clinical reports suggest that premature 
atherosclerosis is a feature of SLE. 
Lipids, atherosclerosis and thrombosis 
Abnormalities of the lipid profile, increased levels of triglycerides (TG) and of very-low 
density lipoproteins (VLDL)-cholesterol and reduced levels of high density lipoproteins 
(HDL)-cholesterol, were found in both young and adult untreated SLE patents (33). Steroid 
treatment may further increase plasma levels of triglycerides and of VLDL-cholesterol, while 
restoring HDL-cholesterol to normal levels (34). Other studies showed that steroids increased 
low density lipoprotein (LDL) cholesterol and its major apopoprotein-B (Apo-B) (35). The 
suggestion that an atherogenic lipid profile coupled to the presence of aCL might contribute to 
the pathogenesis of vascular disease in Sloe (36) was confirmed by a study showing that aCL 
positive SLE patients had lower total cholesterol, HDL-cholesterol and increased Apo-B 
levels than aCL negative SLE patients (37). The majority of the data point to increased levels 
of LDL in SLE. It is known that the atherogenicity of LDL may be increased by lipid 
peroxidation, a process by which free radicals (FR) and reactive oxygen species (ROS) 
produced in vivo, exert an ’oxidative damage’ on lipids, whether isolated or incorporated in 
polyunsaturated fatty acids converting them into lipid peroxides (38). Oxidised-LDL (ox-
LDL) favour monocyte and leucocyte endothelial interactions, recruiting these cells on the 
arterial wall hence promoting the atherosclerotic process (39,40). Moreover, ox-LDL is more 
immunogenic than its native form eliciting specific autoantibodies which are currently viewed 
as independent predictors of carotid atherosclerosis progression (41) and antibodies cross-
reacting with ox-LDL and cardiolipin have been found in patients with SLE (42). To 
complete the atherogenicity of the lipid profile, abnormally high levels of lipoprotein(a) 
(Lp(a)) have been found in patients with SLE, regardless of previous steroid treatment (43). 
This apolipoprotein, which shares some structural homology with plasminogen, competes 
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with the latter and tissue plasminogen activator (tPA) for fibrin binding (45), inhibits 
fibrinogen uptake and degradation by mononuclear cells (46), modulates the expression of 
plasminogen activator inhibitor (PAI) in endothelial cells (47) and stimulates smooth muscle 
cell proliferation (48). Epidemiological studies have ranked Lp(a) as an independent marker 
of cardiovascular and cerebrovascular disease (49). 
Haemostatic variables, atherosclerosis and thrombosis 
Multiple mechanisms contribute to the thrombotic tendency of patients with aPLs. An 
impaired fibrinolytic potential has been reported, often with increased levels of PAI (51,52) 
but these changes are not always correlated with the presence of aPLs or with the occurrence 
of thrombosis (53) and were also found in SLE patients without aPLs (54) as well as in 
normal subjects where hypofibrinolysis represents a predisposing factor for recurrent deep 
vein thrombosis and/or pulmonary embolisms. However, local or systemic increases in PAI 
levels are implicated in the development of atherosclerosis (56). Dysfunction of the 
anticoagulant functions of protein C and protein S (57,58) as well as reduced levels of protein 
S were found in some patients with aPLs but their relationship with thrombosis could not 
always be proven (60). Autoantibodies reacting with protein C were detected in a cohort of 
SLE patients but did not relate to the dysfunctional protein C found in some of the patients 
nor to a history of thrombosis (62). Impairment of antithrombin function has also been 
reported (63). It should be remembered that congenital deficiencies of natural anticoagulants 
predispose to the occurrence of venous thrombosis but rarely of arterial thrombosis. What is 
the explanation for the latter tendency? Several investigators have explored the role of platelet 
and vessel wall derived prostaglandins. Their results are conflicting: in vitro, aPLs added to 
cultured endothelial cells were found to inhibit prostacyclin (PGI2) release in some studies 
(64-66) but not in others (67,68). Likewise, sera from patients with SLE and aPLs enhanced 
the generation of thromboxane-B2 (TxB2) from platelets stimulated with collagen or 
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arachidonic acid but LA had an opposite effect on thrombin stimulated platelets (69). In vivo, 
urinary excretion of TxB2 metabolites was increased in patients with aCL (70) and LA (71), 
although no correlation could be found between aCL titres and TxB2 production but, 
importantly, TxB2 generation was reported to be a persistent phenomenon, supporting the 
parallel persistence of a hypercoagulable state. In keeping with this, and evidence against the 
suggestion that the presence of aCL may represent an epiphenomenon of past thrombotic 
events (72) increased thrombin generation was detected both in thrombotic and non-
thrombotic SLE patients with aPL (73), substantiating the presence of an ongoing 
prothrombotic state. Other studies found increased levels of von Willebrand factor (vWF) in 
thrombotic and non-thrombotic patients with SLE (74-76) and elevated plasma levels of 
fibrinogen (FNG) and vWF correlated to the number of occlusive events in patients with aPLs 
(77). The in vitro observation that vWF factor release from endothelial cells incubated with 
IgG purified from thrombotic APS patients was increased in respect to IgG from non-
thrombotic APS and from controls (78), supports a potential role for vWF in the thrombotic 
tendency of the APS. Epidemiological studies indicate that high plasma levels of vWF and 
FNG are risk factors for atherosclerosis and thrombosis (79,80) 
The “membrane stress syndrome” 
In the mid-1960s it was found that immunologic injury combined with a lipid-rich diet 
caused the development of atherosclerosis in a rabbit model (81). In the late seventies some 
non-specific and specific haematological abnormalities appearing in the course of acute and 
chronic disorders, such as hyperviscosity, reduced fibrinolytic activity and raised levels of 
fibrinogen and factor VIII (82), were grouped into the definition ’haematological stress 
syndrome’ (83). The mechanisms illustrated in the present overview enclose and extend the 
former concepts. Given that aPL do not recognise a definite structure in cell membranes, it is 
possible that aPL may simply induce fluidity changes in membranes that nevertheless trigger 
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cytoplasmic signalling. Accordingly, the term ’membrane stress syndrome’ is proposed to 
unify the concepts of oxidation, inflammation, autoimmunity, thrombosis and atherosclerosis. 
The hypothesis 
Analysis of the lipid profile in SLE patients supports the concept of premature coronary 
and cerebral atherosclerosis in lupus, although prospective studies did not find a relationship 
between aCL and acute cerebrovascular and cardiovascular events (11, 12, 26). Rather, 
elevated levels of aCL were identified as a risk factor for venous thrombosis  
This is in agreement with the observation that most of the coagulation abnormalities 
involved in the pathogenesis of APS exposed patients to the risk of venous thrombosis. 
However, the development of venous and arterial occlusions shares the involvement of the 
vascular endothelium which due to its location is the prime target for oxidant-mediated injury. 
Oxidative and peroxidative processes involved in the genesis of atherosclerosis do occur in 
SLE (85-88). A particular metabolite of lipid peroxidation, 4-hydroxyonenal, activates 
phospholipases C (PLC) and D (PLD) in vascular endothelial cells (9,90). These enzymes are 
able to divert the hydrolysis of phosphatydilcholine (PC), the major phospholipid of the outer 
membrane layer, from the production of PGI2 to that of platelet activating factor (PAF), a 
potent platelet agonist (91). Therefore PLC and PLD seem to control the synthetic ratio of 
PGI2 to PAF synthesis in the presence of oxidant stress. This is yet another mechanism, 
probably independent of aPLs, by which the anticoagulant endothelial lining may acquire 
thrombogenic properties. It may explain the reduced in vivo urinary elimination of PGI2 
metabolites (90, 91) and the discrepancies observed between the production of PGI2 in vivo 
and in vitro, where oxidative damage does not occur. The same studies reported increased 
urinary excretion of 2,3-dinor-TxB2, a platelet metabolite generated through the β-oxidation 
pathway (92), a finding which again reveals ongoing oxidative stress in these patients, since 
ox-LDL may induce platelet activation in vivo (93). In this setting, the synthesis of PGI2 
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seems dependent on the availability of PC and PC appears crucial to membrane integrity and 
function, as its deficiency or peroxidation may predispose to cancer and infection (94,95). In 
this respect, it is of interest that an in vivo study has shown that soybean PC supplementation 
together with soybean fats may enhance phagocytosis and killing activities of 
polymorphonuclear cells (94). It is likely that dietary restriction, immobilization by specific 
antibodies or lipid peroxidation may reduce the availability of PC. However, the oxidative 
state can be counteracted by specific antioxidant drugs. In homozygous homocystinuria, an 
inborn error of cysteine metabolism, characterised by premature atherosclerosis, recurrent 
arterial and venous thrombosis (96), high levels of thiol oxidants are produced that cause 
endothelial cell injury (97) and the urinary excretion of 2,3-dinor-TxB2, the β-oxidation 
pathway catabolite was found to be increased (98) as in the antiphospholipid syndrome. The 
oral administration of probucol, a drug known for its cholesterol lowering effects, but which 
also inhibits LDL peroxidation (99), reduced the urinary excretion of 2,3-dinor-TXB2 (98). 
Lipid peroxidation may influence surface- dependent haemostasis by externalising from 
membrane bilayers phosphatidylethanolamine and phosphatidylserine (100), two 
phospholipids deeply implicated in the coagulopathy of the APS (101, 102). Membrane 
disruption may enhance reactivity of aPL to erythrocytes, neutrophils and platelets (103) with 
its physiopathological consequences (72). In addition, oxidative damage may also break 
through immunological tolerance and enhance autoantibody production (104).  
Future directions 
Information emerging from studies on the consequences of oxidative damage should open 
new directions to follow in the pathogenesis of the APS and explain some apparent 
contradictions. Oxidative stress takes place in the arterial system where primed neutrophils 
may discharge their oxidative content (l05). A vein autografted in the arterial side would be 
exposed to an oxidative injury not present in the venous system: since the phosphalipid 
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composition of endothelial cells varies according to the arterial or venous location (106), lipid 
peroxidation might favour premature occlusion of the graft for deficient release of PGI2 and 
increased vWF release (107) and promote the endothelial expression of neophospholipid 
antigens and corresponding aPL. Oxidative damage of endothelial cells might enhance their 
production of IL-6 which stimulates hepatic synthesis of FNG (108). Moreover, oxidative 
damage impairs the physiological properties of some coagulative proteins: the heparin 
binding site of AT is modified (109), plasmin looses its catalytic potential on fibrin/fibrinogen 
(110), FNG may coagulate in the absence of thrombin (111), PAI can no longer inactivate t-
PA (112) and ox-LDL may reduce protein C activation on endothelial cells (113). In the same 
fashion, oxidative stress may disturb other surface dependent coagulant and anticoagulant 
pathways. Overall, these in vitro findings would favour a hypercoagulable state if operating in 
vivo, adding to the thrombogenic potential of aPL and further challenging our preventive 
options. In this respect, aspirin inhibits platelet but not neutrophil cyclooxygenase, therefore 
cannot totally block TxA production (114). Aspirin treated platelets may synthesise 
vasoconstrictor leukotrienes from neutrophil precursors even when they can no longer 
generate TxA2 (115). Moreover, platelet aggregation induced by shear forces and mediated 
by vWF, is an aspirin-resistant process (116). Can these mechanisms explain some aspirin 
failures in preventing arterial thrombosis in the antiphospholipid syndrome (117,118)? Should 
we consider antioxidant administration combined with antiplatelet or anticoagulant therapy? 
Thrombosis may recur also after oral anticoagulation (118,119) and although this may depend 
on the level of anticoagulation achieved (120) some of the presented coagulation anomalies 
could be involved. The extent of coronary atherosclerosis is affected by steroid treatment in 
patients with SLE (7). Does this imply that steroids may affect oxidation processes? Specific 
studies in the field of membrane and protein oxidation/peroxidation with respect to 
antiphospholipid antibodies may help elucidate the pathogenesis of premature thrombosis and 
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atherosclerosis in the ’membrane stress syndrome’ and may suggest new mechanisms 
amenable to therapeutic intervention. 
 
 
20 
 
CHAPTER III 
METHODS 
Blood sampling. 
Blood samples were almost always obtained between 8.00 and 9.00 a.m. after an overnight 
fast and a resting period of 20 minutes. Blood samples for clotting assays were collected by 
clean venepuncture of an antecubital vein in plastic tubes containing 1/10 volume of 0.129 
trisodium citrate. Blood samples for basal PAI and for pre and post occlusion tPA (after 10 
minutes of application of the cuff of a sphigmomanometer midway between the systolic and 
diastolic pressure of the patient) were drawn in similar plastic tubes containing 1/10 volume 
of 0.129 M trisodium citrate to which  theofilline 0.9 mM and prostaglandin E1 1g/ml were 
added to minimize platelet activation.   
After centrifuging at 2000 x g for 10 min at 4°C and aliquots of platelet poor plasma (PPP) 
were stored at -70°C for all determinations, the residual being spun twice at 10000 x g for 5 
min at 4°C to obtain platelet free plasma (PFP). Control pooled PFP was obtained from 54 
healthy hospital personnel (30F, 24M, mean age 3218 yrs). This was aliquoted and frozen at 
-70°C. Blood samples for serum preparation was collected into glass tubes, allowed to clot for 
2 hours at room temperature and spun at 1000 x g for 10 minutes. They were stores as per 
plasma samples.  
Antiphospholipid antibody assays 
PFP for LA assays was processed immediately. LA was screeend by 1) activated partial 
thromboplastin time (aPTT) using rabbit phospholipid-kaolin (Diamed, Switzerland) 2) 
Kaolin clotting time (KCT) according to the method of Exner (11), 3) dilute Russell’s venom 
viper time (DRVVT) after the method of Thiagarjan (1). A clotting time ratio between sample 
and control plasma >1.2 for the aPTT and >1.18 for the DRVVT and >1.3 for the KCT 
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indicated an abnormal result. In any of the assays, a clotting time of a 1:1 mixture of sample 
and pooled control plasma greater than that of the control plasma alone indicated the presence 
of an inhibitor whose lupus nature was confirmed by the platelet neutralisation procedure 
(PNP) according to the original method of Triplett (2) and by high phospholipid 
concentrations according to Rosove (3). Serum IgG aCL were measured by a commercially 
available ELISA assay (Melisa system, Byk Goulden, Italy). A normal range was established  
using the same 54 healthy hospital personnel as stated above, with the cutoff of 5GPL U/ml 
being 5 standard errors above the geometrical mean (4.1; SEM:0.2; 95% CI 3.7 to 4.5). Titres 
between 5-20 GPL were considered low positive, between 21-80 GPL medium positive and 
over 80 GPL high positive. IgG 2GPI were measured by an immunoassay from Corgenix, 
Westminster, USA. A cut-off for positivity was established in 120 healthy controls at 20 
units. Inter and intra-assay coefficient of variability were 4.1% and 3% respectively.  
ELISA for oxLDL–β2GPI complexes 
Capture anti-β2GPI mAb, WB-CAL-1, was adsorbed on a microtitre plate (Immulon 2HB, 
Dynex Technologies, Inc., Chantily, VA, USA) by incubating at 8 µg/ml (dissolved in Hepes 
buffer, 50µl/well) at 4°C overnight. The plate was blocked with 1% skim milk for 1 h. Serum 
samples (100-fold diluted) were added to the wells (100µl/well) and incubated for 2 h. The 
wells were subsequently incubated with biotinyl-anti-ApoB-100 antibody (1D2) for 1 h and 
HRP-labelled avidin for 30 min. Colour was developed with o-phenylenediamine and H2O2. 
The reaction was terminated by 2N sulphuric acid, and the OD at 490 nm was measured. 
Between each step, extensive washing was performed using Hepes buffer containing 0.05% 
Tween-20. The mean OD of blank wells corrected the raw OD of samples in individual 
assays. When 1.0 U/ml was adjusted to 3 S.D. above the mean of serum samples from 50 
normal subjects, 1.0U/ml of the oxLDLβ2GPI complex was equilibrated to 4.5 g/ml of ApoB 
equivalent. A sample was considered positive when its reactivity was >1.0 U/ml. 
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ELISA for CRP-oxLDL-β2GPI complexes 
Capture anti- β2GPI mAb, WB-CAL-1, was adsorbed onto microtitre plates (Immulon 
2HB; Thermo Labsystems) by incubating at 8 µg/ml (dissolved in Hepes buffer, 50µl/well) at 
4°C overnight. After blocking with 10 mM Tris, 150 mM NaCl, 1.25 mM CaCl2, pH7.4, (Tris 
buffer) containing 0.5% BSA, samples diluted 1:100 with Tris buffer containing 0.2% BSA 
were added to each well and incubated for 2 h. The wells were subsequently incubated with 
HRP-labelled anti-CRP antibodies for 1 h. Extensive washing between steps was performed 
with Tris buffer containing 0.05% Tween-20. Further steps were performed as described 
above for oxLDL–β2GPI complexes. 
Plasma fibrinogen and thrombin time 
Plasma fibrinogen was measured by the a clotting assay (Mascia Brunelli, Italy) according 
to Clauss (4) with a CV of 4.2 %. Thrombin times (Bovine thrombin, Boehringer Mannheim, 
Germany) were performed in duplicate at the same time of the fibrinogen assays.  
Plasma fibronectin  
Plasma fibronectin was measured by nephelometry (Boehringer Mannheim, Germany). 
Von Willebrand factor  
Plasma vWF antigen was assayed by an Elisa method (Boehringer Mannheim, Germany). 
Inter and intra-assay CV for vWF were 3.2% and 4.4% respectively. A normality range 
between 60 and 150 IU/dl for vWF was determined in 54 healthy subjects.  
Natural anticoagulants 
Antithrombin and protein C were measured by amidolytic and immunoassays (Behring, 
Marburg, France) whereas total protein S by immunoassay only (Elisa, Diagnostica Stago, 
Asnieres, France). Free protein S was measured by a double monoclonal ELISA (Diagnostica 
Stago, Asnieres, France). Pooled normal plasma from 65 normal donors served as control 
plasma for PS. Results are expressed as percent of normal. 
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Markers of coagulation activation 
Plasma levels of F1+2, TAT, markers of thrombin generation and D-Dimer were 
measured by ELISA (Enzygnost TAT and Enzygnost F1+2, Behring Corp., Marburg, 
Germany and  Innotest D-Dimer Byk-Sangtec Diagnostica, Dietzenbach, Germany). 
Factor XIII  
Factor XIII was measured  by a photometric assay (Behring, Germany). The assay is 
based on the activation of FXIII present in a sample by exogenous thrombin: activated FXIII 
links a specific peptide substrate with glycine ethyl ester that releases ammonia in the reaction 
with NADH to yield NAD. The variable measured is the decrease in NADH monitored at 340 
nm. A reference range was derived from pooled normal plasma of 30 healthy blood donors. 
Results are expressed as percentage from the reference curve established using serial dilutions 
of pooled plasma. The interassay CV (n=15) was 3.6%.  
Markers of fibrinolysis 
TPA antigen and PAI antigen (as a surrogate of PAI activity) were measured by ELISA 
(Innotest D-Dimer, Innotest t-PA, Innotest PAI, Byk-Sangtec Diagnostica, Dietzenbach, 
Germany). Post occlusion values of tPA were corrected for haemo-concentration according to 
the formula F=Ht1 (1-0.9 x Ht2)/Ht2 (1-0.9 x Ht1). All clotting assays were performed on a 
KC4 Amelung coagulometer (Amelung, Austria) whereas all immunoassays were read on a 
standard microplate reader. 
Vasoactive molecules and oxidative stress markers  
Endothelin-1 was measured by Elisa (R&D Systems, Oxon, UK) following extraction 
from 1 ml of plasma samples using C18 columns (Nichols Institute Diagnostics, San Juan 
Capistrano, CA) according to the manufacturer instructions. Urinary 11-dehydro-
thromboxane B2 was extracted then measured by a competitive EIA according to the 
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manufacturer instructions (Cayman Chemical, MI, USA). F2-isoprostanes were measured by 
gas chromatography followed by mass-spectrometry (5).  
Inflammatory markers 
High sensitivity C-reactive protein (Biosupply Ltd, Bradford, UK) and serum amyloid A 
(Europa Bioproducts, Ely, UK) were measured by immunoassay.  
Immune activation markers  
Neopterin (Biosupply Ltd, Bradford, UK) and soluble CD14 (R&D Systems, Abingdon, 
UK) were measured by immunoassay. 
Nitric oxide metabolites: nitrate, nitrite and nitrotyrosine  
Nitrate (NO3
-
) and nitrite (NO2
-
) were determined using the Griess reaction. Serum was 
diluted 1:4 with PBS (pH 7.4), and 200 µl of this solution was ultrafiltered by centrifugation 
at 10 000 g for 1 h, using 10 kDa molecular weight filters (Ultrafree-MC; Millipore). Only 
clear and colourless filtrates were tested. The assay was performed in standard flat-bottomed 
96-well polystyrene microtitre plates containing 50 µl/well of standard or sample. The assay 
was blanked against PBS. To each well were added 4 µl of nitrate reductase and 10 µl 
NADPH giving final concentrations of 6.3 U/l and 550µmol/l respectively. Plates were 
incubated at room temperature for 2 hours. NO concentration was then determined by the 
addition of 65 µl of Griess reagent 1 and 2 to each well except to blanks, and after 10 min 
incubation at room temperature the absorbance was read at 540 nm. Nitrotyrosine was 
measured by enzyme linked immune assays (HyCult Biotechnology, Uden, Netherlands).  
Other 
Cholesterol, HDL, LDL, ApoAI, ApoB and creatinine were laboratory grade 
measurements. 
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Gene polymorphisms 
Factor V A506G, MTHFR C677T and PT20210  mutations were determined by 
polymerase chain reaction. 
Imaging  
Deep vein thrombosis was diagnosed by Doppler ultrasound, pulmonary embolism by 
perfusional scintiscanning or computed tomography angiography; ischaemic stroke by CT 
scan and/or MRI; myocardial infarction by ECG and serial changes in cardiac enzymes; other 
arterial occlusions were diagnosed by arteriography according to the occlusion site. 
Measurement of intima media of carotid arteries 
High resolution ultrasound of the carotid arteries was performed by an Aloka 2000 
sonograph (Aloka Co Ltd, Tokyo, Japan) equipped with a 5–10 MHz linear transducer. The 
image acquisition followed the Atherosclerosis Risk in Communities Study protocol [12]. 
Transverse and longitudinal views of the far wall of the right and left common carotid (CC) 
arteries (10 mm distal to the carotid bifurcation), right and left carotid bifurcation (B) and 
internal carotid (IC) arteries were taken with the patient in the supine position with their neck 
slightly extended. The means of three measurements taken 1 cm apart at the three different 
sites were computed for each region. For the purpose of statistical analysis, right and left 
measurements were averaged. A plaque was defined as a focal thickening greater than 1.2 
mm. Intra-reader reproducibility was assessed in two ways. First, the same carotid 
measurement was performed twice on 20 individuals yielding a coefficient of agreement of 
almost 97%. Second, the same IMT measurements were performed six times on one 
individual over a 2-month period, yielding a coefficient of variability between 4–5% 
according to carotid segment under study. 
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CHAPTER IV 
ANTIPHOSPHOLIPID ANTIBODIES, COAGULATION, 
FIBRINOLYSIS AND THROMBOSIS 
INTRODUCTION 
Ischaemic stroke (IS) and myocardial infarction (MI) represent the major vascular 
complications of atherosclerosis and are the leading causes of morbidity and mortality in the 
western countries: at a reduced scale they represent also the leading cause of morbidity and 
mortality in the APS. The coagulation and fibrinolytic systems are deeply involved in the 
development of thrombosis and atherosclerosis because they determine the rate of fibrin and 
D-dimer that is turned over on a daily basis; their activity is finely tuned so that very minor 
amounts of fibrin generated prevent bleeding from vessel trauma, but at maximal coagulation 
activation excess fibrin formation may generate an embolic or thrombotic occlusion. Over a 
lifetime different rates of fibrin turnover between these two extremes, dictated by different 
plasma concentrations and activities of several coagulation and fibrinolytic proteins including 
FNG, vWF and PAI may account for the development of atherosclerosis. 
Haemostatic variables and atherothrombosis 
FNG is the most abundant plasma coagulation factor and behaves as an acute phase 
reactant: it is synthesised in the liver under the control of three different genes coding for 
three non identical polypeptide chains (,  and ) linked together by disulphide bonds, that 
allow the assembly of FNG in two symmetrical halves. Under the action of thrombin FNG 
polymerises into fibrin that is covalently cross-linked by factor XIII. FNG is present in 
fibrous and atherosclerotic plaques, its plasma concentration is a major determinant of plasma 
viscosity, of platelet aggregation and of endothelial cell injury, factors that are central to 
thrombosis and atherosclerosis. The Northwick Park Heart Study showed that one standard 
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deviation elevation in plasma FNG was associated with an 84% increased risk of an episode 
of ischaemic heart disease within 5 years (1).  Epidemiological evidence has clearly linked 
high plasma FNG concentrations with the risk of cardiovascular and cerebrovascular disease 
(reviewed in 2).   
vWF is a multimeric glycoprotein circulating in plasma in association with factor VIII, it 
is synthesized constitutively in endothelial cells (in the Weibel-Palade bodies) and in 
megakaryocytes (α-granules of platelets) and its main function is to mediate platelet adhesion 
between themselves and to endothelial cells. Plasma vWF concentration increases after 
endothelial activation or injury favouring thus platelet activation: epidemiological studies 
have ranked vWF as a strong predictor of IS, MI and deep vein thrombosis (DVT) (3). 
Tissue type plasminogen activator (t-PA) and inhibitors such as PAI and α2-antiplasmin 
maintain the balance of the intravascular fibrinolytic activity. Mainly of endothelial cell origin 
t-PA and PAI belong to the serine protease inhibitor super-family and they are necessary to 
prevent excessive fibrin formation and deposition. Population based surveys have highlighted 
their association with IS, MI and atherosclerosis (4-6). Factor XIII (FXIII) is a 
transglutaminase of endothelial origin that cross-links fibrin with itself and with the 
endothelial matrix and is implicated in thrombosis and atherosclerosis (7).  
Haemostatic variables and thrombosis in PAPS 
The association between aPL and thrombosis is widely recognized regardless of the 
underlying disorders associated with the presence and persistence of aPL (8). The 
pathogenesis of vascular occlusion in APS is multi factorial: depressed fibrinolysis and 
interference with the natural anticoagulant systems leads to excess thrombin generation that 
may explain the susceptibility to venous thrombosis. In addition, the joint effect of unopposed 
thrombin generation on thromboxane production via platelet activation and of reduced 
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prostacyclin released from endothelial may explain the susceptibility to arterial thrombosis 
(9).  
Increased plasma levels of FNG and vWF have been reported in APS (10-12), though their 
relationship with type of vascular occlusion is poorly known. Persistent thrombin generation 
has been demonstrated in thrombotic and non thrombotic aPL positive patients with SLE (12) 
in relation to free protein S (f-PS) deficiency (12) underlining an association between aPL and 
a prothrombotic state, eventually mediated by low f-PS (12). The effect of aPLs on the 
fibrinolytic system has been investigated mostly in autoimmune diseases with aPL, with 
controversial results, probably due to the small size of the cohorts and of the heterogeneity of 
the patients studied (13-45) and the contributory role of factor XIII to the hypercoagulable 
state of APS has never been explored.  
To test the hypothesis that aPL, coagulation and fibrinolysis markers related to thrombosis 
subtype in APS, three different studies were carried out: the first assessed the role of FNG and 
vWF, the second the role of coagulation activation and fibrinolysis markers and the third the 
possible role of factor XIII. 
EXPERIMENTAL DATA 
1) ANTIPHOSPHOLIPID ANTIBODIES, FIBRINOGEN, VON WILLEBRAND 
FACTOR AND THROMBOSIS 
This study was carried out on 144 consecutive patients (103F, 41M, mean age 35±14 
years) found positive on two separate occasions three months apart. They were evaluated 
because of a history of thrombosis, for diseases known to be associated with the presence of 
aPL and/or for coagulation anomalies suggesting the presence of a lupus anticoagulant (LA). 
To maintain the focus of the study on the prevalence of arterial and venous thrombosis and its 
relationship with haemostatic variables, women with miscarriages (with or without 
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thrombosis) or with a obstetric history linked to aPL were excluded as they were likely to act 
as confounders.   
APL was detected in 56 (39%) patients with autoimmune thrombocytopaenic purpura 
(ATP) (diagnosed according the American Society of Haematology Criteria) (16), in 43 
(30%) patients with SLE (diagnosed according the American Rheumatism Association 
Criteria (17) and in 45 (31%) patients with no underlying disorder (NUD) (Table 1). The 
methods for diagnosing deep vein thrombosis, pulmonary embolism, ischemic stroke and 
pulmonary embolism as well as the assays for the detection of plasma FNG, vWF, IgG aCL 
and LA are described in the methods chapter.  
Table 1. Demographics. 
 ATP SLE NUD 
Patients (No) 56 43 45 
Female/male 44/12 37/6 22/23 
Age (yrs) (mean±SD) 37±14 29±10 38±15 
Thrombotic patients (No/%) 5 (9) 12 (28) 29 64) 
ATP: autoimmune thrombocytopaenic purpura; SLE: systemic lupus 
erythematosus; NUD: no underlying disorder.  
RESULTS 
Prevalence of lupus anticoagulant and IgG aCL 
At least one LA test was positive in 125 (86%) patients: aPTT in 51 (40%), KCT in 98 
(78%) and DRVVT in 45 (36%). All LA were confirmed by a phospholipid neutralisation 
method. In particular PNP confirmed 43 (83%) aPTTs and 38 (72%) DRVVTs, whereas high 
phospholipid concentration confirmed 59 (62%) KCTs. A total of 126 (87%) patients 
presented with positive levels of IgG aCL, 67 (53%) in the low range, 40 (31%) in the 
medium range and 19 (15%) in the high range. A concordance between IgG aCL and LA was 
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found in 109 (75%) patients: 17 (13%) LA positive patients were IgG aCL negative and 18 
(14%) IgG aCL positive patients were LA negative. 
Prevalence of thrombotic patients according to disease subgroup 
A history of single or multiple vascular occlusions was present in 46/144 (32%) of 
patients (25 females, 21 males). Arterial thrombosis occurred in 12 patients (8%), venous 
thrombosis in 28 (19%) patients and both events in 6 (4%) patients. The prevalence of 
patients with a history of thrombosis was higher in the group with no underlying disorder 
(NUD) 64%, than in the groups with SLE, 28% and ATP 9% (p<0.0001). Of the occlusive 
events (n=76), deep vein thrombosis was the most common, 36 (47%) followed by ischaemic 
stroke 18 (23%) and pulmonary embolism 9 (11%) (Table 2). 
Table 2. Details of vascular occlusions  
 ATP SLE NUD 
Venous occlusions    
Lower limb 5 11 20 
Upper limb  1 2 
Mesenteric   2 
Pulmonary embolism   9 
    
Arterial occlusions    
Ischaemic stroke 2 3 13 
Myocardial infarction 1  1 
Lower limb   3 
Mesenteric   1 
Splenic   1 
Renal   1 
ATP: autoimmune thrombocytopaenic purpura; SLE: systemic 
lupus erythematosus; NUD: no underlying disorder.  
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Relationship between antiphospholipid assays and thrombosis 
Amongst the aPL assays, aPTT and DRVVT correlated to a history of thrombosis (p=0.01 
and p<0.0001 respectively) whereas IgG aCL did not (Table 3A). Considering separately 
arterial and venous thrombosis DRVVT and aPTT both correlated to a history of venous 
thrombosis (p=0.0002 and p=0.009 respectively) but only DRVVT correlated with a history 
of arterial thrombosis (p=0.01) (Table 3B).  
Table 3A. Relationship between antiphospholipid assays and any thrombosis. 
  Thrombosis OR 95% CI p-value 
  + -    
aPTT + 23 28 2.50 1.21, 5.17 0.01 
 - 23 70    
       
KCT + 28 70 0.62 0.3, 1.30 0.2 
 - 18 28    
       
DRVVT + 28 17 7.41 3.36, 16.34 <0.0001 
 - 18 81    
       
IgG aCL + 44 82 4.29 0.94, 19.53 0.057 
 - 2 16    
Table 3B. Relationship between antiphospholipid assays and thrombosis subtype. 
  Thrombosis OR 95% CI p-value 
  Arterial    
  + -    
aPTT + 10 10 1.95 0.75, 5.06 0.2 
 - 42 82    
       
DRVVT + 13 11 3.21 1.32, 7.96 0.01 
 - 32 88    
       
  Venous    
aPTT + 18 14 2.95 1.31, 6.60 0.01 
 - 34 78    
       
DRVVT + 20 12 5.51 2.38, 12.76 <0.0001 
 - 26 86    
 
 
 
 
32 
 
Relationship between IgG aCL and thrombosis 
Sixteen patients (24%) in the low IgG aCL range, 14 (35%) in the medium IgG aCL range 
and 14 (73%) in the high IgG aCL range underwent at least one thrombotic episode. A higher 
mean IgG aCL was found in patients who suffered thrombosis than in those who did not 
(p<0.0001, Table 4). 
Table 4. Geometrical means of FNG, vWF and  IgG aCL according to type and number of thromboses 
      
Any thrombosis Number of occlusions p-value# 
 0 1 2 3+  
 (n=98) (n=26) (n=14) (n=6)  
FNG mg/dl 270 364 422 505 <0.0001 
vWF IU/dl 98 147 143 191 <0.0001 
IgG aCL GPL 15 25 42 124 <0.0001 
      
Venous thrombosis Number of occlusions p-value# 
 0 1 2 3+  
 (n=110) (n=22) (n=8) (n=4)  
FNG mg/dl 284 389 375 387 <0.0001 
vWF IU/dl 102 154 140 183 <0.0001 
IgG aCL GPL 15 32 53 131 0.0001 
      
Arterial thrombosis Number of occlusions p-value# 
 0 1 2   
 (n=125) (n=12) (n=6)   
FNG mg/dl 289 376 665  <0.0001 
vWF IU/dl 108 136 176  0.002 
IgG aCL GPL 18 46 32  0.01 
# p-value for testing mean where no event vs mean where at least one event. All 
variables analysed on log scale, FNG: fibrinogen; vWF: Von Willebrand factor; 
aCL: anticardiolipin antibody.  
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Relationship between von Willebrand factor and thrombosis 
Plasma levels of vWF were <60 IU/dl in 17 (12%) patients, between 61 and 150 IU/dl in 
95 (66%) patients and >150 IU/dl in 32 (22%) patients. Two patients (12%) at vWF <60 
IU/dl, 19 (20%) patients at vWF between 61-150 IU/dl and 25 (78%) patients at vWF 
>150IU/dl experienced at least one thrombotic episode. Significantly higher plasma levels of 
vWF were found in thrombotic than non thrombotic patients (p<0.0001, Table 4). Mean vWF 
was significantly higher in aPL positive thrombotic patients than in a control group of aPL 
negative thrombotic patients with inherited thrombophilia [151 (7.9) vs 121 (4.7), p<0.0001]. 
Relationship between fibrinogen and thrombosis 
Plasma levels of FNG were <300 mg/dl in 75 (52%) patients, between 301-400 mg/dl in 
40 (28%) patients, between 401-500 mg/dl in 19 (13%) patients and >500 mg/dl in 10 (7%). 
Seven (9%) patients at the lowest FNG level, 18 (45%) patients at FNG between 301-400 
mg/dl, 13 (68%) at FNG between 401-500 mg/dl, and 8 (80%) patients at FNG >500 mg/dl 
experienced at least one thrombotic episode (Table 4). Mean FNG in aPL positive thrombotic 
patients was significantly higher than that of aPL negative thrombotic patients [397(18.9) vs 
305 (9.7), p<0.0001)]. 
Regression analysis of FNG, vWF and IgG aCL with thrombotic events 
Two possibilities were considered. 1) That the occurrence of the first event was 
qualitatively different from the occurrence of subsequent events and that this manifested in 
differential rates of change in outcome at the first and subsequent events. 2) That the rate of 
change for the first event was the same as for subsequent events. These hypotheses were 
tested simultaneously and estimates are presented only for those parameters for which 
significant evidence was found of non-zero effect. Data were analysed according to the 
groups presented in Table 5: values of IgG aCL, FNG and vWF in patients with 0,1,2 or 3 
thrombotic events were entered in the regression model.  
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Table 5. Regression analysis of FNG, vWF, and IgG aCL versus numbers of events after adjustment 
for any confounding effect of age, sex or group (ATP, SLE, NUD) as required 
Event 
type 
Variable 
Confounders 
p-value 
Mean % 
increase for 
1
st
 event (95% 
IC) 
p-value 
Mean % 
increase for 
subsequent 
events 
(95% IC) 
p-
value 
All events FNG 
Age             
0.0003 
35% (21, 50) 0.02 11% (2, 20) 0.0016 
 VWF 
Age                 
0.04 
50% (31, 72) 0.001   
 IgG aCL 
Sex                 
0.03 
  54% (24, 90) 0.04 
  
Group         
0.0001 
    
       
Venous FNG 
Age             
0.0002 
27% (12, 43) 0.001   
 VWF 
Age               
0.004 
40% (20, 66) 0.001   
 IgG aCL 
Sex                  
0.02 
  58% (23, 102) 0.001 
  
Group         
0.0001 
    
       
Arterial FNG 
Age             
0.0004 
  37% (34, 51) 0.001 
 VWF 
Age              
0.007 
  18% (1, 37) 0.002 
 IgG aCL 
Sex              
0.003 
64% 8, 192) 0.02   
  
Group        
0.0001 
    
ATP: autoimmune thrombocytopaenic purpura; SLE: systemic lupus erythematosus; NUD: no 
underlying disorder; FNG: fibrinogen; vWF: Von Willebrand factor; aCL: anticardiolipin antibody 
In respect of total events FNG rose by an average of 38% (95% CI; 24%, 54%) on 
occurrence of the first event and by about 10% per event thereafter. By contrast vWF rose by 
about 54% (95% CI; 34%, 75%) at the first event and was unchanged thereafter whether or 
not subsequent events occurred, whilst IgG aCL rose by 75% (44%, 112%) per event 
throughout. When analysed for the number of venous events, FNG rose by 36% (95% CI; 
21%, 53%) and vWF by 50% (95% CI; 29%, 75%) at the first venous event and remained 
unchanged thereafter. With respect to arterial events, FNG rose by 45% (95% CI; 31%, 60%) 
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per arterial event and vWF by 27% (95% CI; 10%, 47%) per arterial event throughout. IgG 
aCL rose by 131% (95% CI; 28%, 320%) at first arterial event and remained constant 
thereafter. After adjustment for confounders (age, sex and group) results were relatively 
unchanged though actual estimates were somewhat diminished (Table 5). 
Relationships amongst IgG aCL, vWF and FNG 
Significant correlations were noted between IgG aCL and vWF (r=0.42, p<0.0001), IgG 
aCL and FNG (r=0.23, p=0.005) and between vWF and FNG (r=0.48, p<0.0001).  
Natural anticoagulant measurements   
Reduced plasma levels of protein C antigen (55%; NV 70-120%) and total protein S 
(58%; 70-120%) were found in two patients: both experienced thrombosis. Values were 
substantially unchanged (53% for protein C and 62% for protein S) of further testing six 
months later. Family members were unaffected by the defect. Thrombin times and plasma 
levels of AT were normal in all patients. 
2) ANTIPHOSPHOLIPID ANTIBODIES, THROMBIN GENERATION AND 
FIBRINOLYSIS  
This study was carried out on 18 patients with thrombotic PAPS (8M, 10F mean age 
37±13), 18 non thrombotic persistent carriers of aPL with no underlying disease (7M, 11F, 
mean age 38 years) and on 20 hospital personnel (9M, 11 F mean age 36±11) as a healthy 
control group. To validate thrombin generation markers in the PAPS group we also employed 
patients with inherited thrombophilia (juvenile ischaemic stroke IS n=8, unexplained deep 
vein thrombosis n=7, deep vein thrombosis secondary to protein C deficiency n=3) without 
aPL. Information regarding smoking status, hypertension, alcohol intake, hypertension, 
menopause and contraceptive use was obtained from all participants (Table 6). 
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Table 6. Demographics 
 CTR APL PAPS 
Subjects 20 18 18 
Sex (F/M) 11/9 11/7 10/8 
Age years (mean±SD) 36±11 39±12 37±13 
IgG aCL <20 GPL - 6 4 
IgG aCL   20-80 GPL - 6 4 
IgG aCL >80 GPL - 2 9 
LA only - 4 1 
Smokers 1 1 1 
Hypertensive 0 1 1 
Menopausal 1 1 1 
CTR: control; APL: antiphospholipid positive without thrombosis; 
PAPS: primary antiphospholipid syndrome; aCL: anticardiolipin; LA: 
lupus anticoagulant.  
Antiphospholipid status of patients 
None of the subjects in the control group had a positive level of IgG aCL or a positive LA 
test. In the aPL group (n=18), 4 subjects (22%) had a confirmed LA only, 6 (33%) had low 
positive IgG aCL, 6 (33%) had medium levels of IgG aCL, and 2 (11%) had high levels IgG 
aCL. All IgG aCL positive subjects had at least one positive confirmatory LA test. In the 
PAPS group (n=18), 1 patient (5.5%) had a confirmed LA (negative  aCL), 4 (22.2%) had low 
positive IgG aCL (matched in all cases by a confirmed LA), 4 (27.7%) had medium positive 
IgG aCL (matched in two cases by a confirmed LA), the remaining 9 (44.4%) had high 
positive IgG aCL (matched in all cases by confirmed LA). PAPS patients presented higher 
geometrical mean levels of IgG aCL than non thrombotics (86.623 vs 38.713 GPL, 
p=0.03). Of the PAPS patients, 6 underwent arterial occlusions (6 F), 3 arterial and venous 
occlusions (1F) and 9 venous occlusions.  
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Comparison of coagulation activation markers between patients and controls 
In the aPL groups, measurements of  F1+2, TAT and D-D made two months apart were 
highly correlated (r=0.89, r= 0.79 and r=0.81 respectively, p always <0.0001). Mean F1+2 
and D-D were significantly higher in PAPS and aPL subjects than in controls whereas those 
of TAT did not differ (Table 7). A weak correlation between mean F1+2 and D-D in the 
PAPS group was noted (r=0.46, p=0.052). Mean D-D (20743 ng/ml) and F1+2 (1.080.15 
nmol/L) of PAPS patients were similar to those of thrombotic patients for reasons other than 
aPL (18124.4 ng/ml and 1.040.13 nmol/L respectively). 
Table 7. Thrombin generation markers, D-dimer and fibronectin across study groups 
 CTR APL PAPS p-value 
Subjects (No) 20 18 18  
F1+2  (nM) 0.6±0.05 1.08±0.07 1.08±0.15 0.006 
TAT    (ng/ml) 3.03±0.43 2.8±0.17 2.5±0.18 NS 
D-D     (ng/ml) 59.7±4.42 109±14.6 207±43.5 <0.0001 
FNT    (mg/dl) 30±0.76 28.1±0.91 26±0.89 0.001 
f-PS     (%) 103±3.15 84±4.9 85.3±3.45 0.0006 
CTR: controls; aPL: persistent positive aPL without thrombosis; PAPS; primary 
thrombotic antiphospholipid syndrome; F1+2: prothrombin fragment 1+2; TAT: 
thrombin-antithrombin complexes; D-D: D-dimer; FNT: fibronectin; f-PS: free protein S. 
 
 
However, mean TAT of PAPS patients was significantly lower than that of thrombotic 
patients for reasons other than aPL (2.50.18 vs 4.10.32 ng/ml, p<0.0001). No further 
measurements were carried out in thrombotic patients without aPL. The following data refer 
again to our aPL positive subjects. Mean PS was lower in PAPS and aPL patients than in the 
control group as well as mean FNT (Table 7). In the PAPS group mean FNT was inversely 
correlated with mean  D-D (r = -0.61 p=0.007)  
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Comparison of fibrinolysis markers between patients and controls 
Mean basal tPA was higher in PAPS (17.00.9 ng/ml, p<0.0001) and aPL subjects 
(12.20.5 ng/ml, p=0.0009) than in controls (8.81.08 ng/ml) and correlated to D-D in both 
groups (r 0.74, p=0.0004 and r 0.534, p=0.023, respectively). Mean PAI was not significantly 
different. Gender analysed data revealed impaired tPA release in PAPS females (from 
16.80.7 to 21.33.9 ng/ml, NS) but not in PAPS males (from 18.22.0 to 33.74.9 ng/ml, 
p=0.01)(Table 8). TPA release was unimpaired in aPL subjects of either sex. Females had 
higher mean PAI than males in the PAPS and aPL group (p<0.0001 and p=0.0002 
respectively) and than control females (Table 8). Having established a reference range (mean 
 2 SD) for PAI values in our 20 control subjects, elevated PAI was present in 22% (4/18, 4F) 
of aPL subjects and in 33% of PAPS patients (6/18).  Deficient tPA release (post values < pre 
values) was present in 11% (2/18, 1F, 1M) of aPL and in 40% (4/18, all F) of PAPS patients. 
Altogether, deficient tPA release and elevated PAI were present in 27% (5/18) of aPL 
subjects (one patient with both defects) but in 55% (10/18) of PAPS patients (4 patients with 
both defects).  
Relationship between free PS, thrombin generation and fibrinolysis defects.  
By determining a reference range for f-PS (102.920%, mean2SD), 50% (9/18) of PAPS 
and 33% (6/18) of aPL subjects had abnormally low levels of f-PS. In both groups, patients 
with low f-PS generated more F1+2 than patients with normal f-PS (1.40.28 vs 0.70.08 
nmol/L, p=0.01 and 1.30.12 vs 0.90.08 nmol/L, p=0.02 respectively). Low f-PS associated 
with fibrinolysis defects in PAPS (90%, 9/10 vs 12.5%, 1/8, p<0.01) and in aPL patients 
(100%, 5/5 vs 7.7%, 1/13, p<0.005). In PAPS, low f-PS was found in 4 patients with elevated 
PAI, in 2 patients with elevated PAI combined with defective tPA release and in 3 patients 
with defective tPA release. In aPL low f-PS was found in 3 subjects with elevated PAI, in 1 
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subject with elevated PAI combined with defective tPA release, in 1 subject with defective 
tPA release and as an isolated finding in 1 case. 
Table 8. Gender analysed fibrinolytic markers across study groups. 
  CTR APL p-value PAPS p-value 
Subjects (M/F)  9/11 7/11  8/10  
       
tPA pre (ng/ml) M 10.8±1.6 12.5±1.1 NS 18.2±2.0 0.01 
tPA post (ng/ml) M 13.8±1.7 19.0±1.7 0.01 33.7±4.9 0.0004 
     P=0.01  
       
tPA pre (ng/ml) F 6.3±0.7 12.1±0.7 <0.0001 17.0±0.9 <0.0001 
tPA post (ng/ml) F 9.5±0.6 21.4±1.7 0.0001 21.3±3.9 0.0003 
     NS  
       
PAI (ng/ml) M 35.8±6.0 24.5±3.0 0.007 23.4±2.9 0.003 
PAI (ng/ml) F 30.4±4.0 42.0±2.2 0.02 64.0±8.2 0.002 
   p=0.0002  p<0.0001  
CTR: controls; aPL: persistent positive aPL (without thrombosis); PAPS; primary 
thrombotic antiphospholipid syndrome; tPA: tissue plasminogen activator; PAI: plasminogen 
activator inhibitor 
3) ANTIPHOSPHOLIPID ANTIBODIES, FACTOR XIII AND FIBRINOLYSIS 
Patients 
The study was carried out on 99 consecutive patients, of whom  29 had thrombotic PAPS 
(22F, 7M, mean age 3510 years), 14 (11F, 3M, mean age 3410 years) were persistent 
carriers of idiopathic aPL in the absence of any underlying disorder and 24 (16F, 8M, mean 
age 368 years) were patients who suffered thrombosis for inherited thrombophilia (IT) 
(Factor V Leiden n=12, prothrombin n=10, protein C deficiency n=2) and not aPL  All 
thrombotic PAPS patients met the Sapporo Revised criteria (1). Twenty two PAPS patients 
suffered venous events (2 events in 5 patients, 3 events in 1 patient), 4 suffered arterial events 
(2 events in 3 patients) and 3 suffered events in both arterial and venous districts. In the IT 
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group, 20 underwent venous thrombosis (5 patients with 2 events) and 4 arterial thromboses. 
Patients with idiopathic aPL were detected because of the presence of a lupus anticoagulant 
on routine clotting screen for minor surgical procedures and/or for health checks and 
clinically never suffered any manifestation of APS. At the time of the study, 25 primary APS 
patients were on warfarin with an INR between 2.0-3.0 and four had an INR between 3.0-4.0. 
In the aPL group 3 were on aspirin, whereas all patients in the inherited thrombophilia group 
were on warfarin within an INR 2.0-3.0. To control for a possible effect of warfarin on FXIIIa 
in a non-thrombotic group, FXIIIa was also measured in 32 patients (18F, 14M, mean age 
4915 years) taking warfarin for valve replacements (mitral n=16, aortic n=16). At the time of 
FXIIIa determination patients with mitral valve replacement had an INR between 3.0-4.0 and 
those with aortic valve replacement had an INR between 2.0-3.0. Healthy hospital personnel 
(n=28, 18F, 10M, mean age 349 years) served as a control group. None of the participants 
were on lipid lowering agents or drugs with anti-oxidant properties at the time of the study. 
RESULTS 
Factor XIIIa and other variables across groups.  
To assess the persistence of activated FXIII, this was re-measured after three months in 15 
primary APS patients yielding a coefficient of correlation r=0.91 (p=<0.0001) and in 15 
thrombotic controls yielding a coefficient of correlation r=0.89 (p<0.0001). The proportion of 
patients with FXIIIa above the mean+2SD of normal controls was 38% (11/29) in PAPS, 7% 
(1/14) in aPL, 16.6% (4/24) in IT, 12.5% (4/32) in valvular controls and 3.5% (1/28) in 
normal controls (p=0.006). Because FXIIIa could be influenced by the intake of warfarin (14), 
FXIIIa was also measured in non- thrombotic valvular controls at different INR intensities, 
though no differences were detected, as FXIIIa was 10624% in those with INR 2.0-3.0 
(n=16) and 11022% in those with INR 3.0-4.0 (n=16). Thus the valvular control group 
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consisted of all 32 patients. Median FXIIIa was increased in PAPS than other groups 
considered (Figure 1). In addition, PAPS had higher FNG and PAI than the other groups 
(Table 9). 
APS aPL T CTR V CTR N CTR
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Figure 1. Median levels of factor XIII activity (FXIIIa) in patients with primary thrombotic 
antiphospholipid syndrome (APS), idiopathic antiphospholipid antibodies (aPL), thrombotic controls 
(T CTR), valvular controls (V CTR) and normal controls (N CTR). *Analysis of variance (Kruskall-
Wallis). APS vs N CTR p<0.001, APS vs aPL p<0.05. (Dunn's Multiple Comparison Test). 
Table 9. Antiphospholipid antibodies, FNG and PAI across groups. 
 CTR IT APL 
PAPS 
 
*p-value 
IgG aCL (GPL) 
63.7 
(1.2-14) 
52.6 
(1.6-12) 
8087 
(16-309) 
159135 
(22-573) 
<0.0001 
IgG 2GPI (U) 
5.22.8 
(2.1-12) 
4.83.5 
(1.3-16) 
11961 
(40-216) 
17246 
76-226 
<0.0001 
FNG (mg/dl) 
25156 
(185-364) 
27962 
(198-405) 
28364 
(176-364) 
34253 
(209-464) 
<0.0001 
PAI (ng/ml) 
309 
(12-44) 
3815 
(20-80) 
3519 
(12-76) 
4318* 
(14-87) 
0.06 
PAPS: thrombotic primary antiphospholipid syndrome; aPL: idiopathic carriers of 
antiphospholipid antibodies; IT: inherited thrombophilia; CTR: normal controls; IgG aCL: 
anticardiolipin antibody; FNG: fibrinogen; PAI: plasminogen activator inhibitor. *Kruskall 
Wallis. APS vs N CTR p<0.05 (Dunn's post hoc). 
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Factor XIII in antiphospholipid positive groups  
Although FXIII was not significantly different between patients with arterial and venous 
occlusions (14554 vs 12538 %) in PAPS, patients with multiple events (n=12) showed a 
higher FXIIIa than those who had suffered one event only (15845 vs 11838%, p=0.02). 
FXIIIa correlated with IgG aCL both in the APS and aPL group (Figure 2A and 2B). Similar 
results were observed between FXIII and IgG a2GPI (Figure 2C and 2D).  
Furthermore, in PAPS patients FXIIIa correlated to PAI (r=0.54, p=0.003) and FNG 
(r=0.51, p=0.005). The correlation between FXIIIa and PAI was almost reflected in aPL 
patients (r=0.51, p=0.06).  
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Figure 2. Spearman rank correlations between: factor XIII activity (FXIIIa) and IgG anticardiolipin 
antibodies (aCL) in primary antiphospholipid syndrome (A) and in idiopathic carriers of 
antiphospholipid antibodies (B); FXIIIa and IgG anti-2-glycoprotein-I (2gGPI) in primary 
antiphospholipid syndrome (C) and aPL (D).  
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Factor XIII in control groups 
In the IT group, FXIIIa positively correlated with FNG (r=0.53, p=0.007) and PAI 
(r=0.04, p=0.05). None of these correlations were noted in the normal control group.  
DISCUSSION 
Thrombotic role of vWF and FNG 
Thrombosis represents the most ominous manifestation of the APS, whether occurring in 
SLE, non-SLE disorders or in otherwise healthy people (8, 18). In the present study patients 
with a history of thrombosis whether arterial or venous, were more frequent in the group with 
no underlying disorders (64%) than in SLE (28%) and ATP (9%) groups. These findings are 
in agreement with previous studies showing a thrombosis prevalence of 54% in patients with 
idiopathic aPLs (18) and with those of a major review which calculated a thrombosis 
prevalence of 25% and 28% in LA positive and IgG aCL positive SLE patients (8). LA was 
found to identify a subset of aPL patients more prone to develop thrombosis both in SLE (12) 
and non SLE disorders (19, 20). Our findings reflect this tendency since DRVVT and aPTT 
strongly correlated to a history of thrombosis (Table). However, when analysed by thrombosis 
subtype, only DRVVT correlated to a history of arterial thrombosis. Whilst IgG aCL strongly 
associated with the number of venous occlusions, its weak correlation with the number of 
arterial thromboses became non-significant after correction for confounders. A relationship 
between high aCL IgG titre and thrombosis was established in both primary and secondary 
APS (21-25) although there are still controversial issues with regards to thrombosis subtype. 
One study did not find a different prevalence of venous thrombosis between IgG aCL positive 
and negative patients (26), a nested case-control study in men revealed high IgG aCL titres to 
be a risk factor for venous but not arterial thrombosis (27) and IgG aCL did not correlate with 
ischaemic stroke in young survivors of myocardial infarction (28). In line with these reports 
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our data support a relationship between IgG aCL and venous thrombosis. Nevertheless arterial 
thrombosis is a consistent feature of the APS. Owing to the role of FNG and vWF as an 
independent risk factors for arterial thrombosis and atherogenesis (29, 30) we hypothesised 
that these two adhesive proteins could be involved in the thrombotic tendency of APS.  
Both proteins strongly correlated to the number of vascular occlusions, the differential 
relationships of FNG with arterial thrombosis and of vWF with venous thrombosis being 
favoured (Table). Also, mean plasma levels of of FNG and vWF were significantly higher in 
aPL positive thrombotics than in aPL negative thrombotic controls (Table), indicating that 
aPL might account for the difference. The in vivo correlation found between IgG and vWF in 
the present study is supported by in vitro data showing that endothelial cells exposed to IgG 
purified from APS patients release higher amounts of vWF than when exposed to IgG purified 
from controls (31). The correlation found between FNG and vWF suggests a pivotal role for 
FNG, being able as fibrin to induce endothelial changes and vWF release (32) and behaving 
as an acute phase reactant to increase its levels in response to cytokines of vascular origin 
(33).  
Impairment of fibrinolysis leading to heightened fibrin turnover 
The occurrence of thrombosis must be underlined by thrombin generation, and a known 
relationship exists between aPLs and increased thrombin generation in patients with SLE 
particularly in SLE patients with aPL related f-PS deficiency (12), a phenomenon 
demonstrated also in non-SLE patients (15, 34). Conversely, data regarding the fibrinolytic 
system in the APS are still controversial, studies revealing normal (12, 13) or abnormal (14, 
15, 35) fibrinolytic patterns. These issues were re-evaluated by measuring several coagulation 
and fibrinolytic parameters in a rare group of asymptomatic carriers of aPL (that is, subjects 
with no other anomaly than the persistence of aPL) and in thrombotic patients with PAPS. 
The conversion of prothrombin to thrombin releases the inactive prothrombin fragment F1+2 
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and newly generated thrombin is neutralised by the antithrombin-heparan sulphate (AT-HS) 
inhibitory system followed by formation of an inactive TAT complex. In this study, elevated 
F1+2 levels were present not only in PAPS patients but also in asymptomatic aPL subjects, 
and within both groups, levels were significantly higher in subjects with low f-PS, implying a 
higher rate of thrombin generation in individuals with acquired f-PS deficiency. However, 
mean TAT levels were neither different between patients and controls, nor did they match the 
elevated levels of F1+2 in the patient groups. These discrepancies, together with the higher 
mean TAT level in thrombotic patients without aPLs compared to that in PAPS patients, 
indirectly suggest a defective function of the AT-HS in subjects with aPLs, in keeping with 
the notion that binding of aPL to heparin-sulphate can prevent formation of TAT complexes 
(36) and in agreement with a report showing higher levels of TAT complexes in SLE patients 
without aPL compared to SLE patients with aPL (37). Thrombin generation leads to FNG 
polimerisation and subsequent degradation by plasmin with release of the fibrin cleavage 
product D-D, expression of fibrin turnover. Mean D-D level was elevated in thrombotic and 
to a lesser extent in non thrombotic patients, further denoting coagulation activation and 
plasmin lysis in asymptomatic carriers of aPLs. Unexpectedly, mean FNT level in the patient 
groups was lower than that of controls and inversely correlated with mean D-D in patients 
with thrombosis. This is an unreported finding which could reflect FNT incorporation into the 
fibrin network with resulting low plasma levels. On the other hand, low plasma FNT may 
adversely affect fibrin clearance by the reticulo-endothelial system allowing the persistence of 
elevated fibrin levels in plasma and/or on the vessel wall (38). Previous reports on fibrinolysis 
in the APS pointed towards a hypofibrinolytic state characterized by elevated PAI (12, 14, 15) 
a picture close to that of patients with idiopathic deep vein thrombosis (39). To overcome the 
inflammatory background of SLE or other autoimmune disorders which could influence the 
acute phase nature of PAI (40), the present study was carried out in subjects with idiopathic 
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aPLs. The higher mean basal tPA levels found in patients compared to controls, their within 
group correlation with D-D and the lack of differences in PAI levels apparently suggested a 
normo-functioning fibrinolytic system. However, gender analyzed data revealed that 
thrombotic females had blunted tPA release and higher mean level of PAI than thrombotic 
males and control females. Whether these abnormalities are due to the presence of aPL or to 
thrombosis per se remains unsettled, although epidemiological surveys outside the setting of 
APS have demonstrated that elevated levels of tPA and PAI in patients with a history of 
thrombosis may predict recurrences, implying that thrombosis may affect levels of tPA and 
PAI beyond the acute event (41). However, also non thrombotic females had higher mean PAI 
levels than thrombotic males and than control females. In this case the difference can only be 
accounted for by the presence of aPL.  
A suggestive explanation exists to interpret our fibrinolysis data. In a normal population 
PAI increases with advancing age in females but not in males (42) the opposite occurs for tPA 
(43). The variations observed in the levels of PAI and tPA throughout our control and patient 
groups (of similar mean age) may simply indicate that aPL are prematurely emphasizing the 
age and sex dependency of these fibrinolytic variables. In conclusion, the results of the 
present study indirectly confirm the inhibitory action of aPL on the AT-HS system, highlight 
the association between acquired f-PS deficiency and increased thrombin generation even in 
asymptomatic carriers of aPLs (12, 15) and support a clustering of low f-PS with fibrinolysis 
defects. As to the mechanism of acquired f-PS deficiency, recent observations suggest that in 
the presence of aPL, C4b binding protein increases its affinity for PS, lowering plasma free 
form levels (44). Therefore f-PS deficiency may mediate the thrombotic tendency of the APS, 
but because of the acquired nature of the defect, its persistence should be serially ascertained 
(12). Further information regarding impaired fibrinolysis in individuals with aPL is provided, 
but a causal relationship with thrombosis could not be defined.  
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Effect of FXIIIa 
To further our research on fibrinolysis we explored the role of factor XIII, a 
transglutaminase that promotes primarily fibrin-fibrin and fibrin-fibronectin cross-linking, 
followed by cross-linking with other haemostatic molecules in a hierarchical order, stabilizing 
the forming clot on the endothelial surface and contributing to cell adhesion (7). FXIIIa was 
particularly elevated in a proportion of our thrombotic PAPS patients, contributing to the 
higher level of this group compared to thrombotic and non-thrombotic controls. This would 
be in keeping with the concept that only thrombotic subjects had undergone activation of the 
coagulation system, clot stabilization, followed eventually by plasmin digestion. Indeed 
FXIIIa positively correlated to FNG, substrate as fibrin of FXIIIa, and PAI antigen, a 
surrogate of depressed fibrinolysis, in both PAPS and thrombotic controls. Given that 
fibrinogen and PAI were higher in PAPS, the overall picture is one of increased FXIII activity 
contributing to fibrin cross-linking in a state of heightened fibrin turnover in PAPS (45). As 
result of enhanced cross-linked, fibrin is less amenable to plasmin digestion, and conceivably 
a fibrin film remains adherent to and maintains the endothelial surface in persistent activation 
(46). Indeed, when re-assessed, FXIIIa well correlated to baseline measurements in a subset 
of our PAPS patients and thrombotic controls.   
Activation of FXIII requires the detachment of its B subunit under the action of thrombin 
(7), the generation of which is heightened in primary APS (45). Interestingly the B subunit of 
factor XIII contains a number of Sushi domains (7), the same domains present on 2GPI, 
target of aPL (47). The relations between FXIIIa and IgG anti-2GPI in our antiphospholipid 
positive groups may indicate a regulatory role for IgG anti2GPI in FXIII activation.  
CONCLUSION 
These data confirm that lupus anticoagulant assays are better related to a history of 
thrombosis than IgG aCL: DRVVT being able to identify patients with a history of arterial 
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thrombosis, whereas IgG aCL levels correlated to the number of venous but not arterial 
events. This further supports the hypothesis that IgG aCL and LA are antibodies with distinct 
specificities and functional properties (48) and they may differentially associate with the risk 
of developing arterial or venous occlusions. Some evidence is given that plasma levels of 
vWF and FNG are associated with the occurrence of thrombosis though the data presented are 
inconclusive as to whether raised plasma FNG and vWF represents a cause or an effect of 
endothelial injury or thrombosis, even considering that FNG and vWF were measured three 
months after the thrombotic episodes, well beyond the acute phase period.   
Although these studies do not address the relationship between aPLs and atherosclerosis, a 
hot topic in the APS (49), the wealth of our data point towards accelerated fibrin turnover in 
patients with aPL, supported by the enhanced activity of factor XIII, and there is more than 
circumstantial evidence to recognise fibrin deposition on the vessel wall as an early 
phenomenon in atherogenesis (7).  
The unsuspected sex dependency of fibrinolytic abnormalities, the hypothesis that aPLs 
might promote in younger subjects a fibrinolytic pattern typical of older populations, the 
differential effect of plasma FNG and vWF on arterial and venous occlusions and eventually 
atherosclerosis in PAPS are issues that only large prospective studies can evaluate.  
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CHAPTER V 
LIPID PROFILE, LIPID PEROXIDATION AND ANTI-LIPOPROTEIN 
ANTIBODIES IN THROMBOTIC PRIMARY ANTIPHOSPHOLIPID 
SYNDROME 
INTRODUCTION 
Lipoprotein imbalance in atherosclerosis 
Dyslipidaemia is a highly prominent atherogenic risk factor intimately associated with 
premature atherosclerosis. Excess plasma levels of circulating cholesterol under the form of 
pro-atherogenic ApoB containing lipoproteins with subnormal levels of anti-atherogenic 
ApoAI containing lipoproteins represents the major dyslipidaemic imbalance. ApoB is the 
predominant protein component of pro-atherogenic, cholesterol-rich LDL, TG-rich VLDL, 
VLDL remnants and intermediate-density lipoprotein (IDL), whereas ApoA-I is the major 
protein component of anti-atherogenic HDL. Elevated serum concentration of LDL-choles-
terol (LDL-C) was considered the most common form of atherogenic dyslipidemia (1), but it 
is recognized that also a low serum concentration of HDL-cholesterol (HDL-C) is a definite 
atherogenic trait (2). Several epidemiological studies have found that low serum HDL-C 
concentrations (defined as <40 mg/dl in both sexes or as <40 mg/dl in men and <50 mg/dl in 
women) (3,4) constitute an independent risk factor for coronary heart disease in both non 
diabetic and diabetic subjects (2-4). Prospective studies have revealed that a decrease of 1 
mg/dl in HDL-C increases the cardiovascular risk by 3% in women and by 2% in men (1). 
Conversely, subjects with elevated HDL-C levels show a decreased risk of CV events (2, 3-
5). The prevalence of low HDL-C concentration may vary from 20% in a general population 
to up to 60% in patients with established cardiovascular disease (CVD) (6). Not only low 
HDL-C concentration associates with an increased incidence of CVD but also with a more 
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aggressive progression of angiographically defined coronary artery disease (CAD), a greater 
risk for carotid atherosclerosis and ischemic stroke mortality (2,3). The Myocardial Ischemia 
Reduction with Aggressive Cholesterol Lowering (MIRACL) trial showed that baseline HDL-
C levels, rather than LDL-C levels predicted the re-occurrence of CVD in patients with acute 
coronary syndromes treated with atorvastatin (7). 
Oxidant/antioxidant balance in atherosclerosis 
Oxidative stress is defined as an imbalance between pro-oxidant and antioxidant factors in 
favor of pro-oxidants and is central to atherogenesis and its cardiovascular consequences (8). 
Analysis of plaque composition has revealed products of protein and lipid oxidation, such as 
oxidized and nitrated amino acids, lipid hydroperoxides, short-chain aldehydes, oxidized 
phospholipids, F2-isoprostanes, and oxysterols, suggesting the local occurrence of oxidative 
stress (9). The preferential retention of LDL in the arterial wall makes LDL a major pro-oxi-
dative substrate within the arterial intima. Various oxidative systems including NAD(P)H 
oxidases, xanthine oxidase, myeloperoxidase, uncoupled nitric oxide synthase, lipoxygenases 
and the mitochondrial electron transport chain can generate reactive oxygen and nitrogen 
species that contribute to the in vivo oxidation of LDL (10).  
This wide array of oxidative enzymes and the consequent oxidation of LDL is 
counteracted by the antioxidant activity of HDL; several enzymes such as paraoxonase 
(PON1) and phospholipase A2 that degrade lipid peroxides and a variety of lactones including 
homocysteine thiolactone are part of the anti-oxidant arsenal of HDL (11-13). However, if the 
antioxidant capacity of HDL is overridden, LDL will oxidise and generate different classes of 
toxic compounds, amongst which F2-isoprostanes and a variety of peroxides, hydroperoxides 
and aldehydes.  
F2-isoprostanes are cyclic prostaglandin-like compounds formed through peroxidation of 
arachidonic acid present in lipoproteins and cell membranes in the absence of cyclo-
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oxygenase: they are currently the most robust and integrative markers of oxidative stress in 
vivo (14), have strong vasopressor acrivity (15), may facilitate platelet activation (16), and are 
strong and independent risk factors for CHD (17, 18).  
Further by products of LDL oxidation in include 1-palmitoyl-2-sn-glycero-3-
phosphorylcholine, 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine, cholesteryl-
linoleate-hydroperoxide, 7-hydroperoxycholesterol, hydroxyoctadecadienoic acid and 4-
hydroxynonenal (8, 19).  
Oxidised LDL and its ligands 
On its own, oxLDL exerts pro-inflammatory activities by inducing the expression of 
adhesion molecules on endothelial cells, by attracting circulating monocytes on the same 
cells, and by promoting the release of chemokines and inflammatory cytokines from 
macrophages (8). Moreover oxLDL is taken up through macrophage scavenger receptors and 
lead to monocyte transformation into cholesterol-loaded macrophages then into foam cells, 
characteristic residents of atherosclerotic plaques (8). 
The oxidative modification of LDL makes this lipoprotein immunogenic so to elicit a 
specific autoantibody response that cross-reacted with anticardiolipin in systemic lupus 
erythematosus (20): in fact some antiphospholipid antibodies can  by directed agains epitopes 
of oxidised phospholipids (21). The studies that have addressed the role of IgG anti oxLDL in 
vascular disease have yielded discordant results (22).  
In an attempt to quench LDL oxidation, β2GPI binds oxLDL but not native LDL in vitro. 
Two chloroform-extractable lipids (oxLig-1 and oxLig-2) were identified as the LDL-derived 
ligands for the specific interaction between oxLDL and β2GPI that is initially only 
electrostatic but later progresses to a covalent bond via Schiff base formation (23). The 
oxLDL/β2GPI complex is also immunogenic and elicits a specific antibody response. When 
IgG anti-β2GPI antibodies are co-incubated with oxLDL and β2GPI, the 
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monocyte/macrophage uptake and intracellular accumulation of oxLDL accelerates, likely via 
FcγRI receptors, leading also to up-regulation of the scavenger receptor CD36 and further 
surface expression of FcγRI receptors (23). Experiments evaluating the intracellular 
trafficking of β2GPI within macrophages showed that un-complexed β2GPI was poorly 
incorporated in late endosomes and stagnated there, whereas complexed β2GPI (to 
phosphatidylserine liposomes or oxLDL) was quickly transported to lysosomes; the addition 
of antibodies to β2GPI further accelerated this process (24).  
EXPERIMENTAL DATA  
1) THE LIPID PROFILE, ANTI LIPOPROTEIN ANTIBODIES AND C-REACTIVE 
PROTEIN. 
The finding that oxLDL and the antibody response it stimulated were of low specificity 
(22) preceded the discovery that β2GPI bound to oxLDL in a stable atherogenic oxLDL- 
β2GPI auto-antigen (23). Although oxLDL- β2GPI concentration is elevated in patients with 
SLE with and without APS neither occur in association with SLE disease activity nor with 
any major clinical manifestation of APS (24). At variance antibodies against oxLDL-β2GPI 
occur in SLE and/or APS in relation to the intima media thickness of carotid arteries (25). 
More recently antibodies against HDL hampering the anti-atherogenic and anti-inflammatory 
properties of HDL have been detected in SLE (26).  
This study investigated an extended lipid profile, the presence of antibodies against HDL 
and ApoA and their relationship with high sensitivity C-reactive protein (hs-CRP) in 
thrombotic patients with PAPS compared to patients with inherited thrombophilia (IT) and 
healthy controls. Hence the study was a cross-sectional case double-control: consecutive 
patients fulfilling criteria for PAPS (27) and patients with IT were invited to participate. 
Exclusion criteria were acute or chronic hepatic, renal, lung disease, diabetes, a recent history 
of acute infection (within six weeks), a positive urinary dipstick for nitrates on the day of 
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sampling, steroid, statin or fibrate treatment. Of 40 PAPS patients, one was excluded because 
had gradually developed systemic lupus erythematosus, one had developed kidney cancer, 
three were pregnant and one had died of a recurrent event. Of 38 IT patients one had had 
recent surgery and one was pregnant. The study therefore included 34 thrombotic PAPS 
patients (arterial occlusions n=10, venous occlusions n=19, arterial + venous occlusions n=5) 
36 thrombotic IT patients (arterial occlusions n=5, venous occlusions n=28, arterial + venous 
occlusions n=3; factor V Leiden n=16, prothrombin 20210 n=10, protein C deficiency n=4, 
free protein S deficiency n=6) and 28 control subjects. In the PAPS group, 3 patients were on 
carbamezapine for post-ischemic epilepsy, two on beta-blockers and 3 were menopausal. In 
the IT group, 2 patients were on beta-blockers and 4 were menopausal. The control group was 
made up of 19 blood donors and 9 healthy hospital personnel: of these 3 women were 
menopausal. Table 1 shows the demographics of the three groups. 
Table 1. Demographics of study groups. 
 CTR IT PAPS 
 (n=28) (n=36) (n=34) 
F/M 16/12 18/18 24/10 
Age  45±13 50±14 44±11 
IgG aCL (GPL) 6.8±3.5 6.4±2.7 131±140 
IgG β2GPI (IU) 2.3±0.8 4.2±0.8 118±67 
Lupus anticoagulant  0 0 30 
PAPS: primary antiphospholipid syndrome; IT: inherited thrombophilia; 
CTR: control; aCL: anticardiolipin; β2GPI: beta-2-glycoprotein-I 
RESULTS 
Comparison of variables across groups 
With regards to the lipid profile the PAPS group showed lower average HDL, LDL, total 
cholesterol and ApoAI concentrations other groups. With regards to antibodies against 
lipoprotein components the PAPS group showed higher IgG anti-HDL and IgG anti-ApoAI 
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titres than other groups. OxLDL-β2GPI and CRP were almost exclusively elevated in PAPS 
(Table 2).  
Table 2. Lipid profile, anti-HDL, anti-ApoAI, oxLDL- β2GPI and CRP across groups  
 CTR IT PAPS p-value 
 (n=28) (n=36) (n=34)  
HDL (mg/dl) 49±15 31±7.6 31±9.4 <0.0001 
LDL (mg/dl) 118±28 93±26 82±23 <0.0001 
CHO (mg/dl) 205±26 187±39 169±33 0.0002 
TG (mg/dl) 83±29 94±42 108±52 0.01 
ApoAI (mg/dl) 1.5±0.23 1.3±0.23 1.2±0.25 0.002 
ApoB (mg/dl) 0.9±0.24 0.8±0.25 0.8±0.21 NS 
IgG anti-HDL (% PC) 100±105 93±81 192±208 0.006 
IgG anti-ApoAI (% PC) 31±16 32±24 91±76 <0.0001 
Ox LDL- β2GPI (U/ml) 2.8±4.0 2.9±3.0 6.4±7.0 0.001 
hs-CRP (mg/dl) 0.22±0.33 0.26±0.2 0.66±0.8 0.003 
PAPS: primary antiphospholipid syndrome; IT: inherited thrombophilia; CTR: control; 
HDL: high density lipoprotein; LDL: low density lipoprotein; CHO: cholesterol; ApoA: 
apolipoprotein AI; ApoB: apolipoprotein B; PC: positive control; oxLDL- β2GPI: oxidized 
LDL/beta-2-glycoprotein-1; hs-CRP: high sensitivity C-reactive protein.  
Relationship amongst variables in the PAPS group 
By univariate analysis only IgG anti-HDL correlated to HDL (Figure 1). Several variables 
correlated to oxLDL-β2GPI, notably LDL, ApoB and IgG aCL (Table 3). A multiple 
regression model with oxLDL-β2GPI as the dependent variable and the lipid fractions as 
independent did not identify independent predictors as most of the independent variables were 
interrelated. A similar model with oxLDL- β2GPI as dependent variable and IgG aCL, IgG 
β2GPI, IgG anti-HDL and IgG anti-ApoAI as independent variables identified IgG aCL and 
 
 
55 
 
IgG anti-HDL as predictors of oxLDL-β2GPI (Table 4). By univariate analysis HDL and 
ApoAI negatively correlated to hs-CRP (r=-0.42, p=0.01 and r=-0.49, p=0.002) respectively.   
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Figure 1. Spearman rank correlation of high density lipoprotein (HDL) with antibody against HDL in 
patients with thrombotic antiphospholipid syndrome. 
Table 3. Determinants of oxLDL-β2GPI in PAPS 
Variable R P-value 
IgG aCL 0.41 0.006 
IgG β2GPI 0.34 0.02 
IgG anti-HDL 0.38 0.01 
ApoB 0.45 0.006 
CHO 0.35 0.04 
HDL -0.34 0.04 
LDL 0.43 0.008 
BMI 0.38 0.01 
PAPS: primary antiphospholipid syndrome; oxLDL-β2GPI: 
oxidized LDL/beta-2-glycoprotein-1; aCL: anticardiolipin; β2GPI: 
beta-2-glycoprotein-I; CHO: cholesterol; ApoB: apolipoprotein B; 
HDL: high density lipoprotein; LDL: low density lipoprotein; BMI: 
body mass index.  
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Table 4. Independent predictors of oxLDL-β2GPI in PAPS  
 Β t p-value 
IgG aCL 0.575 3.653 0.001 
IgG anti-HDL 0.355 2.751 0.009 
oxLDL-ß2GPI: oxidized LDL/beta-2-glycoprotein-1; PAPS: primary 
antiphospholipid syndrome; aCL: anticardiolipin; anti-HDL: anti-high 
density lipoprotein antibodies. 
Relationship amongst variables in the IT group 
By univariate analysis oxLDL-β2GPI correlated to LDL (r=0.43, p=0.009) and anti-HDL 
antibodies (r=0.49, p=0.002) in the IT group. 
Relationship amongst variables in CTR 
By univariate analysis oxLDL-β2GPI correlated negatively to HDL (r=-0.71, p=<0.0001) 
and to ApoAI (r=-0.49, p=0.01) and positively to hs-CRP (r=0.59, p=0.0001). hs-CRP 
negatively correlated to HDL (r=-0.59, p=0.001). 
2) OXIDATIVE STRESS AS A RESULT OF LDL OXIDATION 
The presence of oxLDL, oxLDL-β2GPI and their specific antibodies in the circulation of 
patients with autoimmune disorders was the drive to assess the occurrence of lipid 
peroxidation in PAPS when the methodology became availabe. Oxidative stress had been 
detected in several autoimmune vascular disorders including systemic lupus erythematosus 
(28) but not in patients with PAPS. In a pilot study plasma 8-epi-prostaglandin F2α was 
significantly higher in 10 patients with PAPS (6M, 4F, mean age 35 ± 15 years) than 10 age 
(± 3 years) and sex matched healthy controls (234 ± 56 pg/ml vs 72 ± 14 pg/ml, p=0.0002) 
and strongly related to the plasma IgG aCL titre (r=0.89, p=0.0004)(29). This lead to the 
second study partially reported here in which F2-isoprostanes were measured alongside two 
other vasoactive molecules, TXB2 and endothelin-1 (ET-1) in 14 persistent carriers of aP) 
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(8F, 6M, mean age 39 ± 11 y, mean IgG aCL 187 ± 42 GPL) and on 12 (6F, 6M, mean age 
36 ± 11 y) healthy hospital personnel who served as a control group. A history of thrombosis 
was present in 10 aPL patients who fulfilled thus criteria for PAPS (27) whereas four 
participants were persistent carriers of aPL who never suffered thrombosis. None of the aPL 
participants had systemic lupus erythematosus or any other underlying disease. Neither 
patients nor controls smoked. Of the 10 APS participants, nine were on warfarin at the time of 
study and one was on aspirin (75 mg/day).  
RESULTS 
Baseline comparison between antiphospholipid patients and controls 
APL participants showed enhanced urinary excretion of F2-isoprostanes and of TxB2 as 
well as higher plasma levels of ET-1 than control participants (Table 5). In the aPL group, 
IgG aCL titre positively related to urinary TxB2 (r=0.72, p=0.01).  
Table 5. F2-isoprostane and vasoactive molecules in PAPS and controls. 
 
Control 
(n=12) 
PAPS 
(n=14) 
p-value 
Age (mean±SD) 36±11 39±11  
Sex F/M 6/6 6/8  
Cr clearance (ml/s) 1.95±0.19 1.85±0.27  
ET-1 (pg/ml= 0.77±0.08 2.09±0.2 0.0002 
TxB2 (pg/mmol Cr) 11.6±2.4 42.2±6.8 0.0004 
F2-isoprostane (ng/mmol Cr) 0.139±0.03 0.218±0.02 0.02 
aPL: antiphospholipid antibody; Cr: creatinine; ET-1: endothelin-1; TxB2: 11-
dehydro-thromboxane B2. 
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DISCUSSION  
Thrombotic PAPS were characterised by low plasma concentration of HDL and of its 
major apolipoprotein: whilst this has relevance to venous occlusions (30) and its re-
occurrence in non autoimmune populations (31) as in our IT patients, it did not discriminate 
arterial or venous thrombosis in our PAPS group. Of the previous surveys two showed lower 
mean HDL in PAPS patients (32, 33) while a third did not (34, 35). On the other hand average 
total cholesterol was reported elevated in two studies (32, 34) and low in prevalence (36) and 
average (33) in other two studies as in ours.  
With regards to LDL three studies found elevated mean levels in PAPS (32-34) whereas 
we found lower levels than controls. In the presence of an oxidant environment LDL oxidises 
and releases lipid radicals with powerful biological properties: β2GPI binds and neutralises 
oxLDL in a stable oxLDL/ β2GPI complex (23): supportive of these in vitro data LDL and 
HDL related positively and negatively to oxLDL- β2GPI, in keeping with the notion that 
β2GPI may buffer excessive LDL oxidation determined by the loss of the antioxidant capacity 
of HDL residing mostly in its paraoxonase activity (26).   
Indeed antibodies against HDL and ApoAI are associated with decreased paraoxonase 
activity in vitro and in vivo (26): here they were present only in the PAPS group where IgG 
anti-HDL negatively correlated to HDL and independently predicted oxLDL- β2GPI levels. 
This confirms that IgG anti-HDL may hamper the antioxidant effect of HDL favouring LDL 
oxidation therefore increased oxLDL- β2GPI formation and enhanced oxidative stress 
measured as F2-isoprostanes in our PAPS patients.  
With regards to the reduced average HDL concentration of our PAPS group one cannot 
exclude enhanced clearance of a putative IgG anti-HDL-HDL complex. Moreover HDL 
showed a negative, albeit modest correlation with hs-CRP, indicating that loss of the anti-
inflammatory effect of HDL may contribute to the recently described low-grade inflammation 
of PAPS patients (37). Interestingly the average triglyceride concentration was higher in our 
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PAPS group: this is similar to the picture of SLE where an inhibitory activity on lipoprotein 
lipase accounts for decreased hydrolysis of circulating triglycerides (38). In conclusion 
elevated triglycerides and low HDL in association with antibodies against HDL seems a 
common finding in thrombotic PAPS and may predispose to enhanced oxidative stress. 
Studies assessing the atherothrombotic risk of PAPS populations should take into account this 
interface between traditional and non traditional cardiovascular risk factors.   
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CHAPTER VI 
NITRIC OXIDE AND NITRATIVE STRESS IN THROMBOTIC 
PRIMARY ANTIPHOSHOLIPID SYNDROME 
INTRODUCTION 
Nitric oxide and the vasculature 
Nitric oxide (NO) is an uncharged free radical composed of seven electrons from nitrogen 
and eight electrons from oxygen that acts as a signalling molecule within a source cell or 
diffuses from the source cell to affect adjacent cells (1-3). Within the vasculature, NO is 
produced by endothelial cells, smooth muscle cells, monocytes, neutrophils, eosinophils and 
platelets (4). Endothelial cells generate NO from two related nitric oxide synthases (NOS), 
endothelial/constitutive eNOS and inducible NOS (iNOS): both convert L-arginine to NO• 
and citrulline at different concentrations according to substrate availability (5). Although the 
physiological vascular roles of NO include modulation of vascular tone, inhibition of platelet 
function and angiogenesis, NO also modulates monocyte/macrophage that in turn may 
contribute to pathological vascular tone (4,6).  
Under physiological conditions, the shear force of flowing blood stimulates endothelial 
receptors (7-8) that trigger calcium influx hence the eNOS activation. Under pathological 
conditions, bacterial endotoxins and inflammatory cytokines, such as TNF-alpha and 
interleukins, activate iNOS which produces calcium independent NO at a 1,000-fold rate 
greater than eNOS not only from endothelial and smooth muscle cells but also from 
infiltrating monocytes, lymphocytes and fibroblasts (9).  
Nitric oxide and smooth muscle cells 
NO controls smooth muscle cells contractility by modulating the activity of heme 
containing soluble guanylyl cyclase (sGC) that de-phosphorylates guanosine triphosphate 
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(GTP) to cyclic guanosine 3′,5′-cyclic monophosphate (cGMP). This pathway inhibits 
calcium entry into smooth muscle cells and allows phosphorylation of myosin light chains 
and of sarcoplasmic proteins, leading to calcium sequestration in the sarcoplasmic reticulum 
(10-11) and ultimately leads to smooth muscle cell relaxation (12). Similarly in platelets, NO 
affects cGMP-dependent protein kinase activation that results in decreased intracellular 
calcium, an important second messenger in platelets function (13-16). In fact a decrease of 
intracellular calcium antagonises several calcium dependent enzymes involved in platelet 
aggregation, shape change and release of storage granules (16). Partly through down 
regulation of protein kinase C, cGMP may desensitize the thromboxane A2 (TXA2) receptor, 
preventing TXA2 mediated platelet aggregation and vasoconstriction (16).  
Nitric oxide bio-reactivity   
After eNOS generation, NO binds to the iron (III) hemes of cytochrome c oxidase in 
mitochondria, regulates certain transcription factors such as hypoxia-inducible factor-1 (2). 
Alternatively it diffuses into the vascular lumen where it is scavenged by the ferrous iron 
(Fe
2+
) in the heme moiety of oxy-haemoglobin to form met-haemoglobin and nitrate (NO3
−
) 
(2, 3, 17).  
NO can exist in three closely related redox forms: the free radical NO•; NO
+
 or 
nitrosonium and NO
−
 or nitroxyl anion, resulting from a one-electron reduction of NO•. NO 
can be reduced to nitrous oxide (N2O) or oxidized to nitrite (NO2
−
) (18). NO2
−
 reacts rapidly 
with oxygen, yielding nitrogen dioxide radical (•NO2), which exists in equilibrium with the 
potent nitrosating agents dinitrogen trioxide (N2O3) and dinitrogen tetroxide (N2O4); •NO2 can 
either react with unsaturated lipids directly or participate in nitrosation reactions. S-nitrosation 
may generate S-nitrosothiols that due to their stability represent a storage pool of bio-
available NO (19). In plasma, S- nitrosoalbumin is an important NO adduct that may protect 
NO from inactivation in the oxidative extracellular milieu (20). 
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At low concentrations, intracellular NO may function as an antioxidant through 
termination reactions with lipid radicals (L•, LO•, LOO•), resulting in the formation of less 
reactive secondary nitrogen-containing products (LONO, LOONO) (1). LOONO can either 
decompose to caged radicals (LO• •NO2) with rearrangement of LO• to an epoxide 
(L(O)NO2), dissociate and react with additional NO, or hydrolyze to LOOH and nitrite NO2
−
 
(18). By these reactions, NO suppresses the generation of lipid-derived chemo-attractants for 
monocytes and can thereby be considered an anti-inflammatory and potentially anti-
atherosclerotic molecule (21, 22). 
Nitric oxide and nitrative stress 
The oxidative inactivation of NO by superoxide anion (O2
−
•) is the prevalent mechanisms 
leading to decreased bioavailability of NO, impaired vasomotor tone and enhanced platelet 
function. Reactive oxygen species (ROS) and O2
−
• from monocytes, neutrophils, endothelial 
cells and platelets react with NO at physiological pH to generate peroxynitrite anion 
(ONOO
−
) that occurs at a faster rate (23,24) than that of the SOD reaction or of NO with 
heme compounds (25). Thus, NO can be considered a scavenger of O2
−
• even to the extent of 
acting as an antioxidant; in fact, NO is the only biological molecule that can kinetically out-
compete SOD for O2
−
• (26-28). Exogenous cigarette smoke also yields high levels of NO that 
significantly contributes to peroxynitrite formation (29).  
In vivo peroxynitrite may nitrate protein tyrosinyl residues to yield 3-nitrotyrosine though 
tyrosine does not react directly with peroxynitrite but a hydrogen atom is first abstracted from 
the phenol ring to form a tyrosyl radical that then combines with •NO2 to produce 3-
nitrotyrosine (30). Alternatively peroxynitrite may reaction with carbon dioxide radical 
(CO2•) to form highly reactive nitrosoperoxycarbonate anion (ONO2CO2
−
) (31) that may also 
nitrosate substrates. Peroxynitrite itself is not a direct nitrosating agent, but is involved in the 
nitrosation of thiols to yield RSNO or organic nitrates (30, 32, 33). In addition, CO2 may 
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enhances tyrosine nitration by peroxynitrite in vitro (34). Immunodetectable 3-nitrotyrosine 
has been demonstrated in fatty streaks of coronary arteries of young autopsy subjects and in 
foam cells, vascular endothelium, and the neointima of advanced atherosclerotic lesions in 
older patients and as such is a specific marker of nitrative stress (35).  
As a lipid oxidant, peroxynitrite produces lipid peroxyl radicals and mediates peroxidation 
of diverse classes of lipids including phospholipids and LDL lipids, forming conjugated 
dienes, malondialdehyde, lipid peroxides, lipid hydroxides and F2-isoprostanes (36, 37-38). 
The peroxynitrite induced oxidation of free thiol residues in protein, lipids, deoxyribose, 
guanine bases, methionine, and phenols leads to protein modification and inhibition of 
enzymatic activities (39-46). By the same token, peroxynitrite may have profound effects on 
cell signalling modifying target proteins involved in signal transduction (47).  
EXPERIMENTAL DATA 
1) NITRIC OXIDE AND NITRATIVE STRESS IN PRIMARY THROMBOTIC 
ANTIPHOSPHOLIPID SYNDROME 
The role of NO in PAPS had never been fully appreciated: the few available studies were 
too limited in numbers to provide a full understanding of its significance (48,49). However a 
decreased NO• was detected in animal models of APS (50,51) supporting the possibility that 
NO• might be involved in the vascular pathogenesis of PAPS. To expand on this topic the 
behaviour of NO• metabolites nitrite (NO2
−
) and nitrate (NO3
–
), total antioxidant capacity 
(TAC) (expressed as ONOO
–
 quenching), and nitrotyrosine (NT) was compared in patients 
with thrombotic PAPS, in asymptomatic but persistent carriers of aPL, in patients with IT 
with vascular occlusions, in patients with SLE, and in healthy subjects. Possible relationships 
between NO2
−
, NO3
–
, hs-CRP, and several aPL were also investigated.  
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MATERIALS AND METHODS 
Patients. 
Our study was devised as a cross-sectional case-quadruple control: PAPS patients with 
vascular occlusions represented cases; IT patients with vascular occlusions represented 
thrombotic controls, aPL without vascular occlusions represented non-thrombotic aPL-
positive controls; patients with SLE represented inflammatory controls and healthy subjects 
represented normal controls. All participants were age- and sex-matched (where possible), 
except for SLE patients, who were all female. Consecutive patients with thrombotic PAPS, 
with IT and persistent aPL attending the Coagulation Unit of the Cardarelli Hospital (Naples, 
Italy) were invited to participate between January 2008 and July 2008. Our study was carried 
out according to the revised Declaration of Helsinki, with approval of the Ethics Board of the 
hospital and written consent of all participants. Exclusion criteria were acute or chronic 
hepatic, renal, and lung disease; diabetes; acute infection (within 6 weeks); post-thrombotic 
syndrome with or without venous ulcerations; positive urinary dipstick for nitrites on the day 
of sampling and treatment with statins or fibrates. PAPS and IT patients are seen on average 
every 3 to 4 weeks for oral anticoagulation monitoring and are instructed to self-report any 
illness during the intervening periods; their lipid profiles and kidney and liver function tests 
are checked annually. APL subjects were diagnosed as such either because of the presence of 
prolonged clotting tests in routine assays, subsequently confirmed as lupus anticoagulants 
(LAC), or because of thrombocytopenia or other symptoms that prompted a search for aPL. 
Of the PAPS attendees (n=50), 2 were excluded because they had gradually developed 
ankylosing spondylitis and SLE, one had developed kidney cancer, 2 were pregnant, one had 
suffered a recent recurrent event, one had post-thrombotic syndrome, and 2 were evasive 
regarding their smoking and contraceptive status. Of the IT (n=46) attendees, 2 were excluded 
for post-thrombotic syndrome and venous ulcerations in lower limbs. Of the aPL attendees 
(n=27) one was excluded for development of non-insulin-dependent diabetes; one for the 
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development of SLE, haemolytic anemia, nephrotic syndrome, and pulmonary embolism after 
ovarian hyperstimulation; one for the development of chronic lymphoid leukemia; one for 
spontaneous onset of ischemic stroke; and 2 had moved to a different town. Of the remaining 
aPL subjects 4 had moderate thrombocytopenia (platelets < 100 × 109/l) not requiring 
treatment.  
Consecutive patients with SLE fulfilling the American Rheumatism Association (ACR) 
criteria (52) were enrolled among those attending the Autoimmune Outpatient Clinic of the 
Curry Cabral Hospital, Lisbon (Portugal) between January 2008 and August 2008. Exclusion 
criteria included acute or chronic renal impairment that would significantly alter NO 
metabolites, liver cirrhosis, diabetes, acute infection (within 6 weeks), post-thrombotic 
syndrome with or without venous ulcerations, positive urinary culture following positive 
dipstick for nitrite (urinary excretion in SLE may be increased in the absence of infection), 
and treatment with statins or fibrates. Of 52 patients with SLE, 16 were excluded on the basis 
of the above criteria. Of the remaining 36, one was found weeks later to have tuberculosis and 
2 were pregnant; their samples were discarded. Therefore 33 SLE patients participated in the 
study: of these, 9% had visceral involvement without renal disease, 12% cardiac and lung 
involvement, 9% central nervous system involvement, 66% arthritis, 3% myositis, 9% 
alopecia, 3% haemolytic anemia, 21% thrombocytopenia, 9% neutropenia, 81% presence of 
anti-DNA antibodies, and 90% presence of antinuclear antibodies. The average SLE Disease 
Activity Index (SLEDAI) score was 4.85 ± 3.96 (median 3.5, range 0–16). Their medication 
intake was: prednisolone in 54%, (< 6 mg/day in 27%, 6–10 mg/day in 18%, > 10 mg/day in 
9%) azathioprine in 24% (100 mg/day in 18%, 150 mg/day in 6%), hydroxychloroquine 200 
mg/day in 60%, aspirin in 12%, warfarin in 9%. Twenty-nine healthy hospital staff served as 
normal controls: 15 from Cardarelli Hospital in Naples and 14 from the Curry Cabral Hospital 
in Lisbon. To minimize dietary influences on nitric oxide metabolite concentrations all 
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participants were asked to refrain from foodstuffs containing high concentrations of 
nitrate/nitrite (such as lettuce, spinach, beetroot, radish, salamis, and pickled items) for 3 days 
before blood sampling. The study was therefore carried out on 46 thrombotic PAPS patients, 
21 aPL subjects, 38 IT patients, 33 SLE patients, and 29 control subjects. Their demographics 
are shown in Table 1. 
Table 1. Demographics of participants across groups 
 CTR IT aPL PAPS SLE 
No 29 38 21 46 33 
Age (mean±SD) 41±7 41±14 40±9 43±12 40±12 
Sex M/F 15/14 13/25 6/15 18/28 0/33 
Disease duration, median 
(range) 
 12 (1, 22) 10 (1, 16) 10 (1, 18) 8 (1, 13) 
LA 0 0 44 18 6 
IgG aCL median (range) 
8 
 (2, 18) 
8.4 
 (4, 20) 
24 
 (2, 309) 
100 
 (5, 500) 
62 
 (12, 112) 
IgG a2GPI U/ml median 
(range) 
4 
(2.5, 8.2) 
5 
(2, 12) 
4 
(2, 90) 
146 
(2.6, 184) 
12 
(3.6, 102) 
IgG anti-HDL %  median 
(range) 
61 
(19, 161) 
70 
(22, 292) 
112 
(28, 240) 
70 
(25, 436) 
98 
(25.4, 328) 
IgG anti-ApoAI % median 
(range) 
0.18 
(0.06, 0.57) 
0.14 
(0.02, 1.2) 
1.2 
(0.17, 7.4) 
0.69 
(0.17, 6.3) 
1.2 
(0.17, 6) 
MTHFR +/+ 5 5 6 13 4 
PT20210 2 4 1 2 0 
FVL 1 12 0 2 1 
f-PS deficiency 0 8 4 32 NA 
FVL +  PT20210 0 7 0 0 0 
FVL +  PS deficiency 0 2 0 0 0 
Thrombosis      
Arterial 0 11 0 14 4 
Venous 0 27 0 26 1 
Arterial+venous 0 0 0 6 0 
No 1 0 38 0 19 4 
No 2 0 0 0 16 0 
No 3 0 0 0 3 0 
No 4 0 0 0 2 0 
Smokers      
<6    per day 4 4 3 6 2 
7-15 per day 6 8 2 5 5 
>15  per day 2 1 0 4 1 
Abbreviations: PAPS: primary antiphospholipid syndrome; aPL: persistent carriers of 
antiphospholipid antibody with no underlying disorder and no thrombosis; IT: inherited 
thrombophilia; SLE: systemic lupus erythematosus; CTR: normal controls; LA: lupus anticoagulant; 
aCL:anticardiolipin; 2GPI: beta-2-glycoprotein-I; anti-HDL: anti-high density lipoprotein; anti-
ApoA-I: anti apolipopoprotein A-I; MTHFR: homozygous methylen-tetrahydrofolate reductase C667T 
thermolabile mutation; PT: prothrombin; FVL: factor V Leiden; f-PS: free protein S.  
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RESULTS 
Comparison of variables in PAPS, aPL, IT, SLE, and healthy controls.  
Average plasma NO2
−
 was lower in the PAPS, aPL, and IT groups (Figure 1A), whereas 
NO3
−
 was higher in SLE (Figure 1B) and NT was higher in SLE and PAPS (Figure 1C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Comparison (ANOVA) of nitrite (NO2
–
), nitrate (NO3
–
), and nitrotyrosine (NT) across study 
groups: (A) average concentration of NO2
–
 (Bonferroni’s multiple comparison test: PAPS vs SLE, p < 
0.001; PAPS vs CTR, p < 0.001; PCaPL vs SLE, p < 0.01; aPL vs CTR, p < 0.001; IT vs SLE, p < 
0.01; IT vs CTR, p < 0.001); (B) average concentration of NO3
–
 (Bonferroni’s multiple comparison 
test: PAPS vs SLE, p < 0.001; IT vs SLE, p < 0.001; SLE vs CTR, p < 0.001); (C) average 
concentration of NT (Bonferroni’s multiple comparison test: PAPS vs IT, p < 0.05). PAPS: primary 
antiphospholipid syndrome; PCaPL: persistent carriers of antiphospholipid antibodies without 
thrombosis or miscarriages; IT: inherited thrombophilia; SLE: systemic lupus erythematosus; CTR: 
controls. 
 
 
 
68 
 
Mean plasma TAC was lowest in SLE (Figure 2A), where CRP was highest (Figure 2A 
and 2B). Average TAC was higher in males than in females in all non-SLE groups: in PAPS 
11280 ± 3041 versus 9749 ± 2967 μmol/l (p=0.02); in IT 6392 ± 1399 versus 5325 ± 1720 
μmol/l (p=0.04); and in healthy controls 7967 ± 991 vs 6194 ± 1265 μmol/l (p=0.001). Age, 
sex, and smoking correlated to NO2
–
, NO3
–
 and TAC but had no confounding effect on 
resulting significance findings by ANCOVA. Age and IgG aCL related to NT and their 
confounding effect by ANCOVA reduced the comparative significance (p < 0.02). Age, sex, 
and smoking correlated to NO2
–
, NO3
–
 and TAC but had no confounding effect on resulting 
significance findings by ANCOVA. Age and IgG aCL related to NT and their confounding 
effect by ANCOVA reduced the comparative significance (p < 0.02). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Comparison (ANOVA) of total antioxidant capacity (TAC) and high sensitivity C-reactive 
protein (CRP) across study groups: (A) average concentration of TAC (Bonferroni’s multiple 
comparison test: PAPS vs IT, p < 0.001; PAPS vs SLE, p < 0.001; IT vs SLE, p < 0.05; IT vs CTR, p 
<0.05; SLE vs CTR, p < 0.001); (B) average concentration of CRP (Bonferroni’s multiple 
copmparison: SLE vs PAPS, SLE vs aPL, SLE vs IT, SLE vs CTR, all p < 0.001). PAPS: primary 
antiphospholipid syndrome; PCaPL: persistent carriers of antiphospholipid antibody positive without 
thrombosis or miscarriages; IT: inherited thrombophilia; SLE: systemic lupus erythematosus; CTR: 
controls. 
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Relationship among variables in PAPS  
The effect of antibodies and that of other clinical and laboratory variables on plasma 
concentrations of NO2
–
, NO3
–
, and NT was tested by separate multiple regression models. In 
the model with NO2
–
 as the dependent variable and IgG aCL, IgG anti-β2GPI, IgG anti-HDL, 
and IgG anti-ApoAI antibodies as independent variables, IgG aCL resulted in the only 
negative predictor of NO2
–
 (p = 0.03; Table 2). Average NO2
–
 was lower in patients with a 
history of arterial thrombosis versus those with venous thrombosis (11.41 ± 7.6 vs 18.43 ± 
11.06 μmol/l; p=0.03) although in a separate model with NO2
–
 as the dependent variable and 
age at first thrombotic event and thrombosis number and type as the independent variables, 
thrombosis number negatively predicted NO2
–
 (p=0.001; Table 2). In the model with NO3
–
 as 
the dependent variable and IgG aCL, IgG anti-β2GPI, IgG anti-HDL, and IgG anti-ApoAI 
antibodies as independent variables, IgG aCL was the only negative predictor of NO3
–
 (p = 
0.03) (Table 2). In a different model, with NO3
–
 as the dependent variable and age, sex, 
thrombosis type, smoking, and TAC as the independent variables, arterial thrombosis and 
smoking independently predicted NO3
–
 (p=0.05 and p=0.005, respectively). In a further model 
with NT as the dependent variable and the antibodies as the independent variables none of the 
latter bore any relationship with NT; but in a similar model NT as the dependent variable and 
with NO3
–
, NO2
–
, TAC, smoking, and CRP as independent variables, CRP was the only 
independent predictor of NT (p=0.004) (Table 2). 
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Table 2. Predictors of nitric oxide metabolites and nitrotyrosine in PAPS. 
Variables in regression model    
Independent Dependent Predictors t p-value 
IgG aCL, IgG a2GPI, IgG anti-
HDL, IgG anti-ApoAI  
NO2
-
 IgG aCL -1.87 0.03 
     
Age at first thrombosis, thrombosis 
number & type  
NO2
-
 
Thrombosis 
number 
-3.24 0.001 
     
IgG aCL, IgG a2GPI, IgG anti-
HDL, IgG anti-ApoAI 
NO3
-
 IgG aCL -1.93 0.03 
     
Age, sex, thrombosis type, 
smoking,TAC 
NO3
-
 
Arterial 
trombosis 
1.67 0.05 
  Smoking 2.66 0.005 
     
NO3
-
, NO2
-
, TAC, smoking, CRP NT CRP 2.74 0.004 
Abbreviations: IgG aCL, anticardiolipin; IgG a2GPI, beta-2-glycoprotein-I; IgG anti-HDL, 
anti high density lipoprotein; IgG anti-ApoA-I, anti apolipoprotein AI; NO2
-
, nitrite; NO3
-
, nitrate; 
TAC, total  antioxidant capacity; NT, nitrotyrosine; CRP, C-reactive protein.  
Relationship among variables in aPL.  
In the regression model with NO2
–
 as the dependent variable and IgG aCL, IgG anti-
β2GPI, IgG anti-HDL, IgG anti-ApoAI, aPTT, and DRVVT as independent variables, IgG 
anti- β2GPI showed only a negative trend with NO2
–
 (p=0.07) (Table 3). In the model with 
NO3
–
 as the dependent variable and IgG aCL, IgG anti-β2GPI, IgG anti-HDL, IgG anti-
ApoAI, aPTT, and DRVVT as independent variables, negative predictors were IgG aCL 
(p=0.03) and DRVVT (p=0.03), and a trend was seen for IgG anti- β2-GPI (p=0.06; Table 3). 
In a further model none of the antibodies bore any relationship with NT as the dependent 
variable but with NO3
–
, NO2
–
, TAC, and CRP set as independent variables, NO2
–
 negatively 
predicted NT (p=0.05; Table 3). 
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Table 3. Predictors of nitric oxide metabolites and nitrotyrosine in the aPL group. 
Variables in regression model    
Independent Dependent Predictors t p-value 
Persistent carriers of antiphospholipid antibodies 
IgG aCL, IgG a2GPI, IgG anti-HDL, 
IgG anti-ApoAI, aPTT, DRVVT 
NO3
-
 IgG aCL -2.06 0.03 
  DRVVT -1.93 0.03 
  IgG a2GPI -1.68 0.06 
     
NO3
-
, NO2
-
, TAC, smoking, CRP NT NO2
-
 -1.74 0.05 
Abbreviations: IgG aCL, anticardiolipin; IgG a2GPI, beta-2-glycoprotein-I; IgG anti-HDL, 
anti-high density lipoprotein; IgG anti-ApoAI, anti-apolipoprotein AI; aPTT, activated partial 
thrombiplastin time; DRVVT, dilute Russell viper venom time; NO2
-
, nitrite; NO3
-
, nitrate; TAC, 
total antioxidant capacity; NT, nitrotyrosine; CRP, C-reactive protein; SLEDAI, systemic lupus 
erythematosus disease activity index 
Relationship among variables in IT 
In the regression model with NT as the dependent variable and NO3
–
, NO2
–
, TAC, 
smoking, and CRP as independent variables, only CRP independently predicted NT 
(p=0.0006; Table 4). 
Relationship among variables in SLE  
In the regression model with NO3
–
 as the dependent variable and IgG anti- β2-GPI, IgG 
anti-HDL, IgG anti-ApoA-I, and IgG aCL as the independent variable, IgG aCL negatively 
predicted NO3
–
 (p=0.03); a similar result was obtained when NO2
–
 was substituted for NO3
–
 
(p=0.02; Table 3). In the model with NT as the dependent variable and NO3
–
, NO2
–
, TAC, 
smoking, and CRP as independent variables, NO2
–
  negatively predicted NT (p=0.002) and 
NO3
–
 positively predicted NT (p=0.001; Table 4). Finally, in the model with SLEDAI as the 
dependent variable and NO3
–
, NO2
–
, TAC, CRP, smoking, and NT as the independent 
variables, NT predicted SLEDAI (p=0.009) and a trend was seen for CRP (p=0.08; Table 4). 
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Relationship among variables in the control group  
No effect on NO2
–
 was seen in a multiple regression model with NO2
–
 as the dependent 
variable and age, sex, smoking, IgG anti-HDL, and IgG anti-ApoI as explanatory variables. In 
a similar model where NO3
–
 was set as the dependent variable, smoking independently 
predicted NO3
–
 (p=0.003; Table 4). Similarly, when NT was set as a the dependent variable 
with age, sex, smoking, TAC, NO2
–
 and NO3
–
 as explanatory variables, smoking 
independently predicted NT (p=0.02) alongside NO3
–
 (p=0.04; Table 4). 
Table 4. Predictors of nitric oxide metabolites and nitrotyrosine in non aPL groups. 
Variables in regression model    
Independent Dependent Predictors t p-value 
Inherited thrombophilia 
NO3
-
, NO2
-
, TAC, smoking, CRP NT CRP 3.75 0.0006 
Systemic lupus erythematosus 
IgG aCL, IgG a2GPI, IgG aHDL, IgG 
aApoA-I 
NO2
-
 IgG aCL -2.12 0.02 
     
IgG aCL, IgG a2GPI, IgG anti-HDL, IgG 
anti-ApoAI 
NO3
-
 IgG aCL -1.84 0.03 
     
NO3
-
, NO2
-
, TAC, smoking, CRP NT NO2
-
 -3.25 0.002 
  NO3
-
 3.65 0.001 
     
NO3
-
, NO2
-
, TAC, CRP, smoking, NT SLEDAI NT 2.55 0.009 
  CRP 1.44 0.08 
Normal controls 
Age, sex, TAC, CRP, smoking, NT NO3
-
 Smoking 2.90 0.003 
     
Age, sex, NO3
-
, NO2
-
, TAC, CRP, smoking NT Smoking 2.21 0.02 
  NO3
-
 1.75 0.04 
Abbreviations: IgG aCL, anticardiolipin; IgG a2GPI, beta-2-glycoprotein-I; IgG anti-HDL, 
anti high density lipoprotein; IgG anti-ApoAI, anti apolipoprotein A-I; aPTT, activated partial 
thrombiplastin time; DRVVT, dilute Russell viper venom time; NO2
-
, nitrite; NO3
-
, nitrate; TAC, 
total antioxidant capacity; NT, nitrotyrosine; CRP, C-reactive protein; SLEDAI, systemic lupus 
erythematosus disease activity index 
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DISCUSSION 
A small study had demonstrated lower urinary NO2
–
 in PAPS, in negative correlation with 
serum IgG aCL titre (53). Of the NO metabolites, it is widely accepted that in humans, only 
NO2
–
reflects changes in eNOS activity (54,55) and endothelial dysfunction (56) known to be 
impaired in APS (57). To validate the clinical significance of NO2
–
 and NO3
–
 with regard to 
thrombosis in PAPS we employed as comparator patients with IT who had vascular 
occlusions, aPL patients who had no vascular occlusions, patients with SLE as an 
inflammatory disease control group, and healthy subjects. The low average concentration of 
NO2
–
 found in PAPS and IT suggests that reduced NO2
–
 may be involved in the vascular 
events of these patients, although causality cannot be established since vessel occlusion might 
have led to reduced NO2
–
: in fact, the number of vascular occlusions was a negative 
independent predictor of NO2
–
 in PAPS. Nevertheless NO2
–
 was also low in the aPL group 
who never had vessel occlusions, suggesting that impaired NO2
–
 generation may precede and 
hence represent a predisposing factor for thrombosis. Reduced NO has a wider importance in 
the vascular biology of PAPS. NO maintains vascular homeostasis against the vasopressor 
effects of endothelin-1, of F2-isoprostanes derived from lipid peroxidation, and of 
thromboxane generated after platelet activation (58). Indeed, elevated plasma and/or urinary 
levels of the aforementioned molecules have all been described in PAPS (49,59,60): hence 
loss of the antiplatelet effect of NO may be relevant to thrombosis (61) and loss of its 
vasodilator effect may be relevant both to thrombosis and to atherosclerosis.  
Of further interest, aPL negatively predicted NO3
–
 and/or NO2
–
 in the PAPS, aPL, and 
SLE groups, adding further to the pathogenic potential of aPL. We previously demonstrated 
that monoclonal IgG aCL was associated with decreased concentrations of NO metabolites in 
a mouse model (50). Inducible NOS may generate a 1000-fold higher concentration of NO 
than eNOS, which is associated with vascular damage and cytotoxic effects, whereas NO is 
generated by eNOS for short periods of time to maintain vascular homeostasis (62). Likely 
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only the latter pathway is impaired in PAPS, whereas the former pathway may be more active 
in SLE, the group that showed a greater concentration of NO3
–
, although a large difference 
was not seen because our patients with SLE were mostly clinic attendees devoid of acute or 
chronic renal disease with low disease activity, hence inflammatory activity. Notwithstanding, 
our data in SLE would be consistent with possible iNOS activation, cytotoxic release of NO 
ultimately leading to tyrosine nitration due to the inflammatory nature of the disease (62). 
Among the antibodies that might have had an influence on NO IgG anti-HDL and IgG anti-
ApoAI were included because in previous work their average plasma concentrations was 
elevated in SLE and PAPS, where they adversely affected the antioxidant system associated 
with HDL, favouring oxidation (63,64). In our present study, they failed to show any relation 
with NO metabolites, indirectly confirming their specificity in blunting the anti-atherogenic 
and anti-inflammatory effects of HDL (63). To investigate nitrative stress in PAPS we 
measured crude plasma NT: this was higher in the SLE group, where NT related to disease 
activity and was predicted by NO3
–
, in keeping with findings from other inflammatory 
rheumatic disorders (65). On the other hand, having demonstrated that low grade 
inflammation characterizes PAPS (66), we found that CRP was an independent predictor of 
NT in the PAPS group, suggesting that nitrative stress and low grade inflammation may be 
related phenomena in these thrombotic patients. Interestingly, smoking predicted NO3
–
 in 
PAPS, and it is known that active (29) and passive smoking (67) may induce oxidative stress. 
Our study has several limitations: a) its retrospective design prevented a full appreciation 
of the role of NO in thrombosis as most PAPS patients were diagnosed after vascular 
occlusion; b) our SLE group comprised female patients of whom only 5 had a history of 
thrombosis; however, we had opted for inclusion of the SLE group mostly to show the 
inflammatory behaviour of NO rather than to control for thrombosis, which was provided for 
by the IT group; c) the method we employed for the measurement of NO metabolites is not 
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sensitive enough to detect nanomolar concentrations of NO2
–
 and NO3
–
 (68), and we did not 
evaluate eNOS and/or iNOS gene polymorphisms that may have accounted for differences in 
measured metabolites (69,70), although our groups would have been too small to yield 
significant data. In conclusion, our study, alongside our previous animal data (50), indicates 
an impairment of the vascular biology of NO in PAPS, the consequences of which may be 
thrombosis and atherosclerosis. With regard to the former, we cannot define whether 
decreased NO2
–
 is a cause or an effect of previous thromboses, but the low NO2
–
 in the aPL 
group without vessel occlusions and the relationship between NO metabolites and aPL in the 
PAPS, aPL, and SLE groups indicate that aPL may negatively influence some physiological 
activities of NO. With regard to the latter, patients with PAPS exhibit a certain degree of 
nitrative stress that relates to low grade inflammation, also noted in other settings (71): given 
the finding of NT in vessels of atherosclerotic patients (35), this aspect needs to be further 
explored in PAPS. From a practical point of view, our study provides evidence that smoking 
should be avoided in patients with PAPS.   
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CHAPTER VII 
INFLAMMATION AND IMMUNE ACTIVATION IN THROMBOTIC 
PRIMARY ANTIPHOSPHOLIPID SYNDROME. 
INTRODUCTION 
Inflammatory and immune markers in atherosclerosis 
Basic science studies have demonstrated that atherosclerosis is a chronic inflammatory 
process whereas epidemiological and clinical studies have shown independent relationships 
between plasma levels of certain inflammatory proteins such as C-reactive protein (CRP) and 
serum amyloid A (SAA) and cardiovascular disease. Conceivably altered plasma levels of 
these inflammatory proteins reflect the presence of inflammation in the arterial wall (1, 2) or 
elsewhere in the body that might increase the risk for atherosclerosis. 
C-reactive protein  
CRP is a member of the pentraxin family containing five non-covalently linked protomers 
surrounding a central pore. It is transported free in plasma rather than bound to circulating 
lipoproteins, although it can interact with oxidized phospholipids and oxidized lipoproteins in 
vitro (3). CRP activates complement and binds to Fc receptors, which may facilitate the 
uptake and clearance of apoptotic and necrotic cells during the acute-phase response (4).  
CRP and prediction of clinical cardiovascular events 
Being the first acute-phase protein identified CRP is the best studied marker of 
inflammation in humans. Increased levels of CRP predict first clinical events, recurrent 
events, coronary heart disease end points, and stroke (reviewed in 5). In certain studies, CRP 
was a more powerful predictor of cardiovascular risk than traditional risk factors such as LDL 
(6). The risk prediction was independent of LDL and HDL cholesterol (7) and beyond the 
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power derived from using Framingham risk scores (8). The magnitude of these predictive 
powers have been recently challenged by the Reykjavik Prospective Cohort Study (9), where 
multivariate analysis suggested that measuring CRP added less to the predictive power than 
previous studies and were less powerful than traditional risk factors. After adjustment for 
smoking status, body mass index, and total blood cholesterol, participants in the highest tertile 
of CRP had only a 1.5-fold higher risk for coronary artery disease than those in the lowest 
tertile. In contrast, the odds ratio was 2.4 for subjects with increased cholesterol and 1.9 for 
smokers. Strengths of this study included the large number of subjects (>20,000, the largest 
number reported to date), the large number of cardiovascular events, the length of follow-up 
(20 years), and low rates of dropout in the study population (9). These observations suggest 
that CRP might contribute less to predictions than traditional risk factors of cardiovascular 
disease.  
CRP and atherogenesis  
The atherogenic mechanisms of CRP have been investigated mostly in model systems 
using cultured endothelial cells. CRP is able to impair production of anti-thrombotic 
molecules such as nitric oxide (10) and prostacyclin (11) and increased production of 
potentially atherogenic molecules such as endothelin-1 (12), various cell adhesion molecules 
(12, 13), monocyte chemoattractant protein 1 (13), interleukin-8 (14), and PAI-1 (15). CRP 
induces macrophage secretion of tissue factor (16) and their production of reactive oxygen 
species (17) and pro-inflammatory cytokines (18). CRP also increases the uptake of oxidized 
LDL (3), and favors monocyte adhesion and chemotaxis (19, 20).   
The elevated concentration and the purity of the CRP employed represent inherent 
limitations to these in vitro studies. Given that CRP has been detected 
immunohistochemically in atherosclerotic lesions (3, 21, 22) it appears that CRP might be 
involved from early to late atherosclerosis through a continuum of endothelial cell injury, 
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impairment of vasodilation, enhanced monocyte adhesion, lipid accumulation by monocyte-
macrophages, smooth muscle cell proliferation, plaque rupture and thrombosis.  
Serum amyloid A 
SAA is an amphipathic, α-helical apolipoprotein that is transported in the circulation 
primarily in association with HDL (23-25). Plasma SAA increases rapidly during acute 
inflammation in humans and mice (26). Although most SAA is produced by the liver, it can 
be produced by extrahepatic sources: indeed messenger RNA for SAA has been detected in 
all of the major cell types present in atherosclerotic lesions which contain both acute-phase 
and constitutive forms of SAA protein (27).  
SAA and prediction of clinical cardiovascular events 
In several observational and prospective studies, the risk of cardiovascular disease 
associated with SAA paralleled that seen with CRP although the absolute level of risk was 
generally smaller. A chronic modest increase in SAA level also appears to be associated with 
an increased risk of cardiovascular disease (28-31). 
SAA and atherogenesis 
In vitro and in vivo experiments in animals indicate that apolipoprotein SAA is a 
chemoattractant for inflammatory cells such as monocytes, polymorphonuclear leukocytes, 
and T-lymphocytes (31, 32) involved in atherogenesis. Lipoprotein-associated SAA plays a 
role in cholesterol transport by increasing the delivery of cholesterol to peripheral cells (33, 
34) whereas non-HDL-associated SAA promotes cholesterol efflux by both ABCA1-
dependent and -independent mechanisms (35). SAA circulates in the blood bound to HDL, 
but it is conceivable that SAA not associated with lipoproteins could be formed from HDL in 
the artery wall or secreted directly by artery wall cells (27). Thus, lipoprotein-associated and 
non-lipoprotein-associated SAA might play different roles in the delivery and removal of 
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cholesterol from cells at inflamed or injured sites. SAA has been shown to displace apoA-I 
from HDL in vitro with functional consequences (36).   
Chronic increases of SAA might induce the stimulation of monocyte adhesion and 
chemotaxis into the artery wall and increased delivery of cholesterol to artery wall cells, two 
processes that might contribute to the initiation and progression of atherosclerotic lesions. 
Because SAA binds to proteoglycans (37), chronic inflammation might facilitate the binding 
of SAA-containing HDL to extracellular vascular proteoglycans, which would favor the 
retention and modification of HDL by the vascular matrix preventing HDL from participating 
in reverse cholesterol transport and inhibiting oxidative processes in the artery wall. 
Moreover, modification of the lipid and protein components of trapped HDL might increase 
its interactions with macrophage scavenger receptors and render the lipoprotein atherogenic, 
similar to what happens with LDL (38). Therefore SAA may behave as a marker and a 
mediator of atherosclerosis.  
CD14: membrane bound and soluble  
The CD14 receptor is a 356 amino acid membrane glycoprotein where the C-terminal 
leader sequence of 28–30 amino acids is replaced by a glycosyl phosphatidylinositol (GPI) 
anchor after translation that maintains CD14 attached to the cellular membrane (39). 
Membrane CD14 (mCD14) is expressed on the surface of monocytes and the expression 
increases with differentiation of monocytes into macrophages. Shedding of mCD14 induced 
by serine proteases leads to soluble CD14 (sCD14) present in plasma as two isoforms with 
different molecular weights. Because mCD14 is not a trans-membrane protein a co-receptor is 
needed to activate the mCD14 intracellular signalling pathways. The most important of the 
CD14 co-receptors is the Toll like receptor 4 (TLR4) (39). The TLR4 is a receptor for 
lipopolysaccharide and heat-shock proteins that cannot function in isolation but co-operates 
with mCD14 to generate an innate immune response (40). Binding to the TLR4/mCD14 
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complex initiates trans-membrane signalling through to activation of nuclear factor kappa-
beta, production of pro-inflammatory cytokines from monocyte/macrophages and adhesion 
molecules from endothelial cells (39).   
CD14 and prediction of clinical cardiovascular events 
Immunochemistry studies show that TLR4/mCD14 complex is expressed on macrophages 
and endothelial cells within the atherosclerotic plaque (41) but there is no relationship 
between plasma concentrations of sCD14 and stable coronary artery disease or carotid IMT 
(42-44). 
Neopterin  
Neopterin (NPT) is a pteridine compound deriving from guanosine triphosphate produced 
in large amounts by human monocytes/macrophages upon stimulation with the cytokine 
interferon-γ released by activated T-lymphocytes. As such it is a marker for immune system 
activation that is suitable for the assessment of vascular diseases such as atherosclerosis (45). 
Neopterin and prediction of cardiovascular disease 
Early studies revealed elevated serum NPT in subjects with different stages of peripheral 
vascular disease (46) and with carotid atherosclerosis (47). Having extended the studies to 
subjects with or without stable coronary artery disease NPT resulted predictive of total and 
cardiovascular mortality after adjusting for traditional risk factors for atherosclerosis (48). 
Moreover NPT predicted patients undergoing coronary artery disease progression (49) and 
identified patients at long-term risk of death or recurrent acute coronary events after acute 
coronary syndrome (50) and in patients with chronic stable angina pectoris (51).  
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Antiphospholipid syndrome, immune activation and inflammation 
The presence of antibodies and T-cell clones against β2GPI in the peripheral blood of 
affected patients define PAPS as an autoimmune disorder (52, 53). Antibodies against β2GPI 
promote endothelial cell, monocyte and coagulation activation: the vessel wall shifts to a pro-
adhesive and pro-thrombotic phenotype (54), monocytes express and release TNF and tissue 
factor (55) and thrombosis may ensue. Circulating levels of pro-inflammatory cytokines are 
elevated in APS (56-58) and some novel pro-inflammatory genes are up-regulated in 
endothelial cells stimulated with IgG β2GPI (59) but PAPS is not an inflammatory disorder in 
the traditional sense as only modest increases of CRP have been detected (60-63). Despite the 
presence of auto-reactive T-cell clones (52, 53) in vivo markers of immune activation have 
not been investigated in PAPS. Stimulated T helper cells release IFN-γ that activates 
monocytes with the release of NPT and modulation of their surface component CD14 (45). 
Therefore, NPT is a specific marker of immune cooperation, whereas soluble CD14 (sCD14) 
may also reflect monocyte activation in the absence of IFN-γ as it can behave as an acute-
phase reactant (64). Moreover, the observation that β2GPI is a ligand for oxLDL (65) and that 
the resulting oxLDL-β2GPI complex binds CRP (66) prompted us to evaluate the clinical 
relevance of CRP, SAA (inflammatory markers), NPT and sCD14 (immune activation 
markers) and their relationship with oxLDL-β2GPI-CRP in thrombotic patients with PAPS 
EXPERIMENTAL DATA 
Patients  
The study was conceived as a cross-sectional case double-control to serve as a baseline for 
an interventional trial. Consecutive thrombotic patients fulfilling recent criteria for PAPS and 
patients with IT attending the Coagulation Unit of the Cardarelli Hospital (Naples, Italy) were 
invited to participate in the study that was carried out according to the revised Declaration of 
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Helsinki, with approval of the Ethics Board of the Hospital and the written consent of all 
participants. Exclusion criteria were acute or chronic hepatic, renal, lung disease, diabetes, a 
recent history of acute infection (within 6 weeks), post-thrombotic syndrome with venous 
ulcerations, a positive urinary dipstick for nitrates on the day of sampling, treatment with 
steroids, statins and fibrates. Patients are seen on average every 3–4 weeks for their oral anti-
coagulation monitoring and are instructed to self-report any illness they might incur during 
the intervening periods. Every year, their lipid profile, kidney and liver function tests are 
checked. Of the PAPS attendees (n=50), two were excluded because they had gradually 
developed AS and SLE, one had developed kidney cancer, two were pregnant, one had 
suffered a recent recurrent event, one had post-thrombotic syndrome and two were evasive 
regarding their smoking and contraceptive status. Of the IT (n=46) attendees, two were 
excluded for venous ulcerations in lower limbs. The study therefore included 41 thrombotic 
PAPS patients, 44 IT patients and 39 control subjects. The laboratory criteria for diagnosis of 
APS define Category IIa as lupus anti-coagulant (LA) alone, IIb as aCL alone, IIc as anti-
β2GPI alone and Category I as any combination of the previous: of our PAPS patients, eight 
were in laboratory Category IIa and the remaining in Category I. From the therapeutic 
viewpoint, all were taking warfarin, three were on carbamezapine for post-ischaemic epilepsy, 
two on β-blockers six on folic acid. Of the IT patients, all were on warfarin, two were on β-
blockers five on folic acid and two on angiotensin-converting enzyme inhibitors. The control 
group included 19 blood donors, 9 healthy hospital personnel and 11 subjects on warfarin for 
mitral valve replacement (mitral valve prolapse, n=4; childhood rheumatic fever, n=4; 
ventricular septal defects with congenital mitral incompetence, n=3) that occurred on average 
22±8 yrs earlier. This partially accounts for the lifelong warfarin intake of the other two 
groups. Demographics and clinical features of all participants are shown in Table 1.  
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Table 1. Demographics of participants. 
 Controls   
 Healthy Warfarin IT PAPS 
No 28 11 44 41 
Age (mean±SD) 37±9 60±10 51±14 40±12 
M/F 10/18 4/7 19/25 18/23 
Age at thrombosis  (mean±SD)   39±14 35±11 
Thrombosis type     
Arterial    9 13 
Venous   32 24 
Arterial+ venous   3 4 
Thrombosis number      
1   31 13 
2   10 14 
3 or >3   3 4 
IgG aCL (mean±SD) 11±12 6.3±1.5 7.5±6.8 131±143 
IgG β2GPI (mean±SD) 2.3±1.0 3.1±0.07 4.2±0.8 119±67 
Smoking (sig/day)     
<11 6 2 5 3 
11-20 1 0 2 3 
>20 1 1 3 2 
Ex smoker 0 0 0 4 
Tryglycerides >150 mg/dl 1 2 3 4 
Cholesterol >200 mg/dl 3 4 5 4 
BMI >30 0 0 1 2 
HRT 1 1 2 0 
OC 5 0 2 3 
Menopause 1 3 6 2 
IT: inherited thrombophilia; PAPS: primary antiphospholipid syndrome; aCL: 
anticardiolipin; β2GPI: beta-2 glycoprotein I; BMI: body mass index; HRT: hormone 
replacement treatment; OC: oral contraception.  
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RESULTS 
Comparison of inflammatory and immune markers across groups 
Average plasma levels of CRP, SAA, NPT, sCD14, CRP/oxLDL/β2GPI and 
oxLDL/β2GPI were higher in PAPS than other groups considered (Figure 1). Amongst age, 
gender, menopause, oral contraception, smoking and obesity, ANCOVA identified only age 
as a significant confounder for NPT (p=0.007), sCD14 (p=0.0001), oxLDL/β2GPI (p=0.02) 
and SAA (p=0.04). Age-adjusted significances between groups were p<0.01 for SAA, 
p<0.0001 for NPT, p=0.007 for sCD14, p=0.0001 for oxLDL/β2GPI. Within PAPS, IT and 
CTR, the proportion of participants positive for CRP was 31, 13 and 10%, respectively 
(p=0.02), for SAA 31, 6 and 2%, respectively (p<0.0001), for NPT 68, 27 and 15%, 
respectively (p<0.0001), for sCD14 48, 34 and 23%, respectively (p=0.054), for 
CRP/oxLDL/β2GPI 53, 31 and 18%, respectively (p<0.003), oxLDL/β2GPI 41, 9 and 10%, 
respectively (p=0.0002). Sensitivity and specificity of CRP/oxLDL/β2GPI was 51 and 100%, 
respectively with regards to thrombotic PAPS, but 53 and 64%, respectively with regards to 
arterial thrombosis 
Relationship amongst variables in the PAPS group 
Two regression models were employed: the first assessed the predictive effect of IgG aCL, 
IgG β2GPI, gender, event type, event number, age at event and smoking status on plasma 
levels of CRP, SAA, NPT, sCD14, CRP/oxLDL/β2GPI and oxLDL/β2GPI; the second 
assessed the relationship between immune activation markers and inflammatory markers after 
correction for gender, event type, event number, age at event, smoking status in the absence 
of IgG aCL and IgG β2GPI. Remarkably, in the first model, IgG β2GPI was an independent 
predictor of SAA, NPT, sCD14 and CRP/oxLDL/β2GPI. The number of thrombotic events 
predicted SAA and NPT, whereas arterial thrombosis predicted NPT and sCD14 (Table 2). 
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Figure 1. Average levels of (A) hs-CRP, (B) SAA, (C) NPT, (D) sCD14, (E) CRP bound to the 
oxLDL-β2GPI and (F) oxLDL-β2GPI complex in PAPS, IT and CTR. The long horizontal bar is the 
cut-off level for each variable arbitrarily set at the mean±5  SEM. The P-value represents the overall 
ANOVA significance. Bonferroni’s multiple comparison revealed: for hs-CRP, PAPS vs IT and PAPS 
vs CTR, both p<0.01; for SAA, PAPS vs CTR, p<0.01; for NPT, PAPS vs IT and PAPS vs CTR, both 
p<0.001; for CRP–oxLDL-β2GPI, PAPS vs IT and PAPS vs CTR, both p<0.01; for oxLDL β2GPI 
PAPS vs IT and PAPS vs CTR, both p<0.01. No post hoc values were derived for sCD14. 
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Table 2. Independent predictors of inflammatory and immune activation markers in PAPS including 
IgG aCL and IgG β2GPI as independent variables. 
Dependent variable Predictors β p-value 
SAA Thrombosis number 0.572 0.003 
 IgG β2GPI 0.424 0.06 
    
NPT Arterial thrombosis 0.405 0.03 
 Thrombosis number 0.390 0.04 
 IgG β2GPI 0.477 0.04 
    
sCD14 IgG β2GPI 0.764 0.0001 
 Age 0.993 0.001 
 Arterial thrombosis 0.395 0.01 
    
CRP-oxLDL-β2GPI IgG β2GPI 0.574 0.02 
    
oxLDL-β2GPI IgG aCL 0.714 0.0001 
Independent variables in the model were: age, sex, thrombosis type (arterial, 
venous), thrombosis number, age at thrombosis, smoking status, IgG β2GPI, IgG aCL.  
 
 
 
Indeed, the average plasma concentration of NPT was greater in patients with arterial than 
venous thrombosis (16.7 ± 2.4 vs 11 ± 0.9 nmol/ml, p=0.02) but that of sCD14 did not reach 
significance (data not shown). On the other hand, average plasma concentration of SAA was 
almost 50% higher in patients with arterial than venous thrombosis (85 ± 18 vs 45 ± 9 mg/ml, 
p=0.04). In the second regression model, NPT and sCD14 correlated with each other as did 
CRP/oxLDL/β2GPI and SAA (Table 3).  
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Table 3. Independent predictors of inflammatory and immune activation markers in PAPS excluding 
IgG aCL and IgG β2GPI as independent variables 
Dependent variable Predictors β p-value 
SAA CRP-oxLDL-β2GPI 0.642 0.002 
    
NPT sCD14 0.723 0.002 
    
sCD14 NPT 0.709 0.002 
 Age 0.764 0.025 
    
CRP-oxLDL-β2GPI SAA 0.787 0.002 
Independent variables in the model were: age, sex, thrombosis type 
(arterial, venous), thrombosis number, age at thrombosis, smoking status, 
CRP, SAA, NPT, sCD14, and CRP-oxLDL-β2GPI: each of the dependent 
variables was investigated omitting it from the independent variable list.  
Relationship amongst variables in the IT group 
Multiple regression analysis strongly revealed interrelations between SAA and CRP as 
well as between NPT and sCD14 (Table 4).  
Table 4. Independent predictors of inflammatory and immune activation markers in inherited 
thrombophilia  
Dependent variable Predictors β p-value 
CRP SAA 0.547 0.009 
    
SAA CRP 0.518 0.009 
 sCD14 0.447 0.07 
    
NPT sCD14 0.685 0.0001 
Independent variables in the model were: age, sex, thrombosis type 
(arterial, venous), thrombosis number, age at thrombosis, smoking status, 
CRP, SAA, NPT, sCD14, and CRP-oxLDL-β2GPI.  
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Relationship amongst variables in the control group 
Multiple regression analysis identified oxLDL/β2GPI as an independent predictor of CRP, 
SAA and sCD14, whereas the inflammatory markers were strongly related (Table 5).  
Table 5 Independent predictors of inflammatory and immune activation markers in normal controls 
Dependent variable Predictors β p-value 
CRP oxLDL-β2GPI 1.039 0.0001 
 SAA -0.276 0.03 
    
SAA oxLDL-β2GPI 1.118 0.0001 
 NPT 0.310 0.03 
    
sCD14 oxLDL-β2GPI 0.934 0.008 
    
NPT SAA 0.685 0.0001 
Independent variables in the model were: age, sex, thrombosis type 
(arterial, venous), thrombosis number, age at thrombosis, smoking status, 
CRP, SAA, NPT, sCD14, and CRP-oxLDL-β2GPI: each of the dependent 
variables was investigated omitting it from the independent variable list.  
DISCUSSION 
CRP and SAA are acute-phase plasma proteins principally expressed and induced in the 
liver under the regulation of the pro-inflammatory cytokines IL-1, IL-6 and TNF-α though 
non-acute-phase elevations may occur in several chronic inflammatory diseases such as RA 
and atherosclerosis (67). The current survey reveals that a significant number of thrombotic 
PAPS patients display a low-grade inflammatory state that must be due to the disease itself, as 
IT patients did not show similar elevations of CRP and SAA. Thus, we support a relationship 
independent of thrombosis between LA and the inflammatory markers, CRP (62), factor VIII 
and fibrinogen (61); elevated levels of CRP independently predicted residual or recurrent 
symptoms in a cohort of aPL-positive patients with neurological manifestations, mostly 
cerebral infarctions and transient ischaemic attacks (63).  
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Contrary to the lack of clinical relevance of SAA in a very small PAPS group (68), SAA 
was elevated in our patients particularly in relation to multiple thrombotic events. 
Unfortunately, the cross-sectional nature of the study cannot define whether elevated SAA 
and CRP are cause or effect of previous occlusive events since both molecules are involved in 
the expression of tissue factor on monocytes and endothelial cells (69, 70). Therefore, their 
value as thrombotic risk markers in PAPS may only be assessed with regards to re-thrombosis 
as most PAPS patients will be on oral anti-coagulation after their first occlusive event. 
Compared with IT and controls, our PAPS patients displayed higher plasma 
concentrations of NPT and of sCD14 that correlated strongly in both patient groups. In PAPS, 
NPT was higher in patients with multiple thromboses and both markers related to arterial 
occlusions: monocytes are more likely to be involved in the pathogenesis of arterial than 
venous thrombosis (71). The independent predictive power of IgG β2GPI vs sCD14 and NPT 
reflects the in vitro work describing monocyte activation including tissue factor expression by 
IgG β2GPI (55, 72) that adds to the T-helper activation pathway.  
In a similar context, monocytes may differentiate into foam cells after the uptake of an 
immune complex consisting of β2GPI, oxLDL and a monoclonal aPL (72). Though 
oxLDL/β2GPI complex is formed as an attempt by β2GPI to prevent LDL oxidation and its 
uptake by monocyte scavenger receptors, it is recognized by specific antibodies and up-taken 
by monocytes via Fc receptors (73). Monocytes play a pivotal role in APS: the direct effect of 
IgG β2GPI promotes tissue factor expression (55, 72) and hence clotting in the bloodstream, 
whereas phagocytosis of oxLDL–β2GPI bound to their specific antibody probably favours 
atherosclerosis (74).  
OxLDL/β2GPI complexes are found in primary and secondary APS, SLE (74) and chronic 
nephritis (75), disorders characterized by enhanced oxidative stress (76, 77). In PAPS, we and 
others had noted a correlation between plasma IgG aCL and isoprostanes, sensitive markers of 
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in vivo oxidative stress (78, 79), and in the light of the above this could explain the 
relationship between IgG aCL and oxLDL/β2GPI in the present PAPS population.  
Experimental work reveals that in analogy with certain natural antibodies and scavenger 
receptors, CRP binds phosphorylcholine (PC) moieties on apoptotic cells and on oxLDL in 
what appears a very primitive form of innate immunity (65). More recent in vitro data 
demonstrate that over a 24-h incubation period CRP can bind oxLDL/β2GPI via PC in a 
ternary complex (58). Given the very short half-life (10 min) oxLDL when injected into mice 
and the co-localization of CRP, oxLDL and β2GPI with foamy macrophages in carotid artery 
plaques CRP/oxLDL/β2GPI would fulfill the requirements for a specific marker of 
atherosclerosis (58), a hot topic in APS. In this study CRP/oxLDL/β2GPI was 100% specific 
for PAPS but did not differentiate arterial and venous thrombosis. Interestingly, higher 
CRP/oxLDL/β2GPI was predicted by elevated IgG β2GPI, indicating that an enhanced level of 
LDL oxidation requires buffering from both β2GPI and CRP. LDL oxidation is prevented by 
paraoxonase (PON), the enzyme that accounts for most of the anti-oxidant activity of HDL: in 
PAPS, decreased PON activity associates with elevated IgG β2GPI titres and a monoclonal 
aPL inhibited PON activity (PONa) in vitro (80). On the other hand, β2GPI buffering of 
oxLDL would lead to exposure of cryptic auto-antigenic epitopes on β2GPI with persisting 
antibody stimulation (81). In the case of the oxLDL/ß2GPI complex, the antibody response 
would be mostly IgG aCL; once the CRP/oxLDL/β2GPI is formed, the highly specific IgG 
β2GPI would be stimulated.  
In the control group, no patient had elevated CRP/oxLDL/β2GPI, but some had elevated 
oxLDL/β2GPI that was an independent predictor of CRP, SAA and sCD14: a possibility is 
that CRP/oxLDL/β2GPI and oxLDL/β2GPI are formed at high and low LDL oxidation levels, 
as would occur in PAPS and normal subjects, respectively. In the latter case, only β2GPI is 
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required to buffer oxLDL though the resulting oxLDL/β2GPI complex still associates with 
CRP.  
In conclusion, immune activation and low-grade inflammation occur in PAPS. The former 
was not unexpected but the latter raises further issues: are the inflammatory markers 
measured of liver or vascular origin? Endothelial cells, smooth muscle cells and monocytes 
can produce CRP as well as SAA in atherosclerotic lesions (27, 82, 83). Indeed, 
CRP/oxLDL/β2GPI related to SAA in this survey. Outside the acute setting, mild plasma 
elevations of CRP, SAA and NPT represent an inflammatory signature of advanced 
atherosclerosis (84, 85) but do not add discriminatory diagnostic power over established 
cardiovascular risk factors (30). The picture may be different in PAPS where atherosclerosis 
may not necessarily involve traditional cardiovascular risk factors (86): as number and type of 
events were linked to plasma levels of CRP, SAA and NPT these may represent useful 
markers alongside CRP/oxLDL/β2GPI to predict vascular disease progression and to monitor 
monocyte and vascular activity in interventional trials (87-89). 
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CHAPTER VIII 
ANTIPHOSHOLIPID ANTIBODIES, HAEMOSTATIC VARIABLES 
AND ATHEROSCLEROSIS IN THROMBOTIC PRIMARY 
ANTIPHOSPHOLIPID SYNDROME 
INTRODUCTION  
Antiphosholipid antibodies, arterial disease and atherosclerosis  
The issue of arterial disease and atherosclerosis is at the forefront of clinical research in 
the APS. Amongst non-traditional risk factors for atherosclerosis aPL antibodies partially 
explain, alongside traditional risk factors (1), the elevated risk of cardiovascular disease in 
SLE (reviewed in 2). Before PAPS became a distinct clinical entity, the observation that some 
cases of vascular occlusion in APS were due to a proliferative vasculopathy rather than acute 
thrombosis (2, 3) lead to the search for an association between arterial disease and aPL. Early 
studies focused essentially on aCL, others on the LA. A cross-sectional survey in 234 patients 
who underwent vascular surgery for peripheral arterial disease revealed a positive aPL test in 
25% of patients. These patients were 1.8-times more likely to have had previous lower-limb 
vascular surgery, 5.6-times more likely to have had occlusion of that procedure and four-
times more likely to be female (4). The same authors later reported that aPL-positive (aCL 
and/or LA) patients undergoing lower-limb arterial bypass surgery were more likely to have 
progression of their disease post-bypass compared with aPL-negative patients (73 vs 37%; p < 
0.0001). aPL also appeared superiorly predictive of arterial disease progression compared 
with traditional risk factors (5). A case-control study in 62 patients younger than 50 years of 
age operated for atherosclerotic peripheral vascular disease detected IgG aCL in 14.5% of the 
patients. Interestingly, patients with IgG aCL were mostly female and had a lower prevalence 
of hyperlipidemia/dyslipidemia compared with patients without IgG aCLs (6). In a cohort of 
123 patients with a variety of vascular involvement IgG aCL were more common in patients 
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with cerebral and peripheral involvement (7). With regards to the LA, the dilute Russell's 
viper venom time (DRVVT) and its platelet neutralization procedure was found in 43% of 60 
surgical vascular patients and in none of the 20 general surgical controls (p = 0.0002) (8) 
though a later survey in 150 patients with peripheral vascular disease found a lower 4% 
prevalence (9).  
Other aPL directed against β2GPI complexed with oxLDL and β2GPI complexed with 7-
ketocholesteryl-9-carboxynonanoate (oxLig-1), the very oxLDL-derived moiety that binds 
β2GPI (10) are associated with arterial thrombosis in APS (11). Macrophages uptake β2GPI-
oxLDL much faster in the presence of an antibody towards oxLDL-β2GPI (12) and there is a 
possibility that antibodies against β2GPI–oxLig-1 and β2GPI-oxLDL have atherogenic 
potential in primary APS. 
Measurement of the IMT of carotid arteries via high-resolution ultrasonography of carotid 
is a surrogate but established method to identify at-risk patients very early on (13) This 
methodology was applied to 45 PAPS patients with deep vein thrombosis and to a similar 
number of non-APS thrombotic controls matched by age, sex and other vascular risk factors. 
Having scanned the carotids, the abdominal aorta, and the femoral arteries, IMT and plaque 
prevalence were similar in the two groups and the authors concluded that atherosclerosis was 
not a feature of their PAPS cohort (14). Traditional and non traditional risk factors for 
atherosclerosis such as plasma FNG, vWF) homocysteine (HC) and novel aPL have not been 
explored in atherosclerosis related PAPS.  
Haemostatic variables, homocysteine, paraoxonase and atherosclerosis 
Numerous prospective epidemiological studies and clinical observations have 
demonstrated that plasma FNG is a strong, consistent and independent cardiovascular risk 
factor. A modest 10% increase in plasma FNG predicts future coronary heart disease 
endpoints with an odds ratio of 1.8 (95% CI, 1.6 to 2.00) when the top tertile of the FNG 
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distribution was compared to the bottom tertile (15). On the other hand, in adults without 
clinically overt atherosclerotic disease elevated plasma FNG was related to carotid IMT 
independently of age, body mass index, arterial systolic pressure, cholesterol, LDL-
cholesterol, smoking, CRP and vWF (16). To a lesser extent also PAI is a correlate of IMT 
(17). 
Homocysteine (HC) is a sulfur-containing amino acid, rapidly oxidized in plasma to the 
disulfides homocystine and cysteine-homocysteine. HC is not obtained from the diet but it is 
synthesized from methionine via a multi-step process. First, methionine receives an adenosine 
group from ATP, a reaction catalyzed by S-adenosyl-methionine synthetase, to give S-
adenosyl methionine (SAM). SAM then transfers the methyl group to an acceptor molecule, 
while the adenosine is then hydrolyzed to yield HC. HC is either converted via 
tetrahydrofolate (THF) back into methionine or converted to cysteine. Normal fasting plasma 
HC concentrations range between 5 and 15 µmol/L. Concentrations between 16-30, between 
31-100, and >100 µmol/L define moderate, intermediate and severe hyperhomocyst(e)inemia.  
Homocystinuria due to defective activity of cystathionine ß-synthase is a rare autosomal 
recessive genetic disorder (1:200000 births) leading to severe hyperhomocyst(e)inemia and a 
variety of abnormalities, including a high incidence of vascular pathology that may result in 
early death from myocardial infarction, stroke, or pulmonary embolism. Homocystinuria 
secondary to a heat-labile variant of MTHFR, due to a cytosine to thymine (C to T) transition 
at nucleotide 677 is more common (prevalence). A wealth of studies could not agree on the 
association between elevated HC and coronary artery disease, ischaemic stroke and peripheral 
vascular disease (18). Nevertheless, the Atherosclerosis Risk In Communities study detected a 
relationship between elevated HC and IMT of carotid arteries in asymptomatic subjects (19).  
Paraoxonase-1 (PON1) is a protein of 354 amino acids with a molecular mass of 43 kDa 
synthesized by the liver and circulating in plasma attached to HDL. PON1 accounts for most 
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of the antioxidant effect of HDL against oxidation of LDL and partly explains the protective 
effect of HDL against atherosclerosis. PON1 deficient mice on a high-fat diet develop 
atherosclerotic lesions in the proximal aorta twice as large than normal mice whereas over-
expression of human PON1 confers significant protection against the development of 
atherosclerosis in the same rodent. Moreover, signs of oxidative stress, vascular inflammation 
and thrombotic tendencies have been observed in PON1-deficient mice. In human studies, 
higher PON1 activity is associated with a lower incidence of major cardiovascular events. 
However, it remains uncertain whether this relationship is causal or correlational (reviewed in 
20). 
Herein we present two studies that explored the relation of haemostatic variables, HC and 
aPL with the IMT of carotid arteries and a third study comparing IMT in thrombotic PAPS 
with a second control group of patients with vascular occlusions due to IT to match the 
persistence of a thrombotic risk factor and the indefinite warfarin thrombo-prophylaxis of 
patients with PAPS.  
EXPERIMENTAL DATA 
1) IgG aCL, HAEMOSTATIC VARIABLES AND INTIMA MEDIA THICKNESS 
Patients and methods: this cross-sectional study was carried out on 42 (13 male, 29 
female) patients with idiopathic aPL (mean age 31±10 years), 29 of whom had PAPS and 13 
of whom were persistently positive for aPL in the absence of any underlying disorder. All 
participants were evaluated for a history of thrombosis, for coagulation anomalies suggestive 
of a LA and for a possible false positive venereal disease research laboratory (VDRL). None 
of the patients had suffered infective episodes during the study and a minimum of 9 months 
had elapsed from the last occlusive event in thrombotic patients. This was to allow for the 
acute phase nature of some of the plasma variables measured. A systolic blood pressure 
>140mmHg and/or a diastolic blood pressure >90mmHg was indicative of arterial 
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hypertension (or borderline hypertension). None of the participants in the study had systolic 
or diastolic hypertension. A total cholesterol level higher than 200mg/dl for subjects aged >29 
years, higher than 225mg/dl for subjects aged 30–39 years, higher than 245mg/dl for subjects 
40–49 years higher than 265mg/dl for subjects >50 years of age was indicative of 
hypercholesterolaemia. By this definition, only one patient (aged 28 years) had a slightly 
higher cholesterol level than expected for age (205 mg/dl). Hypertriglyceridaemia was 
defined as triglyceride level higher than 160mg/dl. Six patients had a triglyceride level higher 
than 160mg/dl (182±16mg=dl, range 162-203 mg/dl). None of the patients had diabetes 
mellitus. Demographics of the participants in the study are shown in Table 1. 
Table 1. Clinical characteristics of aPL participants. 
 aPL  (n=42) 
 N % 
Current smokers 2 4.7 
Ex-smokers 4 9.5 
Menopausal 3 7.1 
Oral contraceptive 2 4.7 
Hypercholesterolaemia 1 2.3 
Hypertriglyceridaemia 6 14.2 
Lupus anticoagulant 39 92 
IgG aCL (<20 GPL) 3 7.1 
IgG aCL (20-80 GPL) 17 40 
IgG (>80GPL) 22 52.3 
Platelets >150 x 10
9
/L 33 78.5 
Platelets <150 x 10
9
/L 5 11.9 
Platelets <100 x 10
9
/L 3 7.1 
Platelets < 50 x 10
9
/L 1 2.3 
Non thrombotic 13 30.9 
Arterial thrombosis 5 11.9 
Venous thrombosis 21 50 
Arterial + venous 3 7.1 
Warfarin 25 59.5 
Aspirin 8* 19 
APL: antiphospholipid antibody; aCL: anticardiolipin; 
* includes four non thrombotic participants. 
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RESULTS 
IMT and plasma variables according to gender and thrombotic status 
Table 2 shows the means of variables measured in the total aPL population and then 
according to gender. Mean IMT was 0.44 ± 0.01mm in the common carotid artery, 
0.48 ± 0.02mm in the carotid bifurcation and 0.41 ± 0.01mm in the internal carotid. Males 
showed thicker intima-media of the internal carotid than females as well as higher mean IgG 
aCL (p=0.02) (Table 2). Patients with a history of thrombosis (n=29) had higher mean levels 
of platelets (235 ± 12 vs 143 ± 18, p<0.0001), FNG (334 ± 9 vs 282 ± 13mg=dl, p=0.003) and 
triglycerides (125 ± 8 vs 88 ± 8mg=dl, p=0.006) than patients without such a history. 
Likewise, mean IMT of the carotid bifurcation was thicker in the thrombotic than non-
thrombotic group (0.50 ± ±0.02 vs 0.42 ± 0.02mm, p=0.04) and an almost significant 
difference was noted for the internal carotid (0.44 ± 0.02 vs 0.37 ± 0.02mm, p=0.056).  
Table 2. Average concentration of measured variables according to gender.   
 
Total 
(n=42) 
Male 
(n=13) 
Female 
(n=29) 
p-value 
(M vs F) 
Normal 
Ranges 
Age (years±SD) 36±10 38±9 35±10   
IgG aCL (GPL) 122±17 184±31 95±19 p=0.02 <5 
IgM aCL (MPL) 41±20 20±4.2 50±29  <5 
PLT (10
9
/L) 207±12 228±20 197±15  130-180 
HC umol/L 13±1.8 16±1.6 11±2.5  <12 
FNG (mg/dl) 318±8.3 329±17 313±5  160-360 
VWF (IU/dl) 119±4.3 119±7 119±5  50-150 
PAI (ng/ml) 39±3.4 48±8 35±3 p=0.04 <50 
CHO (mg/dl) 181±5.1 182±9.7 180±6.2  <265 
HDL (mg/dl) 45.8±1.4 43±3 46±1.5  30-70 
LDL (mg/dl) 109.4±9 110±9 109±5  50-190 
TG (mg/dl) 113.6±6.6 125±12 108±8  <160 
IMT IC (mm) 0.41±0.01 0.48±0.03 0.39±0.01 p=0.02  
ACL: anticardiolipin; PLT: platelets; HC: homocysteine; FNG: fibrinogen; VWF: von 
Willebrand factor; PAI: plasminogen activator inhibitor; CHO: cholesterol; HDL: high density 
lipoprotein; LDL: low density lipoprotein; TG: triglycerides; IMT: intima media thickness; IC: 
internal carotid.    
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Relationship between plasma variables and IMT   
The univariate relationship between plasma variables, age and number of thrombotic 
events with IMT of different carotid segments was assessed by simple regression (Table 3).  
Table 3. Correlates of intima media thickness (univariate analysis). 
 Common carotid Carotid bifurcation Internal carotid 
 R2 p-value R2 p-value R2 p-value 
Age 0.32 <0.0001 0.21 0.002 0.22 0.002 
IgG aCL 0.23 0.001 0.30 0.0002 0.40 0.0001 
FNG 0.17 0.006 0.31 0.0001 0.25 0.0008 
LDL 0.15 0.01     
CHO 0.13 0.02 0.14 0.01   
PAI 0.11 0.02   0.22 0.002 
HC 0.09 0.04 0.16 0.009 0.15 0.01 
VWF   0.13 0.01   
No Thr   0.11 0.03   
 
To test which factors independently predicted IMT of carotid artery segments those 
variables related to IMT in the univariate analysis were entered in a stepwise multiple 
regression model. This analysis confirmed IgG aCL, HC and FNG as independent predictors 
of IMT, with differing strength according to the carotid segment under study (Table 4). 
Table 4. Predictors of intima media thickness (multivariate analysis). 
Dependent variable Predictor β p-value 
Common carotid IgG aCL 0.375 <0.005 
Carotid bifurcation FNG 0.441 0.001 
 HC 0.404 <0.0001 
 IgG aCL 0.337 0.008 
Internal carotid IgG aCL 0.502 <0.0001 
 HC 0.405 <0.0001 
 FNG 0.268 0.03 
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2) ANTI β2GPI/oxLDL, ANTI β2GPI-oxLig-1 AND INTIMA MEDIA THICKNESS OF 
CAROTID ARTERIES 
Patients and methods: the study populations were drawn from consecutive patients 
attending the Coagulation Unit of the Cardarelli Hospital in Naples (Italy) who gave informed 
consent before entering the study, carried out according to the revised Declaration of 
Helsinki. All APS patients met the Sapporo Criteria for PAPS (Wilson et al. 1999). They were 
evaluated for a thrombotic event and were found to be positive for LA and aCL antibodies on 
two separate occasions 6 weeks apart. Patients with idiopathic aPL were detected because of 
the presence of a LA on routine clotting screen for minor surgical procedures or for health 
checks and never suffered any vascular manifestation of APS.  
Table 5 Demographics of study patients. 
 CTR 
(n=23) 
IT 
(n=17) 
aPL 
(n=10) 
PAPS 
(n=29) 
Female/male 13/7 11/6 7/3 20/9 
Age (median, range) 35 (20-68) 40 (30-58) 40 (29-54) 38 (27-63) 
IgG aCL (median, range)   59 (16-309) 118 (24-573) 
IgG β2GPI (median, range)   147 (40-216) 183 (1-226) 
FVL 0 12 0 2 
PT20210 1 2 1 1 
PC deficiency 0 3 0 0 
IS  2  8 
MI  0  1 
DVT  11  15 
PE  4  5 
Smoking 3 4 2 5 
Hypertension 0 0 2 5 
Diabetes 0 0 0 1 
High CHO 0 0 0 1 
High TG 0 0 1 2 
Aspirin 0 1 6 0 
Warfarin 0 17 0 29 
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Seventeen patients with IT who underwent vascular occlusions served as a thrombotic 
control group. Vascular events were diagnosed by MRI, doppler ultrasound, ECG and 
echocardiogram according to vascular bed involved. Twenty-three healthy hospital personnel 
served as a normal control group. None of the participants were on lipid lowering agents or 
antioxidant drugs at the time of the study. Plasma from patients and controls were kept at 
808C until analysis. Their demographics and clinical features are presented in Table 5. 
RESULTS 
PON1 activity, β2GPI-oxLDL complexes, anti-β2GPI-oxLDL and anti-β2GPI-oxLig-1 in 
study groups 
PON1 activity (nmol/ml/min) was relatively similar across groups, being 0.96 ± 0.25 in 
normal controls, 0.90 ± 0.34 in thrombotic controls, 0.87 ± 0.40 in idiopathic aPL and 
78 ± 0.35 in thrombotic PAPS patients. Plasma levels of β2GPI–oxLDL complexes were 
highest in the control group (Figure 1A), whereas, those of IgG anti-β2GPI–oxLDL (Figure 
1B) and anti-β2GPI–oxLig-1 (Figure 1C) were highest in the PAPS and aPL groups. These 
variables showed no gender differences in any of the groups, and no differences were noted 
between patients with arterial or venous thrombosis in the PAPS group. 
 
 
101 
 
 
Figure 1. Median plasma levels of β2GPI-oxLDL (A), of IgG anti-β2GPI-oxLDL (B) and IgG anti-
β2GPI–oxLig-1 (C) in the four study groups. CTR: normal controls; THR CTR: thrombotic controls; 
aPL: non thrombotic antiphospholipid positive subjects; APS: thrombotic antiphospholipid positive 
participants. 
Relationship amongst variables in the PAPS group 
Because two patients in this group did not have all variables measured, resulting analysis 
and data refer to 28 patients. With regards to antibody subtypes IgG anti-β2GPI-oxLig-1 
positively correlated to IgG anti-β2GPI (r = 0.49, p = 0.007) and to IgG aCL (r = 0.61, 
p = 0.0005). In decreasing order of strength PONa inversely correlated to IgG anti-β2GPI–
oxLig-1  (r = -0.51, p = 0.004),  to  IgG aCL (r = -0.53, p = 0.003) and to IgG anti-β2GPI 
(r = -0.41, p = 0.02). Of these, only IgG anti-β2GPI–oxLig-1 independently predicted PONa 
(β  = 0.44, p = 0.02) in a multiple regression that took into account the effect of age and sex. 
In addition, PONa inversely correlated to the IMT of the IC (Figure 2A) and of the B (Figure 
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2B). IgG anti-β2GPI-oxLig-1 positively correlated to IMT of all carotid segments (Figure 3A-
C). In a multiple regression model that included IgG anti-β2GPI-oxLig-1, IgG anti-β2GPI, and 
IgG anti-β2GPI-oxLDL as independent variables and IMT as a dependent variable and after 
correction for age and sex, IgG anti-β2GPI-oxLig-1 independently predicted IMT of B 
(β = 0.40, p = 0.01), CC (β = 0.36, p = 0.02) and IC (β = 0.55, p = 0.003). 
 
 
Figure 2. Relationship between paraoxonase activity (PONa) and intima media thickness (IMT) of 
internal carotid (A) and carotid bifurcation (B). 
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Figure 3. Relationship between IgG anti-β2GPI–oxLig-1 and intima media thickness (IMT) of 
common carotid artery (A), carotid bifurcation (B) and internal carotid artery (C) in thrombotic APS 
patients. 
3) DEFINITE EVIDENCE FOR ATHEROSCLEROSIS IN PAPS 
Participants 
The study was devised as a cross-sectional case double-control. To account for the 
occurrence of thrombosis, persistence of aPL and long-term warfarin intake of patients with 
PAPS, we enrolled a group of patients on long-term warfarin for vascular occlusions as a 
result of IT. Normal controls were recruited from hospital personnel undergoing annual health 
checks at the local Occupational Health Department and patients’ friends. From January 2003, 
consecutive thrombotic PAPS patients and patients with IT attending the Coagulation Unit of 
the Antonio Cardarelli Hospital (Naples, Italy) were invited to participate in the study that 
was carried out in accordance with the revised Declaration of Helsinki, with approval of the 
 
 
104 
 
Ethics Board of the Hospital and written consent obtained from all participants. Exclusion 
criteria were acute or chronic hepatic, renal and lung disease and diabetes. As a result of 
obvious difficulties in recruiting thrombotic IT patients perfectly matched by age and gender 
with PAPS and normal controls, by January 2008 we still lacked nine matching IT patients. 
To overcome this impasse, our specialist nurse performed a search by age and gender of our 
database to locate those IT patients who had moved their follow up to different anticoagulant 
clinics within or without the town after our initial diagnosis: a letter detailing our study and an 
invitation to participate was sent to 16 matching IT patients from the database. The first nine 
who agreed and met exclusion criteria entered the study in compliance with our ethics 
approval. All participants underwent a questionnaire to review information on diabetes, liver, 
renal and lung disease, hypertension, menopause, oral contraception, hormone replacement 
therapy and a parental history of cardiovascular disease.  Of our PAPS patients (n = 60), 11 
were excluded: two developed SLE (one of gradual onset, one of abrupt presentation after 
IVF), one kidney cancer, two developed type 2 diabetes mellitus and six because they had 
miscarriages but not vascular occlusions. Of the IT patients (n = 91), 35 were excluded 
because they did not match PAPS patients, three were excluded because of chronic liver 
disease, two because of chronic obstructive pulmonary disease and two developed type 1 
diabetes mellitus. The study, therefore, included 49 thrombotic PAPS patients (18 M, 31 F, 
mean age 37 ± 11 years) and an equal number of IT patients and controls subjects all perfectly 
matched by age and gender. All PAPS participants were on warfarin prophylaxis, three were 
on carbamezapine for post-ischemic epilepsy, two on beta-blockers, six on folic acid and one 
on angiotensin converting enzyme inhibitor. All IT patients were on warfarin prophylaxis, one 
on beta-blockers, seven on folic acid and two on angiotensin converting enzyme inhibitors. 
The control group included 34 healthy hospital personnel and 15 friends of patients. Neither 
patients nor controls were on lipid-lowering agents. A morning sample (after 14 h of fasting) 
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was taken for total-, HDL and LDL cholesterol and TG: healthy controls were also checked 
for genetic thrombophilia and aPL antibodies. Height and weight without shoes and garments 
were taken for BMI calculated as the ratio of weight in kilograms to height in square meters. 
Blood pressures were measured twice on one occasion, 1 min apart, with the participant 
seated and after 5 min of rest with the use of a standard mercury sphygmomanometer. Table 6 
illustrates demographics of all participants. 
Table 6. Demographics of participants in study groups. 
 CTR IT PAPS 
 (n=49) (n=49) (n=49) 
Female (%) 31 (63) 31 (63) 31 (63) 
Mean age (years) 37±11 37±11 37±11 
Mean age 1
st 
 thrombosis (years) 37±11 31±10 32±10 
Heterozygote FVL 4 16 3 
Heterozygote PT 2 12 5 
AT deficiency 0 1 0 
PC deficiency  0 6 0 
f-PS deficiency 1 10 27 
FVL + PT  0 4 0 
Thrombosis type    
Arterial   7 12 
Venous   41 34 
Arterial + venous  1 3 
Thrombosis number    
N = 1  39 29 
N = 2  10 15 
N = 3  0 4 
N = 4  0 1 
Current smokers (%) 12 (24) 13 (27) 18 (37) 
<11/day 9 6 12 
11-20/ day 3 5 6 
>20/day 0 2 0 
Ex-smokers 0 1 4 
Menopausal 4 4 3 
HRT 0 1 0 
Oral contraception 5 0 0 
CTR: control; IT: inherited thrombophilia; PAPS: thrombotic primary 
antiphospholipid syndrome; FVL: factor V Leiden; PT: prothrombin  20210; AT: 
antithrombin; PC: protein C; PS: protein S; HRT: hormone replacement treatment.  
 
 
 
106 
 
RESULTS 
Clinical features and lipid profiles across groups 
Table 7 summarizes the results of this section. PAPS and IT patients exhibited on average 
greater BMIs than controls (Table 2): a BMI greater than 30 was found in 10% (n=5) of 
PAPS, in 6% (n=3) of IT and 2% (n=1) of control participants. Systolic and diastolic blood 
pressures were similar across groups. Average total cholesterol was slightly lower in PAPS 
than other groups, although cholesterols higher than 200 mg/dL were present in 22% (n=11) 
of PAPS, in 28% (n=14) of IT and 6% (n=3) of CTR participants (p=0.01). Average HDL 
cholesterol was lower in PAPS and IT compared with controls whereas LDL cholesterol was 
comparable across the groups. In the same way, the average triglycerides concentration was 
higher in the PAPS and IT groups than in the control group.  
Table 7. Clinical features of participants in study groups. 
 CTR IT PAPS p-value 
 49 49 49  
Parental history of CVD 4 5 4  
BMI 23.4±2.4 25.4±3.5 25.3±3.2 0.001 
Blood pressures     
Systolic (mm/Hg) 123±15 123±15 125±17  
Diastolic (mm/Hg) 77±7.9 78±7.1 80±9.6  
Pulse (mm/Hg) 45±9.8 45±9.8 45±11  
CHO (mg/dl) 181±29 181±36 177±34  
HDL (mg/dl) 56±14.2 40±15 37±10.8 <0.001 
LDL (mg/dl) 109.6±28.5 99.23±27.4 96.5±31.27 0.08 
TG (mg/dl) 83.1±29.2 108.8±44.2 106.2±54.8 0.01 
IMT of carotid artery segments across groups 
A comparison of the three groups under study revealed greater IMT of different carotid 
artery segments in PAPS than other groups (Table 8).  
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Table 8. Intima–media thickness of carotid artery segments across groups. 
 
CTR 
(n = 49) 
IT 
(n = 49) 
PAPS 
(n = 49) 
p-value 
Common carotid (mm) 0.416±0.085 0.448±0.096 0.487±0.123 0.004 
Carotid bifurcation (mm) 0.481±0.108 0.521±0.093 0.556±0.162 0.013 
Internal carotid (mm) 0.385±0.092 0.415±0.092 0.463±0.118 0.001 
PAPS = primary antiphospholipid syndrome; IT = inherited thrombophlia; CTR: controls. 
Bonferroni’s post hoc test; common carotid, PAPS vs CTR p=0.002; carotid bifurcation, PAPS vs 
CTR p=0.01; internal carotid, PAPS vs CTR p=0.001. 
When we divided our participants into age tertiles, PAPS patients in the second and third 
tertiles showed greater IMT than in the other groups (Table 9). Plaques were uncommon in 
the PAPS group and occurred only in the third age tertile: 11% (2/17) of PAPS, 5.8% (1/17) 
of IT and 5.8% (1/17) of control participants. 
Table 9 Intima-media thickness of carotid artery segments by age tertiles. 
 
1st tertile: 16 patients (10 M, 6 F), mean age 26±4.4 years; 2nd tertile: 16 patients (10 M, 
6 F), mean age 36±2.7 years; 3rd tertile: 17 patients (11 M, 6 F), mean age 49±8.5 years 
 
 
 Intima-media thickness of common carotid (mm)  
 CTR IT PAPS P 
1
st
 tertile 0.347±0.030 0.386±0.064 0.406±0.090 0.054 
2
nd
 tertile 0.384±0.047 0.405±0.055 0.468±0.088 0.003 
3
rd
 tertile 0.496±0.074 0.528±0.085 0.581±0.119 0.030 
 Intima-media thickness of carotid bifurcation (mm)  
1
st
 tertile 0.412±0.078 0.479±0.083 0.438±0.081 0.154 
2
nd
 tertile 0.446±0.065 0.504±0.085 0.529±0.094 0.023 
3
rd
 tertile 0.557±0.113 0.564±0.093 0.693±0.171 0.004 
 Intima-media thickness of internal carotid (mm)  
1
st
 tertile 0.320±0.056 0.368±0.091 0.366±0.086 0.217 
2
nd
 tertile 0.374±0.083 0.375±0.061 0.460±0.076 0.003 
3
rd
 tertile 0.444±0.086 0.480±0.077 0.546±0.112 0.007 
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Variables relating to IMT by univariate analysis were entered in a regression model to 
identify those independently related to IMT of different carotid segments: PAPS status and 
age emerged as the most powerful predictors for all carotid segments with triglycerides 
appearing as a strong predictor for the common carotid and female gender for the internal 
carotid (Table 10). A separate comparison of the two thrombotic groups showed greater CC 
(p = 0.023), B (p = 0.04) and IC (p = 0.004) in PAPS than IT after correction for the 
confounding effect of CHO, LDL and TG. However, the average number of thrombotic 
events was greater in PAPS than IT patients (1.52 ± 0.74 vs. 1.20 ± 0.41, p=0.01) with a trend 
for greater IMT in patients with more thrombotic events (not shown). After inclusion of mean 
thrombotic events amongst the confounders, only IMT of the IC remained significantly 
greater in PAPS than IT patients (p = 0.01). 
IMT predictors in PAPS  
IMT of the common carotid correlated with age (r=0.63, p<0.0001), systolic (r=0.63, 
p=<0.0001) and diastolic blood pressure (r=0.50, p=0.0002), IgG aCL (r=0.37, p=0.009) and 
IgG β2GPI titre (r=0.45, p=0.001) and number of occlusive events (r=0.36, p=0.01). Similarly 
IMT of the carotid bifurcation correlated with age (r=0.75, p<0.0001), systolic (r=0.63, 
p<0.0001) and diastolic blood pressure (r=0.58, p<0.0001), IgG β2GPI titre (r=0.46, p=0.001) 
and number of occlusive events (r=0.31, p=0.02). Finally IMT of the internal carotid 
correlated with age (r=0.7, p<0.0001), systolic (r=0.54, p<0.0001) and diastolic blood 
pressure (r=0.54, p<0.0001) and IgG β2GPI titre (r=0.52, p=0.0003). Both IgG aCL and IgG 
β2GPI correlated with age (r=0.34, p=0.01 and r=0.5, p=0.0001 respectively) whereas IgG 
β2GPI correlated with diastolic (r=38, p=0.008) and systolic (r=38, p=0.009) blood pressures. 
Given these interdependences, a multiple regression model identified age and diastolic blood 
pressure as independent predictors of CC IMT (F=10.6, p=0.003 and F=4.6, p=0.04 
respectively), and age as an independent predictor of B (F=26.5, p=0.0001) and IC (F=13.7, 
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p=0.001) IMT. No IMT difference was noted in any carotid segment between nine PAPS 
patients with ischaemic stroke and nine PAPS patients with venous thrombosis matched by 
gender and age (2.7 ± 0.9 years) (not shown). PAPS patients with arterial occlusions showed 
higher mean diastolic pressure than PAPS patients with venous occlusions (84 ± 9 vs 
77 ± 9 mmHg, p=0.01).  
Table 10: Independent predictors of intima media thickness of carotid artery segments across groups 
by multivariate analysis. 
Dependent variable: intima media thickness of common carotid 
Independent variables β SE P 
Parental history cardiovascular disease 0.017 0.021 0.401 
Age 0.007 0.001 < 0.001 
HDL cholesterol 0.000 0.000 0.997 
Systolic blood pressure 0.000 0.001 0.933 
PAPS 0.032 0.008 < 0.001 
Triglycerides 0.000 0.000 0.015 
    
Dependent variable: intima media thickness of carotid bifurcation 
Independent variables β SE P 
Age 0.008 0.001 < 0.001 
HDL cholesterol 0.000 0.001 0.933 
Systolic blood pressure 0.000 0.001 0.589 
PAPS 0.039 0.011 0.001 
    
Dependent variable: intima media thickness of internal carotid 
Independent variables β SE P 
Parental history cardiovascular disease 0.035 0.025 0.164 
Age 0.006 0.001 < 0.001 
HDL cholesterol 0.000 0.001 0.550 
Systolic blood pressure 0.001 0.001 0.444 
PAPS 0.038 0.010 < 0.001 
Triglycerides 0.000 0.000 0.003 
Sex 0.035 0.015 0.021 
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DISCUSSION  
Patients with SLE have a 50-fold greater risk of developing cardiovascular disease in 
comparison to the general population (21) a phenomenon attributed to the development of 
premature atherosclerosis (22). A case-control study found increased IMT in SLE, partially 
explained by the presence of aPL (23) whereas aPL did not discriminate between SLE 
patients with and without carotid plaques (24). Moving this issue into PAPS, the first two 
studies in this chapter addressed whether aPL related to IMT in persistent carriers of aPL 
(thrombotic and non thrombotic) alongside the lipid profile and some haemostatic variables: 
this was appeared as a likely possibility given the enhanced the production of vWF, tissue 
factor and adhesion molecules from endothelial cells incubated in the presence of aPL (25-
27).  
Elevated plasma concentrations of vWF and FNG have been associated with thrombosis 
type and number in PAPS (28) and elevated concentration of adhesion molecules have been 
linked to the severity of APS (29). The univariate association between IgG aCL, vWF, FNG 
and PAI on the one side and IMT on the other strongly favour their involvement in the 
development of carotid atherosclerosis. Multivariate analysis showed that plasma FNG was an 
independent predictor of IMT. Elevated plasma FNG in combination with depressed 
fibrinolysis and enhanced coagulation activation contributes to accelerated fibrin turnover in 
PAPS (30). Depressed fibrinolysis and heightened fibrin turnover contribute to the persistence 
of fibrin deposition on endothelial cells, one of the initiating steps of atherosclerosis (31).  
Most importantly, IgG aCL independently predicted the IMT of the different carotid 
segments examined. Outside the autoimmune setting aCL was an independent risk factor for 
angiographically documented atherosclerosis (32) and in young patients with peripheral 
vascular disease those (6) highlighting aCL as the possible major atherosclerotic risk factor.  
Additionally, also plasma HC also ranked as an independent predictor of IMT in our 
patients. Elevated plasma HC is a risk factor for thrombosis (33) and elevated plasma HC 
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seems to be implicated in the thrombotic tendency of PAPS. In fact, patients with deep vein 
thrombosis who were found to have high aPL titres together with elevated plasma HC 
developed thrombosis at an earlier age than patients with elevated aPL alone or elevated HC 
alone (34). Similarly, in patients with PAPS, plasma HC had some impact on the number of 
occlusive events (35). Thus, plasma HC represents an additional risk factor contributing to the 
development of thrombosis and atherosclerosis in PAPS. Elevated HC and aPL share some 
pathogenic effects. HC may enhance tissue factor activity and PAI generation from the 
vascular endothelium in vitro (36, 37) whereas in vivo it is associated with elevated plasma 
levels of vWF and endothelin-1 (38-40), the same factors that are elevated in PAPS (28, 41, 
42) particularly in patients with arterial disease (41, 42). Furthermore, elevated plasma HC 
and aPL enhance lipid peroxidation (43, 44) another process implicated in atherogenesis (45).  
Indeed, oxidation of LDL plays an important role in atherosclerosis, as oxLDL may 
induce vasoconstriction, expression of adhesion molecules and cellular proliferation (46-48). 
On the other hand, immunisation of hypercholesterolemic rabbits with oxLDL suppresses 
atherosclerosis (49) therefore an immune response to oxLDL may modulate atherogenesis 
(50). An inverse relationship between oxLDL and IgG anti-oxLDL exists in the general 
population, and it was implied that anti-oxLDL helps to remove oxLDL from the bloodstream 
(51). However, this issue is controversial. One study described an inverse and independent 
relationship between anti-oxLDL titre and IMT of carotid arteries in healthy subjects (52), 
whereas, IgG-oxLDL titre positively associated with IMT of the CC artery in another study 
(53). That is, both the antigen and the corresponding antibody seem to have a relation with 
IMT. Similar conflicting information is available for SLE, where oxLDL appeared to be 
related to arterial thrombosis (54) or venous thrombosis (55) in SLE-related APS, whereas, 
more recently oxLDL related to disease activity (56).  
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The approach of our study is a step ahead of the oxLDL/anti-oxLDL system. A complex 
of β2GP with oxLDL and more specifically with the 7-ketocholesteryl-9-carboxynonanoate 
(oxLig-1) moiety from oxLDL and specific antibodies against this complex, IgG anti-β2GPI–
oxLig-1, discriminated arterial disease in SLE related APS (11). The relation of this 
antigen/antibody system with IMT of carotid arteries in PAPS is unknown. Median plasma 
levels of the antigen, oxLDL-β2GPI complex, was higher in our control populations and lower 
in aPL subjects, whereas, the antibodies IgG anti-oxLDL-β2GPI and IgG anti-β2GPI–oxLig-1 
were greatest in the PAPS group, though they did not identify patients with arterial 
thrombosis.  
PONa showed several interesting relationships. In the control group, oxLDL/β2GPI 
inversely related to PONa, indicating that as more LDL becomes oxidised, more oxLDL is 
buffered by β2GPI. This is likely due to an age related decrement of the antioxidant capacity 
of PON (57) given the lack of effect of oxLDL/β2GPI on PONa in our in vitro experiments 
and the loss of correlation between oxLDL/β2GPI and IMT of carotid segments after 
correction for age. We cannot discount the possibility that IgG anti-β2GPI-oxLig-1 appears as 
an attempt to clear oxLDL/β2GP in a fashion similar to that described between oxLDL and 
IgG oxLDL in normal subjects (51). The data of our thrombotic control group partially 
replicate those of our normal control group and altogether they suggest that oxLDL/β2GPI, 
IgG anti-β2GPI–oxLig-1 and anti oxLDL/β2GPI might have a role in vascular ageing in 
normal people. The picture of the PAPS group mirrors that of the control groups. In fact, 
PONa negatively related to IgG β2GPI- oxLig-1, to IgG β2GPI and IgG aCL, in keeping with 
our hypothesis that PONa inhibition participates in APS related vascular damage (58). Here, 
we extend this concept, in that elevated IgG anti-β2GPI-oxLig-1 together with low PONa 
were positive and negative correlates of the IMT of carotid artery segments. Some aPL have 
inhibitory effects on PONa in SCID mice (59). With consideration to the small numbers of 
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our groups, we suggest the following sequence of events. In normal people, an age related 
decrease of PONa allows for oxidation of LDL that is buffered by β2GPI and eventually an 
antibody develops to clear this ternary complex. By contrast, in PAPS, aPL interference with 
PONa tilts the oxidant/antioxidant balance towards enhanced lipid peroxidation (44) that in 
turn contributes to arterial thickening. Although this study was not devised to demonstrating 
premature vascular damage in PAPS, it provides further evidence for PON and IgG anti-
β2GPI-oxLig-1 implication in atherogenic pathways that may represent a target for therapeutic 
intervention. 
In fact, atherosclerosis in PAPS may enhance the cardiovascular risk therefore further 
contributing to the morbidity of affected patients in most arterial districts (32, 60). Data from 
the Italian Antiphospholipid Registry calculated a 2.5% patient/year incidence of recurrent 
thrombosis often fatal (61); a prospective Spanish study demonstrated that 5.2% (7/133) of 
PAPS patients died of recurrent arterial occlusions (62); our own longitudinal study showed a 
5.2% patient/year mortality rate for recurrent arterial thrombosis (63) and a Russian group 
recently reported a 17% 8-year vascular mortality for PAPS % (64). At variance from other 
case–control studies that lacked a control group with vascular occlusions and with a persistent 
risk factor such as genetic thrombophilia we demonstrate that the average IMT of our PAPS 
patients is significantly greater than that of IT and healthy controls. However, because of the 
wide age range, most of the difference of the IMT is found in the second and third age tertiles, 
as one would eventually expect. Indeed age was a significant predictor of IMT in all carotid 
segments considered. The only other study that compared PAPS patients with deep vein 
thrombosis to patients with thrombosis because of other causes (14) expressed atherosclerosis 
as plaques and the prevalence of which was 55% in PAPS and 75% in controls at the carotid 
level. Although not significantly different, this plaque prevalence is much greater than our 
11% and than the 8% of the Spanish study, probably because of the high prevalence of other 
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risk factors for atherosclerosis described in that PAPS population (65). A high prevalence of 
atherosclerotic risk factors was also present in 28 PAPS patients from a Mexican study: their 
healthy controls were adequately matched for dyslipidaemia but not for hypertension and 
obesity: this might have had bearings on the IMT of 2.6 mm in the PAPS group vs. the 1.2 
mm in the healthy group (66). Plaques were not defined in this study. Of the other two 
reports, the average IMT of 25 PAPS Spanish patients was not greater than healthy controls 
(65) whereas the average IMT of 14 Hungarian patients was greater than their controls (67). 
Interestingly, average total or LDL cholesterol in our PAPS patients were not elevated, rather 
average HDL cholesterol was low. In the mid 1990s, a case–control study found IgG aCL in 
14.5% of patients younger than 50 years of age operated for atherosclerotic peripheral 
vascular disease. These, mostly female, had a lower prevalence of 
hyperlipidaemia/dyslipidaemia compared with those negative for IgG aCL (6). A possibility, 
not tested here, is that antibodies against HDL enhance HDL clearance contributing thus to 
the loss of the anti-atherogenic and anti-inflammatory properties of HDL (58). Indeed low 
grade inflammation characterizes thrombotic PAPS (68). The lack of hyperlipidaemia 
strengthens the role of aPL as a unique cardiovascular risk factor in thrombotic PAPS: herein 
IgG aCL and IgG β2GPI correlated with IMT segments although by multivariate analysis only 
the age effect became prevalent. A notable observation derived from the comparison of the 
two thrombotic groups is that the average number of thromboses in the PAPS group 
accounted for the greater IMT of the carotid segments of PAPS compared with IT; in fact 
after correction for this confounding only IMT of the IC remained significantly greater in 
PAPS than in IT. In other words the number of occlusive events may affect IMT.  
In conclusion, we provide the first evidence that premature atherosclerosis as defined by 
IMT occurs in thrombotic PAPS over 30 years of age; however, our design and numbers 
cannot provide an answer as to whether premature atherosclerosis contributes to an increased 
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risk of thrombosis, and the correlation between IMT and number of vascular occlusions may 
even suggest the opposite. Whichever the case, warfarin may prevent thrombosis, but has no 
effect on atherosclerosis, the progression of which should be prospectively assessed and 
eventually managed by specific therapeutic agents to prevent additional vascular morbidity. 
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CHAPTER IX  
CONCLUSION 
Coagulation, oxidation, inflammation, immune activation and nitration in primary 
antiphospholipid syndrome: the atherogenic link  
The possibility that some risk factors for thrombosis and atherosclerosis in the general 
population (1-3) would behave as risk factors thrombosis and atherosclerosis in PAPS proved 
true. In Chapter I plasma vWF and FNG were differentially associated with arterial and 
venous occlusions regardless of sex whereas in Chapter VIII plasma FNG was an independent 
predictor of IMT of carotid arteries alongside IgG aCL. At variance the data on fibrinolytic 
variables were gender related, in that female PAPS showed blunted tPA release and higher 
mean plasma PAI compared to male patients. Epidemiological surveys in the general 
population have demonstrated that females show an age related increase of plasma PAI 
compared to males (4) whereas the opposite occurs for tPA (5), suggesting that aPL may 
emphasize the age and sex dependency of these fibrinolytic variables in PAPS. Moreover 
elevated mean plasma tPA and PAI in patients with a history of thrombosis is a risk factor for 
recurrences (6) and elevated PAI is a risk factor for atherosclerosis (3): indeed Chapter VIII 
shows that plasma PAI associated with IMT of carotid arteries though only by univariate 
analysis. Overall the results on haemostatic and fibrinolytic variables indicate that PAPS 
patients and persistent carriers of aPL in the absence of thrombosis are in a state of 
accelerated fibrin turnover and fibrin deposition on the vessel wall is a recognized early 
phenomenon in atherogenesis (7). 
Thrombotic PAPS patients and persistent carriers of aPL revealed an unusual lipid profile 
characterised by low plasma concentration of HDL and of LDL (8). In PAPS, the presence of 
antibodies against HDL may induce the formation of an antigen/antibody complex that is 
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removed by phagocytic cells allowing for reduced HDL; moreover in vitro studies have 
shown that aPL are able to induce a dose dependent inhibition of the activity of PON (9), one 
of the enzymes that prevents the oxidation of LDL. Whichever the mechanism, in isolation or 
in combination, there will be increased oxidation of LDL, independent of the plasma 
concentration of LDL, with release of F2-isoprostane, a powerful vasoactive agent increased 
in PAPS (10) and a sensitive marker of lipid peroxidation, an early step in atherogenesis (11).   
In an antioxidant attempt to quench LDL oxidation, β2GPI binds to LDL in a stable 
oxLDL/β2GPI complex (12): the plasma concentration of oxLDL/β2GPI was elevated in 
PAPS where it was independently predicted by IgG anti-HDL (8). Interestingly the 
inflammatory marker CRP negatively correlated to HDL and ApoAI suggesting that loss of 
antioxidant capacity allows the emergence of low grade inflammation pursuant the concept 
that oxidation and inflammation are parallel processes in PAPS: indeed not only the plasma 
concentration of oxLDL-β2GPI but also that of CRP was elevated in PAPS (8). 
The low grade inflammation in PAPS was confirmed in another study on the same cohort 
of patients where the elevated plasma concentrations of oxLDL-β2GPI and CRP were 
matched by that of SAA, another inflammatory marker and by sCD14 and NPT, immune 
activation markers. Of these markers, SAA related to the number of thrombosis, but NPT and 
sCD14 were associated to the number of arterial thrombosis (13). Soluble CD14 and NPT are 
respectively shed and released by monocytes activated by interferon gamma of T helper cell 
origin (14). Monocytes are central to the vascular pathogenesis of PAPS: their exposure to 
aPL in the circulation may promote tissue factor expression that enhances systemic 
coagulation possibly explaining arterial thrombosis (15); moreover, in the circulation 
monocytes encounter oxLDL, oxLDL-β2GPI complexes, IgG-oxLDL-β2GPI immune 
complexes and eventually phagocytose them either via scavenger receptors or via Fc gamma 
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receptors, during which process they migrate within the intima of the arterial wall, again an 
early atherogenic step as the loss of the biological activity of NO (16).  
The plasma concentration of NO2
–
, the “vasodilator” metabolite of NO was markedly 
reduced in persistent non thrombotic carriers of aPL and in PAPS, but particularly in patients 
with multiple occlusions, whereas the plasma concentration of NO3
–
, the “inflammatory” 
metabolite of NO was associated with arterial disease (17). Linking with previous data, these 
PAPS patients also showed a moderate degree of nitrative stress, measured as plasma NT, and 
plasma NT was independently predicted by CRP, the same marker associated with oxidation 
(8). Therefore we have a scenario where increased fibrin turnover, even in orally anti-
coagulated PAPS patients (18), oxidative and nitrative stress, loss of the biological activity of 
NO, low grade inflammation and immune activation are all interconnected. Given that these 
phenomena occur at the early stages of atherosclerosis in the normal population, it will be of 
no surprise that they contribute to premature atherosclerosis in PAPS as demonstrated (19).    
Future directions 
The current therapeutic strategy in thrombotic PAPS is to maintain indefinite oral 
anticoagulation to prevent thrombotic recurrences that unfortunately do happen, particularly 
in male patients with strong lupus anticoagulants and high positive aPL (20). At present we do 
not know how to manage PAPS related atherosclerosis. Control of modifiable risk factors is 
intuitive but the progression of heart valve lesions in PAPS is worrying (21) and warrants 
clinical intervention. Treatment may be directed at managing the effects of aPL antibodies or 
at decreasing aPL titres. A pilot study with the use of probucol, a drug with antioxidant 
properties showed significant improvements in fibrinolysis and decreased urinary 
thromboxane, isoprostane and NO metabolites after three weeks treatment (22). Given their 
positive effects on the immune system and on the vascular endothelium statins may be 
suitable candidates within the context of a clinical trial (23). Probucol was non inferior to 
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statins in a head to head trial aimed at regressing atherosclerosis in a general population over 
60 (24). Attempts at reducing plasma levels of aPL via B-cell depletion in PAPS were 
unsuccessful (25) and perhaps plasma cell depletion coupled with antigen 
manipulation/vaccination may represent a breakthrough for antibody mediated disorders (26).  
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